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Abstract 
 
Insufficient efficacy and unsafe treatment options are the current state of the art of prostate 
cancer therapies. This motivated us to develop antiandrogenic drugs with reduced side effects, 
aiming at effective tumor growth prevention and regression for prostatic adenocarcinomas. The 
key enzyme in androgen synthesis CYP17 is to date the most promising target for an overall, 
mild treatment of prostate carcinomas. Thus, it was our aim to develop nonsteroidal CYP17 
inhibitors. In the present work, the synthesis, biological evaluation and molecular modeling 
studies of 69 compounds divided in three main classes are presented. These were published in 
three different international scientific magazines. A further manuscript is already prepared. 
Other related compounds, not essential for this work, are already published or to be published 
soon in four other co-authored works. The compounds discussed in this work belong to the 
following classes: 
 
 
 
 
 
 
 
 
 
 
III.21 and IV.15 were moderate active and selective, while V.19 exhibited 144 nM IC50, good 
CYP3A4 and excellent CYP11B2 and CYP11B1 selectivity. These biological activities were 
discussed, and structural changes, for activity and selectivity improvement are proposed. 
Enantiomeric separation and further in vitro and in vivo tests are still undergoing. In case these 
are successful, clinical trials will be planned.  
Presented classes and their lead representants. 
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Zusammenfassung 
 
Ungenügend wirksame und risikoreiche Behandlungen sind der heutige Stand der 
Prostatakrebstherapien. Dies motivierte uns zur Entwicklung antiandrogener nebenwirkungs-
armer Wirkstoffe mit dem Ziel eine effektive Tumorwachstumprävention und -regression 
prostatischer Adenokarzinome zu erreichen. Das Schlüsselenzym der Androgensynthese CYP17 
ist bis dato das vielversprechendste Target für eine Behandlung des Prostatakarzinoms. 
Dementsprechend war es unser Ziel nicht-steroidale CYP17 Inhibitoren zu entwickeln. In der 
vorliegenden Arbeit wurde die Synthese, biologische Evaluierung und Molecular Modeling 
Studien von 69 Verbindungen in drei Substanzklassen vorgestellt. Diese wurden in drei 
verschiedenen internationalen Zeitschriften publiziert. Ein weiteres Manuskript ist fertigge-
stellt. Andere verwandte, für diese Arbeit nicht essentielle Verbindungen, sind in vier weiteren 
Publikationen niedergelegt. Die vorgestellten Verbindungen gehören folgenden Stoffklassen an: 
 
 
 
 
 
 
 
 
 
III.21 und IV.15 waren moderat aktiv und selektiv, während V.19 mit 144 nM IC50 gut aktiv 
war, gute CYP3A4 und exzellente CYP11B2 und CYP11B1 Selektivität zeigte. Die biologischen 
Aktivitäten wurden diskutiert, und strukturellen Änderungen zur Verbesserung der Aktivität 
und Selektivität vorgeschlagen. Enantiomerentrennung und weitere in vitro und in vivo Tests 
werden gegenwärtig durchgeführt. Für den Fall, dass diese erfolgreich sind, werden klinische 
Studien geplant. 
Vorgestellte Verbindungen und entsprechende Lead-Vertreter. 
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I. Introduction 
 
I.1. Cancer 
 
I.1.a. Quid est cancer? 
The first records of cancer are attributable to Hippocrates (460-370 BC), founder of 
medicine, who first used the Greek terms καρκίνοσ (‘carcinos,’ gr. crayfish) and καρκίνομα 
(‘carcinoma’) to refer to and describe in detail chronic ulcers or growths that seemed to be 
malignant tumors, most likely because the finger-like spreading projections from a cancer called 
to mind the shape of a crab. Benign tumors were called ονκοσ (‘oncos,’ the root of the modern 
word oncology, the study of tumors), Greek for swelling or bulk. More than 400 years later, 
Celsus (28 BC - 50 AC) referred to ‘carcinos’ with the Latin translation ‘cancer’ to refer to 
malignant, invasive tumors, and introduced the Greek work ‘carcinoma’ as such in Latin for 
superficial malignant and premalignant tumors. Galen (130-200 AC) also contributed to the 
early history of oncology with many scientific observations, and used on his part the Greek term 
‘oncos’ to refer also to a malignant-looking tumor.1 
Cancer is a term used for a group of more than 100 diseases in which abnormal cells begin to 
grow out of control and order and are able to invade other tissues. It is estimated to be the 
actual most common cause of death in the US, succeeded by coronary disease, cerebrovascular 
diseases, respiratory diseases and unintentional injuries (accidents).2 Normal body cells grow, 
divide, and die in a controlled way as they are needed to keep the body healthy. However, the 
genetic material (DNA) of a single human cell becomes damaged or changed by environmental 
factors, like chemicals, viruses, tobacco smoke or too much sunlight about 10,000 times every 
day, producing mutations that affect normal cell growth and division. Most of the time when 
DNA becomes damaged, either the cell commits suicide (apoptosis) or is able to detect and 
repair the DNA by itself. In cancer cells, the damaged DNA is not repaired and new cells form 
when the body does not need them. These new cells are created by the division (mitosis) of the 
cell nucleus. In this way, the damaged DNA, which is located in the cell nucleus, gets duplicated 
and the newly formed cells again carry the same damaged DNA. People can also inherit 
damaged DNA, which accounts for inherited cancers. 
These extra cells may form a mass of tissue called a growth or a tumor. Some cancers 
though, like leukemia, do not form tumors, but instead, the cancer cells involve the blood and 
from www.astrologycom.com/vitalism.html 
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blood-forming organs, and circulate through other tissues where they grow. In the same 
manner, not all tumors are cancerous. Cancer cells can spread to other parts of the body 
through the bloodstream and lymph systems where they begin to grow and replace normal 
tissue. Such spreading process is called metastasis. Noncancerous (benign) tumors do not 
metastasize and are very rarely life-threatening. 
Cancers can begin in many different parts of the body and are mostly named after the organ 
or type of cell in which they start. As an example, prostate cancer is the kind of cancer which 
begins in the prostate. Even when cancer has spread to a different part of the body it is still 
named after the place in the body where it started, e.g., prostate cancer that has spread to the 
bone is called metastatic prostate cancer, not bone cancer. This is very important, since 
different types of cancer can act very differently. For example, prostate cancer and lung cancer 
are very different diseases. They grow at different rates and respond to different treatments. 
That is why people with cancer need treatment that is aimed at their particular kind of cancer. 
Cancer types can be grouped into broader categories. The main categories of cancer include: 
 Carcinoma: cancer that begins in the skin or in tissues that line or cover internal organs. 
 Sarcoma: cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other 
connective or supportive tissue. 
 Leukemia: cancer that starts in blood-forming tissue such as the bone marrow and causes 
large numbers of abnormal blood cells to be produced and enter the blood. 
 Lymphoma and myeloma: cancers that begin in the cells of the immune system. 
 Central nervous system cancers: cancers that begin in the tissues of the brain and spinal 
cord. 
Although cancer is not contagious, its occurrence is very high. Half of all men and one-third 
of all women in the US will develop cancer during their lifetimes. The risk of developing most 
types of cancer can be reduced by changes in a person's lifestyle, for example, by quitting 
smoking, limiting time in the sun, being physically active, and eating a better diet.3 The sooner a 
cancer is found and treated, the better the chances are for living for many years. 
 
I.1.b. Risk Factors and Prevention 
Anything that may increase a person’s chance of developing a disease is called a risk factor; 
anything that may decrease a person’s chance of developing a disease is called a protective 
factor. A risk factor shows a higher incidence in a test group to develop cancer, but it does not 
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mean that it will increase your chance to get cancer. Most people who have risk factors never 
develop cancer while also some people are more sensitive than others to the known factors. 
The most important risk factor for cancer is growing older. Most cancers occur in people 
over the age of 65, but still, even children can get cancer, too. While growing older is not 
preventable, the most important, preventable cause of cancer death is tobacco use. Each year, 
more than 180,000 USA citizens die from cancer that is related to tobacco use. Smokers are 
more likely than nonsmokers to develop cancer of the lung, larynx, mouth, esophagus, bladder, 
kidney, throat, stomach, pancreas, cervix and acute myeloid leukemia. 
The most important environmental cause of cancer is ultraviolet (UV) radiation. It causes 
early aging of the skin and skin damage that can lead to skin cancer. It is best to avoid the 
midday sun, use sunscreen with a sun protection factor (SPF) of at least 15 and stay away from 
sunlamps and tanning booths. Ionizing radiation can also cause cell damage that leads to 
cancer. This kind of radiation comes from rays that enter the Earth's atmosphere from outer 
space, radioactive fallout, radon gas (a gas formed in soil and rocks), x-rays, and other sources. 
Wide bodies of water like lakes charge the air negatively, counteracting the cancerous 
positively-charged air. 
Also ingestion or exposure to certain substances may increase the risk of cancer. Many 
studies have shown that exposure to asbestos, benzene, benzidine, cadmium, nickel, vinyl 
chloride and many other chemicals may cause cancer. Having more than two drinks of alcohol 
each day for many years, too, may increase the chance of developing cancers of the mouth, 
throat, esophagus, larynx, liver and breast. Physicians advise people to drink no more than one 
drink per day for women and no more than two drinks per day for men. 
Other risk factors are of biological nature. Being infected with certain viruses or bacteria 
such as: human papilloma viruses (HPVs), hepatitis B and C viruses, human T-cell 
leukemia/lymphoma virus (HTLV-1), human immunodeficiency virus (HIV), Epstein-Barr virus 
(EBV), human herpes virus 8 (HHV8) and helicobacter pylori may increase the risk of developing 
cancer. Also, certain hormones are an important risk factor for cancer. For example high blood 
levels of testosterone may increase the risk of prostate cancer, while otherwise low levels are a 
marker for developing heart diseases and metabolic syndrome diabetes. The family history of 
cancer may also be a significant risk factor, since some gene changes that increase the risk of 
cancer are passed from parent to child. Certain types of cancer like melanoma and cancers of 
the breast, ovary, prostate, and colon occur more often in some families than in the rest of the 
population. However, environmental factors may also be involved and most of the time, 
multiple cases of cancer in a family are just a matter of chance. 
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Furthermore, dietary habits and not enough physical activity or being overweight may 
increase the risk of several types of cancer. Studies suggest, that people, whose diet is high in 
fat have an increased risk of cancers of the colon, uterus and prostate. Lack of physical activity 
and being overweight are risk factors for cancers of the breast, colon, esophagus, kidney and 
uterus. A healthy diet includes a high variety of food high in fiber, vitamins and minerals, and 
less food high in fat. In addition, moderate physical activity (like brisk walking) for at least 30 
minutes on 5 or more days each week is recommended to help control your weight and reduce 
body fat. 
 
I.1.c. Classification, Treatment and Prognosis 
The process of diagnosing a cancerous clinical condition has two parts: grading (determining 
the tumor grade), to establish the pathology (classify the cytology), and staging, to determine 
the advance and implications of the cancer. The classification of a cancer within these two main 
criteria helps develop an individual treatment plan for the patient and predict the patient’s 
prognosis. Generally, a lower degree of each indicates a better prognosis: the likely outcome or 
course of a disease as well as the chance of recovery or recurrence. 
Tumor grade is a system used to classify cancer cells in terms of how abnormal they look 
under a microscope and how quickly the tumor is likely to grow and spread. It ranges G1 to G4 
from well-differentiated (low grade) to undifferentiated (high grade) tumors and GX, if the 
grade cannot be assessed.4 
Many factors are considered when determining the tumor grade, as the specific factors vary 
with each type of cancer. The two main factors are histological and nuclear grade. Histological 
grade, also called differentiation, refers to how much the tumor cells resemble normal cells of 
the same tissue type. Nuclear grade refers to the size and shape of the nucleus in tumor cells 
and the percentage of tumor cells that are dividing. 
Grading systems are also different for each type of cancer. For example, to describe the 
degree of differentiation of prostate cancer cells the Gleason system is used. The Gleason 
system uses scores ranging from Grade 2 (well-differentiated) to Grade 10 (undifferentiated). 
Other grading systems include the Bloom-Richardson system for breast cancer and the 
Fuhrman system for kidney cancer. 
On the other hand, cancer stage refers to the extent or severity of the cancer, based on 
factors such as the location of the primary tumor, tumor size, number of tumors, and lymph 
node involvement (spread of cancer into lymph nodes), but also on the tumor grade. For most 
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cancers, the stage is rated 0 (pre-cancerous abnormal carcinoma in situ, the primary tumor is 
present only where it began) to IV (the primary tumor has spread to other organs). 
These stages are usually based upon the TNM system. It considers the extent of the tumor 
(T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M). A degree 
is added to each letter to indicate the size or expansion of the tumor and the extent of spread. 
The degrees for classifying the primary tumor are: TX (primary tumor cannot be evaluated), T0 
(no evidence of primary tumor), Tis (carcinoma in situ, which means it has not spread to 
neighboring tissue) and T1 to T4 to define a growing size and/or extent of the primary tumor. 
For the regional lymph nodes, the degrees are analogous: NX, N0 and N1 to N3 (number and/or 
extent of spread). As for the distant metastasis, MX means it cannot be evaluated, and M0 and 
M1 describe respectively absence or presence of such. To illustrate this, prostate cancer T2 N0 
M0 means that the tumor has begun to spread outside the prostate, but has not spread to the 
lymph nodes or any other part of the body. Nevertheless, it is to observe, that criteria for stages 
differ for different types of cancer. For example, prostate cancer T3 N0 M0 is stage III; however, 
colon cancer T3 N0 M0 is a stage II cancer. 
The tests used for staging depend on the type of cancer. They include physical exams by 
looking, feeling, and listening for anything unusual as well as imaging studies (x-rays, computed 
tomography (CT) scans, magnetic resonance imaging (MRI) scans, and positron emission 
tomography (PET) scans), which produce pictures of areas inside the body, both useful in 
showing the location of the cancer, the size of the tumor, and whether the cancer has spread to 
the lymph nodes and/or to other organs. Laboratory tests of blood, urine, other fluids and 
tissues taken from the body can provide diverse information about the cancer. A biopsy (the 
removal of cells or tissues for examination under a microscope) is usually performed to provide 
pathology reports, which may include information about the size of the tumor, the growth of 
the tumor into other tissues and organs, the type of cancer cells, and the grade of the tumor. 
Cytology reports also describe findings from the examination of cells in body fluids. Surgical 
reports describe the size and appearance of the tumor and often include observations about 
lymph nodes and nearby organs found during surgery. 
Surgery is the oldest form of cancer treatment and, depending on the kind and stage of the 
cancer, it may vary from a small procedure up to much bigger operations. Besides diagnostic 
and staging surgery, there are several other types of surgery like prophylactic (preventive), 
curative (when it is likely to remove the entire tumor), debulking or cytoreductive (to remove a 
part of the tumor when not all may be removed), supportive (supporting other treatments) and 
restorative (a reconstructive surgery to restore biological functions or the way a person looks 
after another surgery). Surgery is usually the first treatment to be done, accompanied by 
radiation or chemotherapy. 
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Radiation therapy rests on the higher radiosensitivity of quickly dividing cells like cancerous 
cells. By interfering mitosis (cell division) through an ionizing radiation, mainly cancerous cells 
are affected. The damage made to normal cells is what causes side effects. It is usually used for 
curing or shrinking early stage cancer, stopping cancer from recurring in another area, but also 
for treating symptoms of advanced cancers. Because of the damage caused to the normal cells, 
only in some cases a second course of radiation therapy can be given. The most common types 
of radiation are: high-energy photons (most common, radiation comes from cobalt, cesium or a 
linear acceleration machine or ‘linac’), electron beams (for tumors close to a body surface), 
protons (more effective and with fewer side effects) and neutrons (used for cancers of the 
head, neck and prostate, has severe long-term side effects). Minor side effects include fatigue 
(most common, but the exact cause is unknown), skin lesions and others related to the damage 
produced to the treated organs, while the most important side effect is the chance to develop 
second cancers, which relies on changes in the DNA caused by the radiation itself. These may 
appear after 5 years, up to more than 15 years after treatment. 
The word chemotherapy was once used to mean any treatment with any medicine. Mustard 
gas was the first chemotherapeutic to be used for the treatment of cancer during the 1940s. 
The classical administration form of chemotherapeutics is intra venous (i. v.), though 
sometimes other options, like intra muscular (i. m.) and per oral (p. o.), are also possible. The 
appropriate chemotherapeutics, from over 100 systematically used, must be chosen depending 
on cancer type, grade and stage. They can be used to cure the cancer, control it from growing 
and spreading, and to relieve symptoms and improve the quality of life (palliative) when a fully-
recovery is not possible. This treatment can be used alone or in combination with others, 
before (neoadjuvant) or after (adjuvant) the main treatment. Classical chemotherapeutics may 
be divided into cytostatic – growth interfering, and cytotoxic – cell-death inducing. 
Chemotherapeutics may also be classified according to their mode of action in DNA 
interfering (alkylating agents, antimetabolites, antibiotics, topoisomerase inhibitors), 
microtubules interfering (vinca alkaloids, taxanes) and hormonal agents. Alkylating agents 
(cisplatin, carboplatin, cyclophosphamide, chlorambucil) attach alkyl groups to DNA strings 
leading to cell death. Antimetabolites (mercaptopurine, thioguanine, 5-fluorouracil (5FU), 
methotrexate) replace DNA and RNA bases (both purinic and pyrimidinic) and are also 
cytotoxic. Anthracyclines (doxorubicine, epirubicine) and mitoxantrone (an anthracenedione, 
similar in structure to anthracyclines) are antibiotics, which intercalate between bases in a DNA 
string. Topoisomerase inhibitors like etoposide, teniposide, irinotecan and topotecan interfere 
with the folding and unfolding of DNA strings, thus interfering with transcription (coding) and 
replication of DNA. Vinca alkaloids (vincristine, vinblastine) and taxanes (paclitaxel, docetaxel) 
prevent microtubule (a component of the cytoskeleton) function and are cytostatic. Hormonal 
agents are hormones, derivatives or other small molecules which interfere with the hormonal 
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household, responsible for tumor growth in some cancers like breast (estrogen receptor 
modulators: tamoxifen; aromatase inhibitors: letrozole, fadrozole) and prostate cancer 
(antiandrogens, GnRH analogs, 5α-reductase inhibitors, CYP17 inhibitors), and for treating side 
effects (dexamethasone). Antisense therapeutics for neoplastic diseases are still in research. 
Their mode of action relies on the interference of a synthetic strand of DNA or RNA with the 
messenger RNA (mRNA), produced by a gene which is to be responsible for the abnormal 
function of cells, thus turning the gene off. 
These medicines are usually given in cycles to reduce the harm to healthy cells and allow the 
drugs to kill more cancer cells. The exact course and duration of the therapy depends on each 
clinical condition. During therapy, diverse side effects, which vary from patient to patient, may 
be observed. This relies on the fact, that chemotherapeutics usually target in a greater degree 
all quickly dividing cells in the body such as cells that grow hair (leads to hair loss), cells in your 
bone marrow (may cause tiredness, easy bruising and a higher risk of infection), cells of the skin 
and mouth (dryness and sores in mouth and skin), and cells in your stomach and intestines 
(vomit, diarrhea). They may also cause loss of libido. 
Immunotherapy relies on the immune system for lymphocytes, antigen-presenting cells 
(monocytes, macrophages, dendritic cells) and antibodies to kill cancerous cells, either by 
modifying the patient’s own immune system (cancer vaccines, nonspecific immunotherapies 
and adjuvants), by the introduction of foreign antibodies (monoclonal antibodies), and by using 
antibodies to deliver other drugs to a cancerous cell, but also on other, nonimmunorelated 
mechanisms. Cancer vaccines are classified into tumor cell (made from killed tumor cells), 
antigen (by using only one or a few antigens), dendritic cell (with the most cancer-specific 
antigens), anti-idiotype (for the specific idiotype for the precise kind of cancer) and DNA 
vaccines (to instruct cells to create antigens) and are all still under research. Nonspecific 
immunotherapies include the use of cytokines (interleukins, interferons) and many other 
adjuvant therapeutics (Bacille Calmette-Guérin (BCG), detox, qs-21, keyhole limpet hemocyanin 
(KLH)) to regulate and improve the patient’s immune system. Classical (‘naked’) monoclonal 
antibodies target specific cancerous cells and induce cell-death (rituximab, alemtuzumab). 
Other naked monoclonal antibodies attach themselves to cancerous cells, disrupting specific 
growth processes like mitosis (trastuzumab, cetuximab), angiogenesis (development of new 
cancer supporting blood vessels, bevacizumab) and other processes. Conjugated monoclonal 
antibodies deliver other drugs (currently under study), toxins (under study) or radioactive 
substances (ibritumomab, tositumomab) to cancerous cells. 
Treatment options and prognosis depend not only on the stage of the cancer, but also on the 
patient’s health and most importantly on whether the cancer has just been diagnosed or has 
recurred (come back). 
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Figure 1. Human male urogenital system including the 
penis, testicles, seminal vesicles and prostate. 
I.2. The Prostate 
 
I.2.a. Biological Function 
The word prostate derives from the Greek word προςτάτησ (‘prostates’) and literally means 
‘one standing before.’ It is a walnut-sized tubuloalveolar (its secretory portions end in tubular 
and alveolar configurations) exocrine (secrete their products into ducts) gland of the male 
mammalian reproductive system. The prostate starts to develop before birth and continues to 
grow until a man reaches adulthood. Its secretion is slightly alkaline (pH 7.29) to neutralize the 
acidity of the vaginal tract (prolonging the lifespan of sperm) and constitutes 10-30% of the 
volume of the seminal fluid that, along with spermatozoa, constitutes semen. The rest of the 
seminal fluid is produced by the two seminal vesicles.5 
The prostate (Figure 1) is located between 
the lower part of the rectum and the pubic 
bone. It is sheathed in the muscles of the 
pelvic floor, which contract during the 
ejaculatory process, and surrounds the 
urethra just below the urinary bladder. 
Within the prostate, the urethra coming from 
the bladder is called prostatic urethra and 
merges with the two ejaculatory ducts. The 
seminal vesicles are located behind the 
bladder. The excretory ducts of the seminal 
glands open into the vas deferens as it enters 
the prostate gland. 
The prostate can be sectioned into lobes 
and zones, the lobe classification (Figure 2) 
being more often used in anatomy, while the 
zones classification (Figure 3) is useful for 
pathology studies. 
The anterior lobe is used to describe the anterior portion of the gland lying in front of the 
urethra. It is devoid of glandular tissue being formed completely of fibromuscular tissue. The 
median lobe is a cone-shaped portion of the gland situated between the two ejaculatory ducts 
and the urethra. The lateral lobes (right and left lobes) form the main mass of the gland. They 
are separated by the prostatic urethra. The posterior lobe is used by some to describe the 
from http://www.utdol.com/patients/content/topic.do 
  
 
Introduction – I.2. The Prostate 27 
postero-medial part of the lateral lobes that can be palpated through the rectum during digital 
rectal examination (DRE, see chapter I.3.b). 
 
 
 
 
 
 
 
 
 
 
 
 
The prostate gland has four distinct glandular regions, two of which arise from different 
segments of the prostatic urethra: 
The peripheral zone (PZ) composes up to 70% of the normal prostate gland in young men. It 
is the sub-capsular portion of the posterior aspect of the prostate gland which surrounds the 
distal urethra. It is from this portion of the gland that more than 70% of prostatic cancers 
originate. 
The central zone (CZ) constitutes approximately 25% of the normal prostate gland. This zone 
surrounds the ejaculatory ducts. Central zone tumors account for more than 25% of all prostate 
cancers. 
The transitional zone (TZ) is responsible for 5% of the prostate volume. This zone is very 
rarely associated with carcinoma. It consists of two paraurethral (next to the urethra) lobules 
anterior to the peripheral zone. The transition zone surrounds the proximal urethra, and is the 
region of the prostate gland which grows throughout life and is responsible for the disease of 
benign prostatic enlargement or hyperplasia (BHP). 
Figure 2 (up). Prostate horizontal 
sectional view. Division in 5 lobes: 
anterior, median and posterior lobes 
and two (left and right) lateral lobes. 
Figure 3 (right). Prostate division 
into 4 zones: central, fibromuscular, 
transitional and peripheral zones, and 
periurethral gland region. Prevalence of 
prostatic disorders by zone. 
from http://training.seer.cancer.gov/ ss_module02 
_prostate/unit02_sec02_anatomy.html 
from http://demarzolab.pathology.jhmi.edu/Reprints/nrc2090_published.pdf 
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The anterior fibro-muscular zone (or stroma) accounts for approximately 5% of the prostatic 
weight. This zone is usually devoid of glandular components and composed only, as its name 
suggests, of muscle and fibrous tissue. 
The last anatomically discrete area within the glandular prostate is the periurethral 
(surrounding the urethra) gland region, which represents less than 1% of the total volume of 
the glandular prostate. Its ductal network represents a more proximal extension of the 
networks of the peripheral and transition zone areas. 
 
I.2.b. Prostatic Disorders 
The most common prostatic disorders are of inflammatory or neoplastic (development of 
new tissues) nature: prostatitis, benign prostate hyperplasia (BPH) and prostate cancer.6 
Prostatitis is literally the inflammation of the prostate gland. In modern medicine, it is a 
commonly used term for several different complications in the urogenital system between the 
pelvic bone and the rectum, which are not always attributable to inflammation of the prostate. 
Symptoms of a clinically relevant prostatitis are pain and difficulty while urinating (alguria), 
frequent urination (pollakisuria), complications of the urinary flow, and pain during and 
especially after ejaculation. No specific markers exist for the diagnosis of prostatitis, and since 
the symptoms are similar to those of other prostate disorders, the same diagnostic tests are 
performed. There are different forms of prostatitis, each with different causes and outcomes. 
Acute prostatitis can lead to urinary obstruction, and in such way chills and fever. It is usually 
of bacterial nature, commonly from E. coli bacteria, which are found in the urine. Both the 
leukocyte count and the prostate specific antigen (PSA, see chapter I.3.b) levels are high. It is 
successfully treated with antibiotics such as fluoroquinolone and tetracyclines. Chronic 
bacterial prostatitis is the milder, more difficult to treat form of acute bacterial prostatitis, but 
the treatment remains the same. 
Chronic nonbacterial prostatitis or male chronic pelvic pain syndrome, which comprises 
about 95% of all prostatitis diagnoses, can have many different causes: from an 
autoimmunological failing, over neurogenical inflammation up to myofascial pain syndrome 
(MPS, a painful musculoskeletal condition). There are two kinds of chronic pelvic pain 
syndrome: inflammatory and noninflammatory. Treatments for either clinical condition include 
alpha blockers, phytotherapy, physical therapy, psychotherapy, antihistamines, anxiolytics, 
nerve modulators and more. More recently, a combination of trigger point and psychological 
therapy has proved to be effective as well. 
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Benign prostatic hyperplasia (BPH) is the noncancerous enlargement of the prostate, so that 
it obstructs the urethra. It is one of the most common pathologies in elderly men, accounting 
for 25-40% of men over 50 years old being diagnosed with this disease. Symptoms include 
pollakisuria, or taking some time to start urinating (hesitancy). Common treatment for BPH 
includes ‘watchful waiting’ until the disease develops into a more serious clinical condition, 
medication, a minimally invasive procedure or, in extreme cases, surgery that removes the 
prostate (prostatectomy). 
For the treatment of BHP, medication has to be considered depending on the goals of the 
treatment. Alpha blockers provide symptomatic relief of BPH symptoms. Available drugs 
include doxazosin, terazosin, alfuzosin and tamsulosin. 5α-reductase inhibitors (finasteride, 
dutasteride) are another treatment option for stopping the prostate from growing. 
Minimally invasive procedures include transurethral (through the urethra) needle ablation 
(removal of tissue) of the prostate (TUNA) and transurethral microwave thermotherapy 
(TUMT). These outpatient procedures may be followed by the insertion of a temporary 
prostatic stent, to allow normal voluntary urination, without exacerbating irritative symptoms. 
The surgery which is most often performed in such cases is called transurethral resection of 
the prostate (TURP or TUR). In TURP, an instrument is inserted through the urethra to remove 
prostate tissue that is pressing against the upper part of the urethra and restricting the flow of 
urine. Older men often have corpora amylacea (amyloids), dense accumulations of calcified 
proteinaceous material, in the ducts of their prostate. The corpora amylacea may obstruct the 
lumens (interior space) of the prostatic ducts, and may underlie some cases of BPH. Also urinary 
frequency due to bladder spasm, common in elderly men, may be confused with prostatic 
hyperplasia. 
It is believed that prostate cancer begins with a pre-cancerous condition called prostatic 
intraepithelial neoplasia (PIN). PIN begins to appear in some men in their 20s and almost half of 
all men have PIN by the time they reach 50. Even though PIN cells look abnormal under the 
microscope, they are not invasive, but a high-grade PIN increases the probability by 20%, that 
the patient already has prostate cancer. Another possible finding during a biopsy is atypical 
small acinar proliferation (ASAP), also called atypia. Atypia cells look cancerous, but there are 
too few of them to be certain. Nevertheless, the chance of already having prostate cancer is of 
40-50%. A third finding may be proliferative inflammatory atrophy (PIA). The cells look 
abnormal under the microscope, and they may turn into prostate cancer directly or by first 
changing into high-grade PIN. 
Prostate cancer is one of the most common cancers affecting older men in developed 
countries. Although it is very often diagnosed at an early stage, it is a significant cause of death 
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for elderly men. It is like other cancers, a complex disease with many risk factors: race, age, 
genetics, and lifestyle habits can all contribute to its development. 
The most common site of origin of prostate cancer is in the peripheral zone (the main 
glandular zone of the prostate), thus prostatic adenocarcinoma (adeno – lat. gland), the most 
common prostate cancer, is not always easy to detect through a DRE (see chapter I.3.b). 
Small cell carcinoma is made up of small round cells, and typically forms at nerve cells. Small 
cell carcinoma is very aggressive in nature and, as it does not lead to an increase in PSA, it can 
be somewhat harder to detect than adenocarcinoma; this usually means that it has reached an 
advanced form upon detection. 
Squamous cell carcinoma is a nonglandular cancer. Similar to small cell carcinoma, there is 
no increase in PSA when it is present and is also very aggressive in nature. 
Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate. It is the most 
common kind of skin cancer, and in the prostate it is a cancer of the prostatic capsule. Recent 
research reveals that it may be of aggressive nature since it may easily develop extraprostatic 
(outside the prostate) extension and metastasis. 
There are other, more rare, forms of prostate cancer. These include sarcomas and 
transitional cell carcinoma; the latter rarely develops in the prostate but derives from primary 
tumors present in the bladder or urethra. 
 
I.3. Prostate Cancer 
 
I.3.a. Reach of Prostate Cancer 
Cancer is the most deadly of modern diseases. The American Cancer Society has revealed 
that cancer has taken over heart disease as the number one cause of death in USA citizens 
under 85. In 2002, 476,009 USA citizens under 85 died from cancer compared to 450,637 from 
heart disease. It is estimated that 565,650 people will die in the USA from cancer in 2008. This is 
because deaths from heart disease are reducing at a greater rate than deaths from cancer 
(586,8 per 100,000 in 1050 to 211,1 in 2005 for coronary disease, while 193,9 to 183,8 for 
cancer).2 
Roughly one of four people die from cancer in the USA.7 The greatest reduction in cancer 
deaths in the past 10 years has been due to greatly reduced numbers of smokers, but better 
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screening methods and newer treatments have also helped. The American Cancer Society 
claims that a third of all cancer deaths are due to smoking and another third is due to obesity 
and poor diet. The best way to avoid dying from cancer is to have a healthy diet, exercise, not 
smoke and have regular health checkups. Also, African-american people are in higher risk of 
cancer than White people, followed by Hispanics, Asians and Native-americans. 
Although roughly 52% of all new estimated cases for 2008 are attributed to the male 
population (745,180 new cases) and 48% to the female population (692,000 new cases), 
lifetime probability of developing cancer between 2002-2004 is 1 in 2 for men and 1 in 3 for 
women. 
The leading cancer type in the male population is prostate cancer. 1 of 6 men will develop 
prostate cancer (25% of all newly-developed cancers) during their lifetime, preceded by 1 in 3 
for lung and bronchus cancer and 1 in 18 for colon and rectum. For women, leading cancer sites 
are breast (1 in 8, 26% of all newly-developed cancers), lung and bronchus (1 in 16) and colon 
and rectum (1 in 19). 
Furthermore, prostate cancer is the second leading cause of death after lung and bronchus 
between other cancer types. 294,120 men and 271,530 women are expected to die from cancer 
in the USA alone during 2008. This explains from a 31% of all male cancer deaths from lung and 
bronchus, succeeded by 10% from prostate cancer and 8% from colon and rectum. For the 
female population, leading cancer death rates are from lung and bronchus (26%), breast (15%) 
and colon and rectum (9%). 
This high death rate attributed to prostate cancer is underestimated when looking at the 5-
year survival rates for prostate cancer (99% for 1996 to 2003) compared to other kinds of 
cancer (overall cancer: 66%, colon and rectum: 66%, lung and bronchus: 16%, pancreas: 5%). 
The reason for that is the slow nature of prostate cancer. In most men with prostate cancer, the 
disease grows very slowly. The majority of men with low-grade, early prostate cancer (which 
means that cancer cells have been found only in the prostate gland) live a long time after their 
diagnosis. The belief that people usually do not die from prostate cancer, but rather live with it 
until they eventually die of some other, unrelated cause, has two sides. It is true, that a small 
percentage of the people with prostate cancer (15-20%) will die from it if compared to other, 
more aggressive cancers. But still, it is the second leading cause of death among cancers. 
The most important risk factor for prostate cancer is age; more than 70 percent of men 
diagnosed with this disease are over the age of 65. Rates of prostate cancer vary widely across 
the world. Although the rates vary widely between countries, it is least common in South and 
East Asia, more common in Europe, and most common in the United States. There is some 
evidence that dietary factors are involved, such as vitamin E and selenium, which may have a 
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Figure 4. Digital rectal examination 
(DRE) to feel abnormal tissues in the 
prostate. 
protective effect. Genetic factors also appear to play a role, particularly for families in which the 
diagnosis is made in men under age 60. 
About 90% of prostate cancers are diagnosed at an early stage. Nevertheless, the treatment 
selection is very difficult. Since prostate cancer is predominantly a disease of older men, many 
will die of other causes before a slowly advancing prostate cancer can spread or cause 
symptoms. The age and underlying health of the man, as well as the grade and stage of the 
disease and response of the cancer to initial treatment, are important in prognosing the 
outcome of the disease. The decision whether or not to treat localized prostate cancer with 
curative intent is a patient trade-off between the expected beneficial and harmful effects in 
terms of patient survival and quality of life. 
 
I.3.b. Symptoms and Diagnosis 
Neither the believed pre-cancerous condition PIN, nor most prostate cancers, cause 
symptoms for many years. By the time symptoms occur, the disease may have spread beyond 
the prostate. Even more, these symptoms are not exclusively related to prostate cancer, but to 
many other prostatic diseases, like BPH or prostatitis. Usual symptoms are of urinary kind, such 
as trouble urinating and a weak flow of urine, pain or burning during urination and needing to 
urinate often, especially at night. Also, difficulty having an erection, blood in the urine or semen 
and frequent pain in the lower back, hips, or upper thighs, are common symptoms.8 
The absence and unspecificity of symptoms makes early 
screening the modality of choice. Two tests have to be 
performed to assure a smaller risk of not detecting prostate 
cancer. One is the digital rectal exam (DRE, Figure 4), in which 
the physician inserts a lubricated, gloved finger into the 
rectum to feel the size and surface of the prostate gland. 
Healthy prostate tissue is soft, while malignant tissue is firm, 
hard, and often asymmetrical or stony. The other is a blood 
test used to measure a protein produced by the prostate that 
normally is present in the blood, the prostate-specific antigen 
(PSA). Since the PSA level increases with age, early yearly 
monitoring and establishing a baseline helps in noting 
immediately any significant increase. Though prostate cancer 
may show low PSA levels, a highly elevated PSA count above 
20 ng/mL is considered a strong indication of prostate cancer. 
But again, prostatitis and BPH may also increase PSA levels. 
from http://www.med.nyu.edu/healthwise/ 
article.html?hwid=ncicdr0000062965 
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Other variations of the PSA test are the PSA velocity (the rate at which serum PSA levels 
change over time) and the percent-free PSA or PSA II. The PSA II measures the percent of PSA 
that is free in the blood compared to the PSA that is bound to other proteins, so that a low 
percentage of free PSA (even if the total PSA is not especially high) may mean that prostate 
cancer is more likely. The fact that approximately 90% of all prostate cancers in the USA are 
currently diagnosed at an early stage relies on the widespread implementation of PSA testing. 
If a man's PSA level is elevated and digital rectal exam is abnormal, the diagnosis of prostate 
cancer is usually confirmed by a biopsy and establishing the Gleason score. There are 2 types of 
biopsy procedures used to diagnose prostate cancer: the transrectal biopsy, in which tissue 
from the prostate is removed by inserting a thin needle through the rectum and into the 
prostate, and the transperineal biopsy, by inserting a thin needle through the skin between the 
scrotum and rectum and into the prostate. The advantage of the transrectal biopsy over the 
transperineal is the use of transrectal ultrasound (TRUS) to guide the needle, which is at the 
same time used to perform a visual examination of the gland and surrounding tissue for 
tumors. 
The Gleason score is a grading system used to characterize the aggressiveness of prostate 
cancer, which provides an estimate of the cancer's potential to grow and spread to other parts 
of the body. A pathologist examines two tissue samples taken from different areas of the tumor 
and assigns a score of 1 to 5 to each sample. The less resemblance of the cellular structure of a 
tumor to a normal prostatic tissue, the more likely it is to grow faster and spread outside the 
prostate and the higher the score. The sum of the two produces the Gleason score. Gleason 
scores of 2 to 4 indicate that the cells are well differentiated, whereas 8 to 10 means they are 
poorly differentiated. 
After prostate cancer has been diagnosed, other tests are performed in order to determine 
the stage of the disease. These include: radionuclide bone scan, a nuclear imaging procedure 
that is used to detect metastasis to bones, since it is the first place where prostate cancer 
spreads; nuclear magnetic resonance imaging (NMRI), a computerized picture made by 
magnetic fields and radio waves that can show detailed, cross-sectional images of the inner 
body; computer-assisted or computerized axial tomography (CAT scan), an x-ray procedure that 
produces three-dimensional images of internal organs and glands by using contrast substances; 
positron emission tomography (PET), an imaging technique which uses γ-radiation and assesses 
particular features of the tumors biology, such as whether it is responsive to androgen 
suppressive agents; seminal vesicle biopsy, the removal and microscopic analysis of fluid from 
the seminal vesicles; and pelvic lymphadenectomy, a surgical procedure to remove the lymph 
nodes in the pelvis, after which the tissue is analyzed under the microscope. 
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Figure 5. As prostate cancer progresses from Stage I to Stage IV, the cancer cells grow within the prostate, 
through the outer layer of the prostate into nearby tissue, and then to lymph nodes or other parts of the body. 
The stage of the cancer is determined based on these results and on the Gleason score. The 
traditional 0-IV stages classification (Figure 4) has been recently replaced by a newer A-D 
convention: 
 Stage 0: (TX, T0) no cancer is detected. 
 Stage I (also called A1, T1): cancer is found in the prostate only. It cannot be felt during a 
DRE and is not visible by imaging. The Gleason score is low. It is usually found accidentally 
during surgery for other reasons, such as benign prostatic hyperplasia. 
 Stage II (A2, stage B1/B2, T2): cancer is more advanced than in stage I, but has not spread 
outside the prostate. The Gleason score can range from 2-10. 
 Stage III (stage C1/C2, T3/T4): cancer has spread beyond the outer layer of the prostate to 
nearby tissues and may be found in the seminal vesicles. The Gleason score can range 
from 2-10. 
 Stage IV (D1/D2/D3, T4): cancer has metastasized to lymph nodes near or far from the 
prostate or to other parts of the body, such as the bladder, rectum, bones, liver, or lungs. 
Metastatic prostate cancer often spreads to the bones. The Gleason score can range from 
2-10. 
An important factor for prognosis besides the stage is, if whether the cancer has recurred or 
not. Recurrent prostate cancer is cancer that has come back after it has been treated. The 
cancer may come back in the prostate or in other parts of the body. 
 
from http://www.med.nyu.edu/healthwise/article.html?hwid=ncicdr0000062965 
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I.3.c. Classic and Alternative Therapies 
After establishing the grade and stage of the disease, an appropriate treatment can be 
chosen. Due to the advanced age of over 70% of prostate cancer patients, and since 90% of 
prostate cancers are discovered at an early stage, the treatment of choice is watchful waiting, 
also called active surveillance or expectant therapy. A medical or an interventional treatment is 
usually recommended for high-grade cancers, while observation may be recommended for low-
grade cancers, especially when the patient is elderly or has other medical conditions.9 
Watchful waiting is an option recommended for patients with early-stage prostate cancer, 
particularly those who have low-grade tumors (low Gleason score, low PSA levels) with only a 
small amount of cancer seen in the biopsy specimen and nonpalpable tumors. Older patients 
and those with serious medical problems are also good candidates for active surveillance. These 
patients have regular examinations (DRE), PSA testing, and sometimes scheduled biopsies. If 
there is evidence of cancer growth, active treatment may be recommended. The risk of this 
treatment is that the tumor may grow between monitoring visits and spread to other parts of 
the body. 
There are two kinds of radiation therapy: internal and external radiation therapy. They both 
involve the delivery of radiation energy to the prostate in order to slowly disintegrate the 
tumor. Brachytherapy is a minimally invasive internal radiation therapy, which involves 
implanting low or high dose radiation (LDR or HDR) seeds in the prostate using a needle. This 
therapy is usually more effective for younger patients in good health with localized prostate 
cancer. It has recurrence-free survival rates of 77-93%. Possible side effects are scrotal burning, 
incontinence and impotence. Electron beam radiation therapy (EBRT) is the most common 
external radiation therapy. Intensity modulated (IMRT) and 3D-conformal RT (3D-CRT) are 
newer noninvasive variations of EBRT. The energy is usually delivered in an outpatient setting 
using an external beam of radiation 5 times a week over 6-8 weeks. Success rates lie over 85% 
especially when used in combination with other therapies like a hormonal therapy. Side effects 
may include tiredness, diarrhea, frequent and burning urination and proctitis (inflammation of 
the anus and the lining of the rectum). 
Radical prostatectomy is a surgical procedure to remove the entire prostate gland and 
nearby tissues, sometimes even lymph nodes in the pelvic area. It is an aggressive, major 
intervention (even though sometimes a milder, laparoscopic surgery may be possible), reason 
why it cannot be performed in elder patients. The major side effect of this operation is that not 
always a nerve-sparing surgery, for the nerves needed for an erection, is possible. 
Since the rate of cell division in prostatic adenocarcinomas is comparable to that of healthy 
cells, chemotherapy is not a suitable therapy. Nevertheless, it is used as a salvage (last resort) 
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therapy for metastatic prostate cancer to slow disease progression and postpone symptoms. 
The most commonly used chemotherapeutics for prostate cancer are: mitoxantrone, 
doxorubicin, vinblastine, paclitaxel, docetaxel, etoposide and estramustine (prostate cancer 
specific alkylating agent). 
Cryosurgery is the use of needles to apply freezing gases in this case to kill cancerous cells in 
localized cancers. It is an alternative for external radiation resistant cancers and an effective 
primary treatment for early stage prostate cancer. The freezing and thawing processes destroy 
cells through dehydration, drastic changes in the pH levels, or prevention of the flow of red 
blood cells. Subjecting the prostate gland to freezing temperatures, specifically negative 40 
degrees Celsius, also activates an anti-tumor response in the body. The procedure lasts no 
longer than two hours, with a possible overnight admission. Data for survival rates are not yet 
established, but very promising. Side effects may include pelvic pain, scrotal swelling and 
impotence. 
Hormonal therapies aim at reducing androgen levels, hence the name androgen suppression 
(AS) or androgen deprivation therapies. Proof of principle was achieved already in the 1940s by 
C. B. Huggins, Nobel Prize for Physiology or Medicine (1966) holder, and C. V. Hodges,10 for 
proving androgens as an important growth factor for prostate cancer. He did so by 
demonstrating in castrated and testosterone suppressed rats (treated with estrogens) the 
regression of an implanted prostate cancer tumor. Nowadays there are several classic and new, 
experimental AS approaches. The classical procedure by excellence is the surgical removal of 
the testes (orchiectomy). Through this invasive therapy, the production of about 90% of all 
androgens may be stopped. The remaining androgen production is mainly carried out in the 
adrenals, which is enough to keep the tumor on growing, reason why orchiectomy is usually 
accompanied by medical castration. 
The medical castration called combined or multiple androgen blockade (CAB), also called 
combined or total hormone blockade, is another classic AS therapy. Commonly, CAB treatment 
starts with an antiandrogen (flutamide, bicalutamid: androgen receptor antagonists; 
finasteride, dutasteride: 5α-reductase inhibitors), a few weeks after which a gonadotropin-
releasing hormone (GnRH) agonist (buserelin, goserelin) is administered. GnRH agonists 
themselves lead to a hormone flare which is a reaction that causes the body to flood with 
testosterone for 7 to 10 days. This can be painful, deadly, or both for patients with advanced 
prostate cancer with distant bone metastasis. Antiandrogens block the body’s ability to use 
testosterone, so the flood of testosterone never reaches the prostate gland. This form of 
combined androgen blockade is common for patients in later stages of prostate cancer. 
Very often after a medical or surgical castration, prostate cancer cells become resistant to an 
AS therapy and become so called androgen or castration-resistant, or hormone-refractory or 
  
 
Introduction – I.4. CYP17 37 
castration refractory prostate cancer (HRPC). Antiandrogens then stimulate cancer growth, 
while its removal initially stops cancer from growing. This is one of the main reasons why AS 
therapy, being also a mild one, is usually saved as a last resort for after the patient has 
developed metastatic prostate cancer and become also considerably older. 
A hormonal therapy, suitable for early and advanced (metastatic), as well as for HRPC, is the 
use of CYP17 inhibitors. By blocking the biological pathway of androgen biosynthesis at an early 
stage, production of testosterone and all other androgens may be stopped in the testes, 
adrenals and in the castration-resistant prostatic tumor, thus preventing the tumor from 
growing further and, according to recent studies, even delaying the development of bone 
metastasis for a period of up to eight years.11 
 
I.4. CYP17 
 
I.4.a. CYP Superfamily 
CYP is the abbreviation for cytochrome P450. Cyto is derived from the Greek κίτοσ (kytos) 
which means a hollow, cell or container, and chrome from the Greek χρώμα (chroma), which 
means color. ‘P450’ refers to a feature of this pigment (hence ‘P’) in the carbon monoxide 
absorption difference spectrum at 450 nM caused by the presence of a thiolate in the axial 
position of the heme (a porphyrin complexing an iron(III) cation) in the active site, opposite to 
the carbon monoxide ligand. Thus, cytochrome P450 makes allusion to the 450 nM color 
absorbing enzyme in cells. Cytochrome P450 is a very large and diverse superfamily of 
hemoproteins (heme containing), member of an even wider superfamily of heme-containing 
monooxygenases, besides secondary amino monooxygenase – SAMO, and heme chloroperoxi-
dase – CPO. CYPs are involved in xenobiotic (foreign bodies, drugs) metabolism (70-80% of 
human xenobiotic metabolism), cholesterol biosynthesis, and steroidogenesis (synthesis of 
steroids) in eukaryotic organisms (thus in humans) and are found mainly in the endoplasmic 
reticulum and inner mitochondrial membrane of cells. CYP enzymes usually contain about 500 
amino acids, and more than 7700 distinct CYP sequences (thus 7700 different enzymes) are 
known. They have been identified from all lineages of life, including mammals, birds, fish, 
insects, worms, sea squirts, sea urchins, plants, fungi, slime molds, bacteria and archaea. 
In the human species, 18 CYP families divided in 43 subfamilies are present, containing 
altogether 57 genes and 59 pseudogenes. Each gene is responsible for coding one protein, 
resulting thus in 57 human CYP enzymes. Families may be divided according to their biological 
function in: drug and steroid metabolism (CYP1, CYP2, CYP3) through redox metabolism (mainly 
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for the excretion of xenobiotics) or anabolism (biosynthesis), and steroid anabolism 
(biosynthesis; CYP11, CYP17, CYP19, CYP21), while the other enzymes are involved in the 
metabolism of vitamins (CYP24, CYP26), cholesterol (CYP39, CYP46, CYP51), fatty acids (CYP4) 
or varied functions (CYP5, CYP7, CYP8, CYP27), or have even yet unknown function (CYP20). 
The monooxygenase reaction, also called oxyreductase, is the insertion of one atom of 
oxygen into an organic substrate (RH) while the other oxygen atom is reduced to water: 
RH + O2 + 2H
+ + 2e- → ROH + H2O 
This sum reaction is actually a part of a catalytic cycle (Figure 6). In the normal state, the 
iron(III) is coordinated by the porphyrin, the thiolate of the cysteinate, which holds the heme, 
and a water molecule. The cycle starts with the displacement of the water molecule by the 
substrate (1), leading to the donation of an electron by the cofactor NAD(P)H (2), thus changing 
the oxidation of the ferrous iron(III) to ferric iron(II). Through addition of an oxygen molecule 
(3), the oxidation step changes back to (III) and a second electron coming usually from 
cytochrome b5 (cyb5) negatively charges the oxygen (4). A water molecule results from the 
successive addition of two protons, proceeding from surrounding water or amino acid residues, 
and resulting in a highly reactive iron(V)-oxo system (5). The oxygen then inserts between the 
R-H bond of the substrate (6), thus returning the electronic configuration of the iron back to (III) 
which is stabilized again by a water molecule. 
 
Figure 6. CYP catalytic cycle 
under presence of NADPH and 
cyb5 as cofactors (1-6), the 
‘peroxide shunt’ under presence 
of a peroxide (S) and 
complexation with CO2 (C). 
from http://commons.wikimedia.org/wiki/Image:P450cycle.svg 
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I.4.b. Steroidogenesis and Physiological Role 
While drug metabolism is mainly regulated by CYP enzymes, mineralo- and glucocorticoids, 
and sex steroids are also mainly synthesized by CYP enzymes. Cytochrome P450 17α-
hydroxylase/17, 20-lyase (17α-hydroxylase and 17, 20-lyase refer to the catalytic properties of 
the enzyme to hydroxylate the carbon 17 in α position and to cleave the bond between carbon 
17 and 20), or CYP17 for short, is the key enzyme in the biosynthesis of sex-steroids (Figure 7). 
It is a microsomal P450 system anchored to the membrane of the endoplasmatic reticulum and 
consists of 467 amino acids. CYP17 is located in membranes of the adrenal cortex, testis and 
ovary. Bound to the membrane next to it are the electron-transferring cofactor cyb5 and the 
P450 reductase, which on its part transfers an electron from the cofactor NADPH, as explained 
in the common mechanism for the monooxigenase or hydroxylase activity of CYP enzymes 
(Figure 6). Although the exact mechanism for the lyase step is yet unknown, it is believed, that 
it follows the tetrahedric nucleophillic addition (SNt) of the iron(III)-bound oxygen radical to the 
carbon 20, resulting in a tetrahedric intermediate, for the steroid to leave it then through the 
cleavage of the 17-20 bond. 
Making use of its hydroxylating properties, CYP17 catalyzes the conversion of progesterone 
and pregnenolone into the corresponding 17α-hydroxy intermediates, as well as corticosterone 
into cortisol and corticosterone into cortisol (Figure 7). Through its lyase abilities, it yields the 
C19 androgens (they have only 19 carbons) androstenedione and dehydroepiandrosterone 
(DHEA) from their respective hydroxylsubstrates. Androstenedione and DHEA are transformed 
into each other through the catalytic properties of 3beta-HSD. From there on, estrone and 
testosterone are synthesized from androstenedione, while the most potent estrogen and 
androgen, estradiol and dihydrotestosterone, both derive from testosterone. By inhibiting 
CYP17, the production of all androgens (male hormones) and estrogens (female hormones) is 
stopped. In the adult or senior man, this blockade has minor side effects regarding the 
suppression of estrogens as well as androgens. The apparent obstruction of cortisol production 
by CYP17 inhibition can be overpassed through alternate pathways (Figure 7), while CYP17 
inhibitors have demonstrated not to lower cortisol plasma concentration in clinical trials, but to 
only bring it back to normal values in Synacthen (induces cortisol production) pre-treated 
patients. Besides, the 50-100-fold elevations of corticosterone have enough weak 
glucocorticoid activity to prevent glucocorticoid deficiency and adrenal crisis. Furthermore, the 
cortisone-cortisol equilibrium also prevents the absence of cortisol. 
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C. B. Huggins and C. V. Hodges showed in the 1940s that surgical castration leads to the 
inhibition of tumor growth in rats, which was attributed to the lower testosterone levels, 
induced years later in another test through the application of estrogens.10 F. Labrie, the founder 
of CAB, hypothesized in the 1980s that additionally counteracting adrenal androgens by 
application of antiandrogens would further inhibit tumor growth.12 This approach has been 
widely used in the past and has shown partially positive results, especially in patients with 
minimal disease and good performance status.13 Nevertheless, notable side effects are 
observed, such as heart disease and development of androgen-resistant metastases for which 
this treatment is not suitable anymore.14 
Testicular, adrenal and tumor in situ androgen level suppression may be achieved by other 
approaches, such as targeting CYP17. 
 
I.4.c. Novel Target for Prostate Cancer: State of the Art 
Many are the facts which account for the advantage of a CYP17 inhibitory therapy. As 
already mentioned, this mild therapy is best suited for patients of advanced age, as is the case 
of most prostate cancer patients. Since all prostate cancers are androgen-dependant at the 
beginning, and most of them are diagnosed at an early stage, this could be the best option as 
initial treatment for preventing their growth and spreading, thus shrinking the tumor. Because 
of the gentle nature of the AS therapy and the good results in controlling advanced cancers, 
and also because of the slow cell-division rate of prostate cancer, the treatment of choice is 
watchful waiting to save the AS therapy for when the cancer has advanced (and the patient is 
much older, thus more difficult to be treated). Sometimes during the normal development of 
Figure 7. Steroidogenesis of androgens 
(blue), estrogens (red), gluco- and 
mineralocorticoids (green) and alternative 
pathway for the synthesis of cortisol 
(yellow arrows). 
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the disease, as well as after most AS therapies, prostate cancers metastasize and become 
resistant to current AS therapies. This is believed to be due to the storage of androgens in the 
tumor and to the natural mutation of the tumor cells to produce androgens themselves. Since 
CYP17s expression is up-regulated in such castration-resistant metastases, its inhibition should 
be the best method to further lower androgen levels in situ in such cells.15 Summarizing, CYP17 
inhibitory therapy is not only suited but also apparently the best option for treating prostatic 
adenocarcinomas of any grade and stage. 
Proof of principle was achieved by ketoconazole (Figure 8), the first CYP17 inhibitor to be 
used off-label for the treatment of prostate cancer. Because of the external mode of use of this 
antimycoticum, selectivity issues for an internal use were not considered. Due to its unselective 
inhibition of many different CYP enzymes, this drug was considered to be too toxic for 
systematic use and its usage discontinued.16 
Despite of the market’s low rentability for the development of new prostate cancer drugs, 
due to the advanced age of the patients, the slow nature of the disease, and the excuse of the 
high 5-year survival rates (it is the second leading cause of death among cancers due to the high 
occurrence and recurrence of prostate cancer), some industrial companies (Cougar 
Biotechnology, Takeda and others) and academic research groups (Hartmann, Brodie, Miller 
and others) investigate in the CYP17 inhibitory field. In this way, abiraterone (Figure 8) was 
developed by Cougar Biotechnology, and is recently undergoing phase III clinical trials.17 It 
shows high activity in post-docetaxel HRPC patients, produces no alteration of cortisol levels 
and, in contrast to ketoconazole, it seems to have no dose-limiting toxicity. The main drawback 
of this drug is its steroidal scaffold, as steroidal compounds often show side effects due to 
interactions with steroid receptors. 
N N O
O
O
N
N
Cl
ClO
ketoconazole abiraterone
N
HO
pregnenolone
HO
O
Figure 8. Pregnenolone as 
CYP17 substrate for androgen 
biosynthesis, ketoconazole as 
unselective non-steroidal 
CYP17 inhibitor, abiraterone 
as substrate-derived CYP17 
inhibitor. 
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II. Aims and Strategy of this Work 
 
II.1. Problematic and Aims 
Prostate cancer is one of the major causes of death in the male population. Relying on its 
mildness, effectiveness and clinical experience, the most promising prostate cancer therapy is 
androgen suppression (AS). One drawback of surgical and medical AS treatment is their limited 
and insufficient inhibition. Besides, another main drawback of medical AS is that current 
antiandrogens stimulate the development of hormone-refractory prostate cancer (HRPC). 
Those are the reasons why AS is not made use of for early cancers, even if it has been shown to 
relay bone metastasis for eight years in early cancers. This drawback should be overcome by 
CYP17 inhibitors, which should be equally and even more effective in HRPC. Since CYP enzymes 
are the main responsibles in xenobiotic metabolism, hepatotoxicity is a main issue in the 
development of such inhibitors. One steroidal CYP17 inhibitor is currently in clinical trials, while 
others are being developed. Nevertheless, steroidal drugs usually account for several side 
effects. 
The sequence identity and sequence homology between CYP enzymes is usually very high. 
Furthermore, they have a very similar secondary protein folding, thus very similar binding sites. 
In such manner, the selectivity issue becomes even much more critical while trying to develop 
CYP17 inhibitors, which should inhibit the enzyme of transforming the substrate by blocking its 
binding site. Furthermore, the substrates for the sex and mineralo- and gucocorticoid forming 
enzymes bear all a steroidal scaffold and are respectively very similar. All these similarities 
increase furthermore the relevance of developing nonsteroidal inhibitors in order to achieve 
selectivity towards CYP enzymes. 
These selectivity problems and the fact, that CYP17 is a vital enzyme, makes the use of 
suicide inhibitors, that means inhibitors which bind covalently, thus irreversibly, to the enzyme, 
unacceptable. 
In such manner, our aims are the design, synthesis and evaluation of potent and selective 
nonsteroidal competitive CYP17 inhibitors, which should complex but not covalently bind to the 
substrate’s binding site. 
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II.2. Working Strategy 
 
II.2.a. Molecular design 
 
In this work, a classical medicinal chemistry approach was used. Starting from compounds 
with known CYP17 activity, other core structures were designed and synthesized, and evaluated 
step by step regarding their potency and selectivity (‘screening’), in order to repeteadly 
optimize them, through small structural variations, in terms of potency and selectivity toward 
other therapeutical targets. 
In such manner, starting from biphenylic compounds (Figure 9), aromatic and heteroarylic 
annulations to both benzene rings were made, leading to two major compounds classes: ABD- 
and ACD-ring substrate mimetic naphthalenes as CYP17 inhibitors. From there on, through 
replacement of the D-ring with a more similar to the substrate 5-membered aryl, and making 
use of the knowledge gained about functional groups interacting with our enzyme which was 
reaffirmed by modeling studies, abiraterone analogues were achieved as highly potent and 
selective CYP17 inhibitors. 
 
 
 
 
  
 
 
 
 
Figure 9. Designed, synthesized and evaluated classes, developed through the medicinal chemistry approach 
used, and CYP17’s binding site from our enzyme model. In light green, pregnenolone as substrate; in magenta, the 
enzyme’s heme; and in red, dark green, blue, yellow, orange and cyan, the enzyme’s tertiary structure. 
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Subject of this work are the mentioned classes of the annulated biphenyls, ABD- and ACD-
ring mimetics and abiraterone analogues as CYP17 inhibitors and pyridyl-substituted 
naphthalenes as dual inhibitors of CYP17 and CYP11B2 published in three major scientific 
journals with the primary author listed as first author and some other also highly potent 
compounds belonging to similar classes, synthesized by the same person, and mentioned 
before the introduction of this work. 
Very important for inhibiting a binding site is to have the certainty of how a compound will 
lie in the pocket, and in which direction it will orient itself. Thus, the key consideration for 
inhibiting a CYP enzyme’s binding site is in relation to their common feature: the heme. 
Substrates will orient towards the heme, since the catalytic reactions are performed in that 
region. Because of that, the heme iron is a good anchor point for blocking the binding site, 
fixing the inhibitor in the catalytic region of the enzyme. sp2 hybridized nitrogen atoms are well 
known to be very good at complexing iron(III) ions, and many N-bearing aromatic heterocycles 
are described, pyridine undergoing one of the best coordinations. 
Other important characteristics of the substrates to be considered, in order to maximally 
increase the chance of our compounds to lie in the same manner as them, are the lipophillity, 
and planarity and rigidity of the steroidal backbone. This is successfully maintained in the 
developed aromatic systems, leading to good inhibitory results. 
A third characteristic germane to the substrates is the oxygen functionality at the carbon 3 
position. This was also to be carried over to our systems through the introduction of different 
electron donor and acceptor groups. 
 
II.2.b. Biological Evaluation 
In order to evaluate and successfully identify potential therapeutic drugs, our well-
established screening system (Figure 10) was used. After the design and synthesis of 
prospective candidates, they were initially tested for their CYP17 inhibitory potency using our in 
vitro human CYP17 assay, by incubating the microsomal fraction of our recombinant E. coli cells 
stably expressing human CYP17. The products were detected and quantified by means of UV-
spectroscopy.
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Highly active and promising compounds were subsequently tested for hepatotoxicity on 
different naked hepatic enzymes (BD Biotechnologies, Supersomes™), such as CYP3A4, 
responsible for over 50% of xenobiotic metabolism, CYP2D6 and CYP1A2, which show 
pronounced genetic polymorphism and other enzymes, CYP2B6, CYP2C9 and CYP2C19, all 
relevant to xenobiotic metabolism, and which constitute altogether more than 90% of drug 
metabolism. 
Later on, highly active, non-toxic compounds were evaluated for inhibitory activity on human 
CYP11B2 and human CYP11B1, using respective recombinant V79 cells for each enzymatic 
assay. The assays were performed analogously, as previously described by us. The importance 
of testing our compounds for selectivity in both enzymes relies on the facts described above: 
similarity between CYP17, CYP11B2 and CYP11B1 (chapters I.4 and I.5). 
Selected, highly promising compounds are to be tested later on in an NCI-H295R (a human 
adrenocarcinoma cell line) cells test, expressing CYP17, CYPscc, CYP11B2, CYP11B1, CYP21, and 
many other relevant enzymes, and thus resembling a self-consistent a priori steroidogenetical 
model suitable for predicting the overall influence of the test compounds in a more complex 
environment similar to a cancerous tumor. Following that test, compounds are to be evaluated 
in a rat testes test, allowing to observe, between other important factors, if the designated 
compounds show similar activity on the rat enzyme, before testing them in the living animal. 
This has to be checked before, since there are differences between the enzymes of both species 
with underlying 68% sequence identity and 82% homology. The final pre-clinical step 
performed by us is the in vivo evaluation in the rat and eventually in other animals, for the 
determination of pharmakokinetics and -dynamics. 
Figure 10. Screening 
system used by us for the 
evaluation of the 
synthesized compounds as 
CYP17 inhibitors 
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Abstract 
Twenty-one novel compounds originating from two classes of annulated biphenyls were 
synthesised as mimetics of the steroidal A- and C-rings and examined for their potency as 
inhibitors of human CYP17. Selected compounds were tested for inhibition of the hepatic CYP 
enzyme 3A4. Potent CYP17 inhibitors were found for each class, compound 9 (17 and 71% at 
0.2 and 2 µM, respectively) and 21 (591 nM). Compound 21 showed only weak inhibition of 
CYP3A4 (32 and 64% at 2 and 10 µM, respectively). Both compounds, however, exhibited 
moderate to strong inhibition of the glucocorticoid-forming enzyme CYP11B1. The most 
interesting compounds were docked into our protein model. They bound into one of the modes 
which we have previously published. New interaction regions were identified. 
 
Introduction 
Prostate cancer is a major cause of death in elderly men worldwide.1 It is widely 
demonstrated that high androgen levels (testosterone and dihydrotestosterone) stimulate 
tumor growth in prostate cancer.2 Thus, androgen receptor antagonists3 and gonadotropin-
releasing hormone analogues4 are used as a standard therapy. The major drawback of these 
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therapies is the fact that they do not reduce androgen concentrations or only affect testicular 
androgen production, allowing androgens still to be produced in the adrenals. 
Therefore, a new promising target is 17α-hydroxylase-17, 20-lyase (CYP17), the key enzyme 
for the biosynthesis of androgens. It is catalyzing the conversion of pregnenolone or 
progesterone to DHEA or androstenedione, respectively. Even more, this target has already 
clinically proven success with the antimicotic ketoconazole which is also a weak inhibitor of 
CYP17.5 In previous works, we could demonstrate in-vitro and in-vivo activity for steroidal6 and 
non-steroidal7-10, 11 compounds. Some of these compounds had been designed as mimetics of 
the steroidal AC-rings (Chart 1).10, 11 Since they had shown a high activity and a good selectivity, 
we chose them for further optimizations. 
Very recently,12 we found new highly potent 
and selective compounds, which showed better 
pharmacokinetic and pharmacodynamic 
profiles than abiraterone, a CYP17 inhibitor 
currently undergoing clinical phase II,13 by 
replacing the A-ring-mimicking benzene nucleus 
with different heterocycles. 
In order to further explore the spatial 
limitations surrounding the A- and C-ring 
binding regions, in this work, we expand the 
corresponding biphenyl rings by annulations of 
different aromatic and non-aromatic rings. In 
this way, two different compound classes were 
synthesised (Chart 2), by either annealing the C-
ring (compounds 1-11) or by otherwise 
annealing the A-ring (compounds 12-21). Like in 
previous works,10-12 1-imidazole linked with a 
methylene spacer was introduced as 
nitrogen-bearing heterocycle, since the 
complexation of the heme iron by an 
aromatic nitrogen is an important prerequisite for inhibition of cytochrome P450 enzymes.14 
We have also shown10-12 that the introduction of a fluorine, hydroxy, and methoxy group in the 
A-ring strongly contributed to a better inhibition of our target enzyme. 
In the following, the synthesis, CYP17 inhibitory activities, and molecular modelling studies 
are presented and these data are compared to the ones recently obtained with ABD- and ACD-
N
N
R1
R2N
N
R
O
HO
A
C
B
D
C
A
D
B
Pregnenolone
ABD-ring mimetics ACD-ring mimetics
N
N
R1
R2N
N
R
C
A
C
A
A-ring annulated C-ring annulated
D
A
HO
A
C
B
D
Abiraterone
N
n
n
Chart 1. Substrate, abiraterone, described ABD- 
and ACD-ring mimetic CYP17 inhibitors and A- and C-
ring annulated compounds of the present study. 
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ring mimetics (Chart 1).9 Besides, for reasons of selectivity, inhibition of the most crucial hepatic 
CYP enzyme CYP3A4 was monitored, and for selected compounds inhibition of the 
glucocorticoid-forming enzyme CYP11B1 was also determined. The most promising compounds 
were docked into our protein model, and the key interactions with the enzyme were 
elucidated. 
N
H
F
N NS
R1O
X
R1O
N N
R3
R2
N
N
R1
N
N N
 
                      1, 2                                                  3                                           4, 5                                             6-11 
N
R1X
N
R2
N
S
N
N N N
O
O
N N
R2
 
 
                    12-16                                            17                                              18                                            19-21 
 
Compound R1 R2 R3 X 
1 Me    
2 H    
4 p-F-(C6H4)    
5 3-thiophenyl    
6 Me H H CH 
7 H H H CH 
8 Me Et H N 
9 H Et H N 
10 Me Et Et N 
11 H Et Et N 
12  Et  S 
13  Et  NH 
14  H  O 
15  H  S 
16  H  NH 
19 OMe H   
20 H H   
21 OH Et   
 
Chart 2. List of synthesised compounds 1-21. 
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Chemistry 
The syntheses of compounds 1-21 are shown in Schemes 1-7. In pursuing our aim to explore the 
binding regions surrounding the A- and C-rings, different aromatic and non-aromatic moieties 
were annulated to the A (Schemes 1-5) or C (Schemes 6, 7) ring. The coupling of the biphenylic 
moiety was achieved by means of Suzuki coupling15 (Method C) except for the synthesis of 
compounds 1 and 2 (Scheme 1) where a Negishi coupling had to be applied. When the 
necessary bromides for the couplings were not commercially available, they were prepared by 
bromination using NBS (N-bromosuccinimide) (Scheme 3). The imidazoles were introduced by 
performing a SNt reaction with 1,1’-carbonyldiimidazole (CDI) and the corresponding alcohol
16 
(Method A) or via SN2 reaction of an alkyl bromide with imidazole (Scheme 3).The alcohols were 
obtained from either the carboxylic derivatives (Schemes 1, 4) or from the aldehydes (Methods 
D, E). In most cases, the methoxy-substituted compounds were submitted to an ether cleavage 
(Method B). For the preparation of compound 21, the hydroxyl group on the naphthalene had 
to be protected before the Suzuki coupling due to otherwise very low yields.15 
 
 
 
Scheme 1. Synthesis route of compounds 1 and 2 
Reagent and conditions: (i) a: 4-bromo-anisole, tert-
BuLi, THF, -78°C, 30 min; b: ZnCl2, 0°C, 30 min; c: 
PdCl2(PPh3)2, 16 h; (ii) LiBH4, toluene, THF, Et2O, 
110°C, 16 h; (iii) Method A1: CDI, imidazole, NMP, 
180°C, 16 h; (iv) Method B: BBr3, DCM, -78°C to 0°C, 
16 h. 
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3b 3a 3
Scheme 3. Synthesis route of compounds 4 and 5 
Reagents and conditions: (i) NBS, CCl4, 75°C, 16 h; (ii) 
Imidazole, K2CO3, 18-crown-6, acetonitrile, 100°C, 16 h; 
(iii) Method C1: 4-fluorophenylboronic acid (5: 3-
thiophenylboronic acid), Na2CO3, Pd(PPh3)4, 
toluene/MeOH/H2O, 70°C, 5 h. 
N (i) N
Br Br
4a
4b
4: R = p-F-(C6H4)
5: R = 3-thiophenyl
Br
N
Br
N N
N
R
N N
(ii) (iii)
Scheme 2. Synthesis route of compound 3 
Reagent and conditions: (i) Method C1: Na2CO3, Pd(PPh3)4, toluene/EtOH/H2O, reflux, 5 h; (ii) Method D: 
NaBH4, MeOH, rt, 2 h; (iii) Method A2: CDI, acetonitrile, reflux, 18 h. 
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Scheme 4. Synthesis route of compounds 6 and 7 
Reagents and conditions: (i) KMnO4, pyridine, H2O, 50°C, 
4 d; (ii) LiAlH4, Et2O, 35°C, 16 h; (iii) Method C2: 4-
methoxyphenylboronic acid, Cs2CO3, Pd(OAc)2, TBAB, 
toluene/EtOH/H2O, 110°C, 16 h; (iv) Method A1: CDI, 
imidazole, NMP, 180°C, 2 d; (v) Method B: BBr3, DCM, -
78°C to 0°C, 16 h. 
Scheme 5. Synthesis route of 
compounds 8-11 
Reagents and conditions: 
(i) Method C2: 4-methoxyphenylboronic acid, Cs2CO3, 
Pd(OAc)2, TBAB, toluene/EtOH/H2O, 110°C, 16 h; (ii) 
Method E: EtMgBr, THF, 0°C to rt, 16 h; (iii) Method A1: 
CDI, imidazole, NMP, 180°C, 1-2.5 d; (iv) Method B: BBr3, 
DCM, -78°C to 0°C, 16 h. 
Y
X
Br
(HO)2B
CHO
+ Y
X
CHO
Y
X
OH
R
Y
X
N
R
N
(i) (ii) or (iii)
(iv) 12: X= S, Y= CH, R= Et 13: X= NH, Y= CH, R= Et
14: X= O, Y= CH, R= H 15: X= S, Y= CH, R= H
16: X= NH, Y= CH, R= H
17: R= H 18: R= H
12b-16b 12a-18a
12-18
O
O
S
N
O
19b, 20b: (iii) OH 19a, 20a: (v) N N
R1 R1 R1
19a: R1= OMe, R2= Et, R3= H
20a: R1= H, R2= Et, R3= H
21b: R1= TBDMSO, R2= R3= Et
19b: R1= OMe, R2= Et
20b: R1= H, R2= Et
21c: R1= TBDMSO, R2= H
R2R3R2R3
19: R1= OMe, R2= Et, R3= H
20: R1= H, R2= Et, R3= H
21: R1= OH, R2= R3= Et
21b: (v), (vi)
R2
21c: (iv)
Scheme 6. Synthesis route of compounds 12-18 
Reagents and conditions: (i) Method C1: Pd(PPh3)4, TBAB, Na2CO3, toluene/EtOH/H2O, reflux, 16 h; (ii) Method 
E: 12a-13a: EtMgBr, THF, 0°C to rt, 16 h; (iii) Method D: 14a-18a: NaBH4, MeOH, reflux, 2 h; (iv) Method A1: 
CDI, NMP, reflux, 3 h. 
Scheme 7. Synthesis route of compounds 19-21 
Reagents and conditions: (i) TBDMSCI (tert-Butylchlorodimethylsilane), CH2Cl2, imidazole, rt, 4 h; (ii) Method 
C1: boronic acid, Na2CO3, Pd(PPh3)4, toluene/MeOH/H2O, 70°C, 5 h; (iii) Method D: 19b, 20b: NaBH4, MeOH, 
reflux, 2 h; (iv) Method E: 21c: EtMgBr, THF, rt, 5 h; (v) Method A1: 19a, 20a: CDI, NMP, 170°C, 7 h; (vi) 21b: 
TBAF, THF, rt, 4 h. 
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Results 
Biological Results. Inhibition of CYP17 was evaluated using human enzyme expressed in E. 
coli.17 The percent inhibition values of the compounds were determined with the 50,000 g 
sediment of the E. coli homogenate, progesterone (25 µM) as substrate and the inhibitors at 
concentrations of 0.2 and 2.0 µM. Separation of substrate and product was accomplished by 
HPLC using UV detection.7 
In contrast to the reference compound ketoconazole, the C-ring-annulated compounds (1-
11, Table 1) mostly showed moderate to no inhibition with exception of the quinoline 
compound 9, which showed 71% inhibition at 2 µM. The prolongation of the C-ring in 
compounds 1-5 led to non-active compounds. The quinolines 8-11 bearing an ethyl moiety at 
the methylene linker showed an overall better activity than the naphthalenes 6 and 7. 
Table 1. Inhibition of CYP17 by C-ring annulated compounds 1-11 
 
 
 
                        1, 2                                                  3                                           4, 5                                             6-11 
 
Comp. 
Structures CYP17 
R1 R2 R3 X % Inhibition 
a 
0.2 μM 2 μM 
1 Me    0 18 
2 H    6 13 
3     0 12 
4 p-F-(C6H4)    1 12 
5 3-thiophenyl    0 11 
6 Me H H CH 0 5 
7 H H H CH 1 12 
8 Me Et H N 3 32 
9 H Et H N 17 71 d 
10 Me Et Et N 6 57 
11 H Et Et N 5 57 
KTZ b     19 c 
 
a
 Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. 
Concentration of progesterone (substrate) was 25 μM.  
b 
KTZ: ketoconazole. 
c 
% inhibition at 1.0 μM. 
d
 IC50= 817 nM 
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The A-ring-annulated compounds (12-21, Table 2) showed moderate to good activities. 
However, they did not exceed the activity of compound 9. The most active compounds in this 
class showing percent-inhibition values of more than 70% at 2 µM are compound 13 bearing an 
indole (H-bond donor) and compounds 19 and 21 bearing a methoxy group (H-bond acceptor) 
or a hydroxyl group (H-bond acceptor and donor), respectively, at the 6-position of a 
naphthalene. Absence of these substituents in the latter compounds diminishes the inhibitory 
activity (compound 20). The introduction of an ethyl moiety at the methylene linker led to an 
increase in activity for compounds 15 to 12 and 16 to 13. All other aromatic heterocycles 
resulted in only moderate inhibitors. 
Table 2. Inhibition of CYP17 by A-ring annulated compounds 12-21 
 
N
R1X
N
R2
N
S
N
N N N
O
O
N N
R2
 
                  12-16                                            17                                              18                                            19-21 
 
 
Comp. 
Structures CYP17 
R1 R2 X % Inhibition 
a 
0.2 μM 2 μM 
12  Et S 7 40 
13  Et NH 21 75 d 
14  H O 5 27 
15  H S 0 21 
16  H NH 2 39 
17    5 39 
18    0 17 
19 OMe H  19 74 e 
20 H H  7  43 
21 OH Et  16 74 f 
KTZ b    19 c 
 
a
 Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. 
Concentration of progesterone (substrate) was 25 μM.  
b 
KTZ: ketoconazole. 
c 
% inhibition at 1.0 μM. 
d
 IC50= 667 nM. 
e
 IC50= 703 nM. 
f
 IC50= 591 nM. 
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When comparing the activities of the compounds of this study to the ones of the parent 
compounds,11 it must be mentioned that the structural modifications did not increase activities. 
Regarding selectivity against other CYP enzymes, a broader spectrum of our compounds was 
tested for inhibition of the hepatic enzyme CYP3A4. This enzyme is responsible for the 
metabolism of lipophilic substances and, therefore, responsible for about 50% of current 
prescription drugs.18 While compounds 12-19 showed a strong inhibition of this enzyme (>85% 
inhibition at 2 µM), compound 21 exhibited low inhibitory activity towards CYP3A4 (32% at 2 
µM and 64% at 10 µM). 
Thus, compound 21 together with the most promising compound 9 of the C-ring-annulated 
class of compounds, were further tested for inhibition of the steroidogenic enzyme CYP11B1. 
Its importance relies on the fact that it catalyzes the last step in glucocorticoid formation, 
namely the transformation of 11-deoxycortisol into cortisol. For the assay,19 V79MZh11B1 cells 
expressing human CYP11B1 were used. Both compounds showed strong inhibition of the 
enzyme at the tested concentrations (9: 86 and 94% at 0.2 and 2 µM; 21: 81 and 95% at 0.2 and 
2 µM). 
Molecular Modelling. Using selected compounds, we explored the binding modes of the A- 
and C-ring-annulated biphenyls. Several active and less active compounds (C-ring: 6-11 (R, S); A-
ring: 13 (R, S), 16, 17, 19 (R, S) and 21) were docked by means of the GOLD v 3.0.1 software20 in 
the active site of our homology model of CYP17.12 
Aware of the limitations of docking,21 the resulting poses of each compound were clustered 
with AClAP (autonomous hierarchical agglomerative cluster analysis)22 and the representative 
poses of each cluster were subjected to a critical visual inspection. H-bonds, π-π, and 
hydrophobic interactions, as well as steric clashes were measured and evaluated. The necessity 
of iron-nitrogen complexation14 for inhibitory activity was also considered. Furthermore, the 
GOLD v 3.0.1 software, used with a slightly modified GOLDSCORE, was tested on different 
crystallised CYP enzymes. This program could reproduce quite well the correct orientation of 
co-crystallised ligands (data not shown). Moreover, GOLD v 3.0.1 produced reliable poses for 
abiraterone in our CYP17 model,12 oriented like described for pregnenolone.23 With these 
findings, the obtained results can be considered very probable. 
All compounds principally showed poses in BM1 – one of two binding modes we have 
identified for biphenyl type inhibitors12 – with the modified biaryl-skeleton oriented almost 
parallel to the I-helix (Fig. 1). Furthermore, the observed increase in activity caused by the ethyl 
group at the methylene spacer can be explained by the anchoring function of this substituent, 
namely by hydrophobic interactions with the tiny hydrophobicpocket next to the heme, as 
already described.12 
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(A)                                                                                                  (B) 
 
Figure 1. A cross-section of the solvent accessible surface of CYP17 is shown, revealing the active-site cavity 
with docked: (A) C-ring annulated 6 (green), 7 (yellow), 8 (magenta) and 9 (cyan) and (B) A-ring annulated 
compounds 13 (cyan), 19 (magenta) and 21 (yellow). Further, heme, interacting residues and ribbon rendered 
tertiary structure of the active site are shown. Figures were generated with Pymol (http://www.pymol.org). 
 
Regarding the docked C-ring annulated compounds, both enantiomers of compounds 6-11 
showed mainly one binding mode, except for compounds 6 and 7, which switch the annealed 
ring towards or opposite the I-helix (Fig. 1A). The annealed ring is directed towards the kink of 
the I-helix,12 stabilised in its orientation by π-π and hydrophobic interactions with the residues 
Phe114, Gly301-Ala302, Glu305, Thr306, Ile371, and Val482 (Fig. 1A). Nevertheless, for all three 
compound couples sterical hindrance, changing in its extend from pair to pair (8-9 < 6-7 < 10-
11) between the annulated C-ring and the surrounding amino acids, was observed. The 
extension of the annealed ring system, like the introduction of a space-demanding group, e. g. 
ethyl was crucial, as seen by the reduced activity of compounds 10 and 11 with respect to 8 and 
9. 
For the inhibitory activity of compounds 8-11, the presence of the aromatic nitrogen in the 
annealed C-ring was striking; it delocalizes the negative charge of the ring system and is capable 
of H-bond formation with the catalytically important Thr306 and the 1-N of the imidazole. 
Compounds 6-11 (R, S) showed the ability of forming an H-bond net between the R1 
substituent of the A-ring (Table 1) and the amino acids Arg109 and His235, as it was already 
observed for their parent compounds.9 OH showed the highest activity values, leading to the 
conclusion that an H-bond donor group in this position was necessary. 
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As for the A-ring annulated compounds, 13 (R, S), 16 (R, S), 17, 19 (R, S) and 21 were docked 
into our homology model (Fig 1B). Even these elongated compounds are basically oriented in 
BM1. However, the extension of the A-ring caused a shift in the interaction area. The 
substituent R1 showed H-bond formations with Asn202, Lys231, His235, and, eventually, 
Arg109, but even hydrophobic interactions between the OMe group in R1and Ile198 and Ile238. 
Almost the same hydrophobic interactions, as reported previously,12 between the aromatic 
core structure and the prevalently hydrophobic surroundings of the active site could be 
observed. Additionally, the extended A-ring can undergo π-π and hydrophobic interactions with 
Phe114, Ile205, His235, Gly297, and Thr294. Comparing compounds 13 and 16-17, the presence 
of a H-bond donor hetero-atom in the annealed A-ring appeared necessary for H-bond 
formation with His235 and Asn202, with the intent to mimic the para-OH of some of the most 
active parent compounds.9 
Discussion and Conclusion 
Similar to our ABD-mimetics,9 the annulation at the A-ring led mostly to low to moderately 
active compounds with exception of 9 which showed good inhibition of CYP17. On the other 
hand, the annealing of an additional ring at the C-ring resulted in moderately to highly active 
compounds, similar to our findings in the class of ACD-ring mimetic inhibitors.9 
The best compounds in terms of activity in each class are 9 for the A-ring-expanded and 21 
for the C-ring-annulated compounds. Compound 21 is also selective against CYP3A4. Based on 
both biological results and molecular modelling studies (Fig. 1), we conclude that space 
occupancy in both the A-ring and the C-ring area is appropriate for the design of new lead 
structures. The presence of specific heteroatoms, especially N in the annealed rings, is 
recommended, since this structure modification is capable of H-bond formation and of 
modifying the electrostatic properties of the annealed ring system. The importance for CYP17 
activity of an ethyl substituent at the methylene linker was reiterated as well. 
One of our goals in this work was the discovery of a new, more complex lead structure, with 
the aim of increasing potency and selectivity towards other CYP enzymes. This was achieved 
with compounds 9 and 21. For further increasing the activity of compound 9, we suggest an 
lead structure optimised by substitution of the annealed ring with a 5-membered aromatic ring 
bearing a heteroatom, like imidazole, or the exchange of the whole bicyclic structure at the C-
ring with a 7-membered ring. These modified compounds are likely to better fit in the active 
site, due to reduced steric hindrance and hydrophobic repulsion. 
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Experimental Section 
Chemistry. Melting points were determined on a Mettler FP1 melting point apparatus and 
are uncorrected. IR spectra were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 
1H-NMR spectra were measured on a Bruker DRX-500 (500 MHz). Chemical shifts are given in 
parts per million (ppm), and TMS was used as an internal standard for spectra obtained in 
CDCl3. All coupling constants (J) are given in Hz. ESI (electrospray ionization) mass spectra were 
determined on a TSQ quantum (Thermo Electron Corporation) instrument. Elemental analyses 
were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland 
University. Column chromatography was performed using silica-gel 60 (50-200 µm), and 
reaction progress was determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). 
Boronic acids and bromoaryls used as starting materials were commercially obtained 
(CombiBlocks, Chempur, Aldrich, Acros). 
Methyl 5-(4-methoxyphenyl)benzo[b]thiophene-2-carboxylate, 1b. To a solution of 1-
bromo-4-methoxybenzene (1.32 mL, 10.52 mmol) in dry THF (20 mL) cooled at -78 °C t-BuLi (1.5 
M, 14.48 mL, 21.72 mmol) was added slowly. After 30 min ZnCl2 (0.5 M, 24.53 mL, 12.26 mmol) 
was added carefully and after 10 min it was let to warm up to rt. After additional 20 min methyl 
5-bromobenzo[b]thiophene-2-carboxylate (1.90 g, 7.00 mmol) and bis-(triphenylphosphine)-
palladium (II)-dichloride (0.49 g, 0.70 mmol) were prepared in dry THF (30 mL) under protecting 
atmosphere and the reagent was added at 0 °C and the reaction mixture left stirring overnight. 
yield: 1.45 g (69 %); Rf = 0.35 (PE / EtOAc, 2:1); δH (CDCl3, 500 MHz) 3.87 (s, 3H), 3.96 (s, 3H), 
7.01 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 8.8 Hz, 2H), 7.67 (dd, J = 1.8 Hz, J = 8.5 Hz, 1H), 7.89 (d, J = 
8.5 Hz, 1H), 8.01 (s, 1H), 8.09 (s, 1H). 
(5-(4-Methoxyphenyl)benzo[b]thiophen-2-yl)methanol, 1a. To a solution of 1b (0.55 g, 1.84 
mmol) in THF (30 mL), toluene (15 mL) and diethyl ether (15 mL) LiBH4 (0.05 g, 2.21 mmol) was 
added and heated to reflux for 2 h. yield: 0.47 g (95 %); Rf = 0.53 (PE / EtOAc, 2:1); δH (CDCl3, 
500 MHz) 3.87 (s, 3H), 4.95-5.01 (m, 2H), 6.99-7.01 (m, 3H), 7.53 (dd, J = 1.8 Hz, J = 8.4 Hz, 1H), 
7.56-7.59 (m, 2H), 7.85 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H). 
Method A: CDI reaction. To a solution of the corresponding alcohol (1 eq) in NMP or 
acetonitrile (10 mL / mmol) was added CDI (5 eq). Then the solution was heated to reflux for 4 
to 18 h. After cooling to ambient temperature, it was diluted with water (30 mL) and extracted 
with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine, dried 
over MgSO4 and evaporated under reduced pressure. Then the desired product was purified by 
chromatography on silica gel. 
1-((5-(4-Methoxyphenyl)benzo[b]thiophen-2-yl)methyl)-1H-imidazole, 1. Synthesised 
according to Method A1 using 1a (0.25 g, 0.93 mmol) and CDI (1.20 g, 7.40 mmol); yield: 0.20 g 
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(68 %); white solid: mp 169 °C; Rf = 0.44 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm
-1) 3106 (w), 1607 
(w), 1516 (m), 1453 (w), 1436 (w), 1277 (m), 1254 (m), 1231 (m), 1194 (w), 1072 (w), 1031 (m), 
1015 (w), 908 (w), 806 (s), 744 (s), 667 (m); δH (CDCl3, 500 MHz) 3.86 (s, 3H), 5.35 (s, 2H), 6.99-
7.01 (m, 3H), 7.12 (s, 1H), 7.17 (s, 1H), 7.52-7.56 (m, 3H), 7.62 (s, 1H), 7.80 (d, J = 8.4 Hz, 1H), 
7.86 (s, 1H); δC (CDCl3, 125 MHz) 46.3, 55.3, 114.3, 119.1, 121.5, 122.6, 123.3, 124.2, 128.3, 
130.0, 133.4, 137.2, 137.9, 138.3, 139.8, 139.8, 159.1. 
3-((1H-Imidazol-1-yl)methyl)-6-(4-fluorophenyl)-1H-indole, 3. Synthesised according to 
Method A2 using 3a (0.25 g, 1.04 mmol) and CDI (0.34 g, 2.08 mmol); yield: 0.15 g (52 %); 
brown solid: mp 171-173 °C; Rf = 0.24 (EtOAc / MeOH, 95:5); δH (CDCl3, 500 MHz) 5.29 (s, 2H), 
6.91 (bs, 1H), 7.02 (bs, 1H), 7.06 (t, J = 8.8 Hz, 2H), 7.18 (dd, J = 1.7 Hz, J = 8.3 Hz, 1H), 7.28 (d, J 
= 2.5 Hz, 1H), 7.41 (d, J = 8.5 Hz, 1H), 7.50 (d, J = 1.7 Hz, 1H), 7.52 (dd, J = 5.3 Hz, J = 8.8 Hz, 2H), 
7.71 (bs, 1H), 10.90 (bs, 1H); δC (CDCl3, 125 MHz) 42.8 (CH2), 110.1 (CH), 115.5 (CH), 118.4 (CH), 
119.3 (CH), 119.8 (CH), 121.8 (Cq), 124.7 (CH), 125.5 (Cq), 128.7 (CH), 128.9 (CH), 135.1 (CH), 
136.8 (Cq), 137.2 (Cq), 138.0 (Cq), 162.1 (CF); MS (ESI): m/z = 292 [M
++H]. 
1-((4-(4-Methoxyphenyl)naphthalen-1-yl)methyl)-1H-imidazole, 6. Synthesised according to 
Method A1 using 6a (0.38 g, 1.42 mmol) and CDI (1.84 g, 11.35 mmol); yield: 0.37 g (83 %); 
white solid: mp 192 °C; Rf = 0.25 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm
-1) 3109 (w), 1609 (m), 
1507 (s), 1460 (w), 1392 (w), 1284 (m), 1246 (s), 1176 (w), 1108 (w), 1076 (w), 1031 (m), 830 
(m), 770 (m), 735 (w), 664 (w); δH (CDCl3, 500 MHz) 3.89 (s, 3H), 5.61 (s, 2H), 6.97 (s, 1H), 7.04 
(d, J = 8.6 Hz, 2H), 7.11 (s, 1H), 7.19 (d, J = 7.3 Hz, 1H), 7.36 (d, J = 7.3 Hz, 1H), 7.39 (d, J = 8.6 Hz, 
2H), 7.46-7.49 (m, 1H), 7.53-7.56 (m, 1H), 7.61 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.4 Hz, 
1H); δC (CDCl3, 125 MHz) 48.8, 53.4, 55.3, 113.8, 119.4, 122.5, 125.7, 126.1, 126.4, 126.7, 127.3, 
129.6, 130.4, 131.0, 131.1, 132.2, 132.5, 137.5, 141.2, 159.1; (ESI): m/z = 315 [M++H]. 
8-(1-(1H-Imidazol-1-yl)propyl)-5-(4-methoxyphenyl)quinoline, 8. Synthesised according to 
Method A1 using 8a (0.40 g, 1.36 mmol) and CDI (0.88 g, 5.45 mmol); yield: 0.24 g (51 %); white 
solid: mp 135 °C; Rf = 0.27 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm
-1) 2967 (w), 1609 (m), 1515 (s), 
1465 (w), 1284 (m), 1248 (s), 1176 (m), 1110 (w), 1074 (w), 1031 (m), 824 (s), 735 (w), 666 (m), 
541 (w), 530 (w), 514 (w); δH (CDCl3, 500 MHz) 1.06 (t, J = 7.3 Hz, 3H), 2.33-2.49 (m, 2H), 3.89 (s, 
3H), 6.64-6.67 (m, 1H), 7.04 (d, J = 8.7 Hz, 2H), 7.06 (s, 1H), 7.13 (m, 1H), 7.35 (d, J = 8.7 Hz, 2H), 
7.38 (dd, J = 4.1 Hz, J = 8.6 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.55 (d, J = 7.5 Hz, 1H), 7.79 (s, 1H), 
8.25 (dd, J = 1.7 Hz, J = 8.6 Hz, 1H), 8.94 (dd, J = 1.7 Hz, J = 4.1 Hz, 1H);δC (CDCl3, 125 MHz) 11.4, 
28.2, 55.4, 57.0, 114.0, 118.0, 121.2, 125.3, 126.8, 127.0, 128.9, 131.0, 131.4, 134.7, 137.1, 
137.8, 140.3, 145.7, 149.4, 159.3; (ESI): m/z = 344 [M++H]. 
8-(1-(1H-Imidazol-1-yl)propyl)-2-ethyl-5-(4-methoxyphenyl)quinoline, 10. Synthesised 
according to Method A1 using 10a (0.40 g, 1.25 mmol) and CDI (1.61 g, 9.96 mmol); yield: 0.27 g 
(59 %); white solid: mp 157 °C; Rf = 0.24 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm
-1) 2969 (w), 1609 
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(s), 1576 (w), 1517 (s), 1498 (w), 1460 (w), 1285 (w), 1247 (s), 1177 (m), 1110 (w), 1072 (w), 
1032 (m), 825 (w), 738 (m), 664 (m); δH (CDCl3, 500 MHz) 1.08 (t, J = 7.3 Hz, 3H), 1.47 (t, J = 7.6 
Hz, 3H), 2.37-2.51 (m, 2H), 3.06 (q, J = 7.6 Hz, J = 15.1 Hz, 2H), 3.91 (s, 3H), 6.69 (m, 1H), 7.05 (d, 
J = 8.7 Hz, 2H), 7.14 (s, 1H), 7.27 (d, J = 3.8 Hz, 1H), 7.35-7.39 (m, 3H), 7.55 (d, J = 7.5 Hz, 1H), 
7.82 (s, 1H), 8.15 (d, J = 8.7 Hz, 1H); δC (CDCl3, 125 MHz) 11.4, 13.2, 28.0, 31.9, 55.4, 57.1, 113.9, 
117.9, 121.1, 125.1, 125.3, 125.8, 128.8, 131.0, 131.7, 134.7, 137.1, 137.2, 140.0, 145.2, 159.2, 
162.6; (ESI): m/z = 372 [M++H]. 
1-(1-(4-(Benzo[b]thiophen-5-yl)phenyl)propyl)-1H-imidazole, 12. Synthesised according to 
Method A1 using 12a (1.33 g, 4.94 mmol) and CDI (4.00 g, 24.7 mmol); yield: 0.51 g (32 %); 
white solid: mp 101-103 °C; Rf = 0.24 (DCM / MeOH, 20:1); IR (ATR) υ (cm
-1) 1496 (m), 1223 (m), 
1073 (m), 805 (vs), 758 (s), 702 (s), 663 (s); δH (CDCl3, 500 MHz) 0.98 (t, J = 7.3 Hz, 3H, CH3), 
2.28 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.08 (t, J = 7.6 Hz, 1H, CH), 7.00 (s, 1H), 7.13 (s, 1H), 7.29 (d, J = 
8.1 Hz, 2H), 7.39 (d, J = 5.4 Hz, 1H), 7.49 (d, J = 5.4 Hz, 1H), 7.55 (dd, J = 1.7, 8.4 Hz , 1H), 7.64 
(dd, J = 1.7, 8.3 Hz, 2H), 7.73 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 8.00 (s, 1H); δC (CDCl3, 125 MHz) 
11.1 (CH3), 28.6 (CH2), 63.3 (CH), 117.8, 120.0, 121.9, 122.8, 123.7, 124.0, 127.0, 127.2, 127.8, 
128.7, 136.1, 136.7, 138.8, 139.1, 139.4, 140.2, 141.3; MS (ESI): m/z = 319 [M++H]. 
5-(4-(1-(1H-Imidazol-1-yl)propyl)phenyl)-1H-indole, 13. Synthesised according to Method 
A1 using 13a (1.10 g, 4.38 mmol) and CDI (3.55 g, 21.88 mmol); yield: 0.33 g (25 %); white solid: 
mp 158-159 °C; Rf = 0.15 (DCM / MeOH, 20:1); IR (ATR) υ (cm
-1) 3143 (br), 1593 (w), 1471 (w), 
1222 (w), 1075 (m), 891 (s), 805 (s), 772 (s), 739 (s), 660 (m), 574 (w), 539 (w); δH (CDCl3, 500 
MHz) 0.86 (t, J = 7.3, 3H, CH3), 2.15 (q, J = 7.23, 7.6 Hz, 2H, CH2), 4.93 (t, J = 7.6 Hz, 1H, CH), 6.50 
(s, 1H), 6.90 (s, 1H), 7.04 (s, 1H), 7.13-7.17 (m, 3H), 7.30 (dd, J = 8.5, 9.5 Hz, 2H), 7.52 (d, J = 8.3 
Hz, 2H), 7.67 (s, 1H), 7.74 (s, 1H), 8.89 (s, 1H); δC (CDCl3, 125 MHz) 11.0 (CH3), 28.4 (CH2), 63.5 
(CH), 102.6, 111.4, 119.0,121.4, 125.2, 127.7, 128.4, 130.8, 132.1, 135.6, 135.8, 137.3, 142.6; 
MS (ESI): m/z = 302 [M++H]. 
1-(4-(Benzofuran-5-yl)benzyl)-1H-imidazole, 14. Synthesised according to Method A1 using 
14a (0.50 g, 2.23 mmol) and CDI (1.81 g, 11.1 mmol); yield: 0.26 g (43 %); white solid: mp 127-
129 °C; Rf = 0.22 (DCM / MeOH, 20:1); IR (ATR) υ (cm
-1) 3109 (w), 1511 (m), 1463 (m), 1439 (m), 
1249 (m), 1130 (m), 1107 (m), 1083 (m), 1028 (s), 909 (m), 876 (m), 836 (m), 802 (vs), 779 (s), 
748 (vs), 704 (m), 662 (vs), 631 (m), 523 (s); δH (CDCl3, 500 MHz) 5.17 (s, 2H, CH2), 6.82 (d, J = 
3.0 Hz, 1H), 6.95 (s, 1H), 7.12 (s, 1H), 7.23 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 5.4 Hz, 1H), 7.55~7.60 
(m, 4H), 7.66 (d, J = 8.4 Hz, 1H), 7.76 (s, 1H); δC (CDCl3, 125 MHz) 50.5 (CH2), 119.7, 123.8, 
127.7, 127.9, 129.9, 135.5, 137.4, 141.7,145.7; MS (ESI): m/z = 275 [M++H]. 
1-(4-(Benzo[b]thiophen-5-yl)benzyl)-1H-imidazole, 15. Synthesised according to Method A1 
using 15a (0.7 g, 2.91 mmol) and CDI (2.36 g, 14.6 mmol); yield: 0.18 g (21 %); white solid: mp 
164-165 °C; Rf = 0.25 (DCM / MeOH, 20:1); IR (ATR) υ (cm
-1) 1434 (w), 908 (m), 807 (m), 759 
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(m), 708 (m), 663 (m); δH (CDCl3, 500 MHz) 5.18 (s, 2H, CH2), 6.95 (s, 1H), 7.12 (s, 1H), 7.25 (d, J 
= 8.1 Hz, 2H), 7.38 (d, J = 5.4 Hz, 1H), 7.49 (d, J = 5.4 Hz, 1H), 7.55 (d, J =8.4 Hz, 1H), 7.59 (s, 1H), 
7.64 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 8.00 (s, 1H); δC (CDCl3, 125 MHz) 50.5 (CH2), 
119.3, 121.93, 122.83, 123.7, 124.1, 127.3, 127.9, 129.9, 135.0, 139.1, 140.2, 141.4; MS (ESI): 
m/z = 291 [M++H]. 
5-(4-((1H-Imidazol-1-yl)methyl)phenyl)-1H-indole, 16. Synthesised according to Method A1 
using 16a (0.80 g, 3.58 mmol) and CDI (3.55 g, 21.88 mmol); yield: 0.24 g (25 %); white solid: mp 
217-218 °C; Rf = 0.16 (DCM / MeOH, 20:1); IR (ATR) υ (cm
-1) 1509 (m), 1232 (m), 1099 (m), 1072 
(m), 915 (m), 883 (m), 801 (m), 732 (s), 662 (m), 619 (m), 574 (s), 528 (m); δH (CDCl3, 500 MHz) 
5.16 (s, 2H, CH2), 6.61-6.63 (m, 1H), 6.97 (s, 1H), 7.13 (s, 1H), 7.22 (d, J = 8.4 Hz, 2H), 7.25 (s, 
1H), 7.43 (dd, J = 8.4, 9.4 Hz, 2H), 7.61 (s, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.84 (s, 1H), 8.31 (s, 1H); 
δC (CDCl3, 125 MHz) 50.6 (CH2), 103.0, 111.3, 119.2, 121.6, 127.6, 127.8, 128.4, 130.8, 132.4, 
134.0, 135.5, 140.53, 142.63; MS (ESI): m/z = 274 [M++H]. 
6-(4-((1H-Imidazol-1-yl)methyl)phenyl)benzo[d]thiazole, 17. Synthesised according to 
Method A1 using 17a (0.40 g, 1.66 mmol) and CDI (2.15 g, 13.26 mmol); yield: 0.29 g (70 %); 
white solid: mp 143 °C; Rf = 0.47 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm
-1) 3370 (w), 2927 (w), 
2856 (w), 1708 (w), 1506 (m), 1468 (m), 1441 (m), 1391 (m), 1284 (w), 1232 (m), 1108 (w), 1077 
(m), 1030 (w), 886 (w), 813 (s), 739 (s), 697 (w), 663 (s); δH (CDCl3, 500 MHz) 5.18 (s, 2H), 6.95 
(s, 1H), 7.13 (s, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.64 (bs, 1H), 7.71 (dd, J = 1.8 Hz, J = 8.5 Hz, 1H), 
8.12 (m, 1H), 8.18 (d, J = 8.5 Hz, 1H); δC (CDCl3, 125 MHz) 50.6, 119.3, 120.1, 123.8, 125.8, 
127.9, 128.0, 134.6, 135.3, 138.1, 140.6, 152.7, 154.3. 
1-((4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)methyl)-1H-imidazole, 18. Synthesised 
according to Method A1 using 18a (0.13 g, 0.54 mmol) and CDI (0.70 g, 4.30 mmol); yield: 0.06 g 
(43 %); white solid: mp 149 °C; Rf = 0.38 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm
-1) 3112 (w), 3041 
(w), 2930 (w), 2877 (w), 1728 (w), 1677 (w), 1588 (w), 1497 (s), 1309 (s), 1284 (m), 1246 (m), 
1068 (s), 897 (m), 876 (w), 807 (m), 748 (m), 699 (w), 662 (w), 530 (w); δH (CDCl3 + CD3OD, 500 
MHz) 5.13 (s, 2H), 6.88 (d, J = 8.3 Hz, 1H), 6.96 (bs, 1H), 7.00-7.04 (m, 3H), 7.18 (d, J = 8.0 Hz, 
2H), 7.36 (s, 1H), 7.48 (d, J = 8.0 Hz, 2H), 7.64 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 17.8, 29.8, 
31.0, 51.1, 64.8, 64.8, 116.0, 117.9, 120.1, 120.3, 127.6, 128.2, 128.9, 134.1, 134.5, 137.6, 
141.1, 143.8, 144.1; (ESI): m/z = 293 [M++H]. 
1-(1-(4-(6-Methoxynaphthalen-2-yl)phenyl)propyl)-1H-imidazole, 19. Synthesised according 
to Method A1 using 19a (0.75 g, 1.71 mmol) and CDI (1.50 g, 9.30 mmol); yield: 0.23 g (39 %); 
white solid: mp 136-138 °C; Rf = 0.27 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1), 2936 (w), 1676 (s), 
1602 (m), 1502 (m), 1462 (m), 1200 (s), 1021 (m), 844 (s), 814 (s), 665 (s), 532 (m); δH (CDCl3, 
500 MHz) 0.98 (t, J=7.25 Hz, 3H, CH3), 2.27-2.30 (m, 2H, CH2), 3.94 (s, 3H, OCH3), 5.06 (t, J=7.61 
Hz, 1H, CH), 6.99 (s, 1H, Im-H5), 7.11 (s, 1H, Im-H4), 7.16-7.19 (m, 2H, Aromat), 7.28 (d, J=8.19 
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Hz, 2H, Aromat), 7.65 (s, 1H, Im-H2), 7.66-7.68 (m, 3H, Aromat), 7.80 (t, J=8.51 Hz, 2H, Aromat), 
7.95 (d, J=1.26 Hz, 1H, Aromat); δC (CDCl3, 125 MHz) 11.1 (CH3), 28.6 (CH2), 55.3 (CH), 63.0 
(OCH3), 105.6 (C-5´), 117.7 (Im-C4), 119.2 (C-7´), 125.6, 125.7 (Im-C5, C-3´), 127.0, 127.3 (C-1´, 
C-4´), 127.6 (C-3, C-5), 129.1 (C-2, C-6), 129.7 (C-8), 133.9 (C-2´), 135.4 (C-4), 139.0 (C-1), 141.0 
(Im-C2), 157.9 (C-6´); MS (ESI): m/z = 343 [M+-H]. 
1-(1-(4-(Naphthalen-2-yl)phenyl)propyl)-1H-imidazole, 20. Synthesised according to 
Method A1 using 20a (0.50 g, 1.9 mmol) and CDI (1.50 g, 9.30 mmol); yield: 0.23 g (39 %); white 
solid: mp 136-138 °C; Rf = 0.29 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1), 1687 (m), 1499 (s), 1223 
(m), 1072 (m), 1015 (m), 809 (vs), 758 (s), 733 (s), 662 (s); δH (CDCl3, 500 MHz) 0.98 (t, J=7.25 
Hz, 3H, CH3), 2.24-2.33 (m, 2H, CH2), 5.08 (t, J=7.56 Hz, 1H, CH), 7.00 (t, J=1.26 Hz, 1H, Im-H5), 
7.11 (t, J=1.26 Hz, 1H, Im-H4), 7.30 (d, J=7.88 Hz, 2H, aromat), 7.47-7.53 (m, 2H, aromat), 7.65 
(s, 1H, Im-H2), 7.69-7.72 (m, 3H, aromat), 7.85-7.92 (m, 3H, aromat), 8.01 (d, J=1.57 Hz, 1H, 
aromat); δC (CDCl3, 125 MHz) 11.1 (CH3), 28.6 (CH2), 63.1 (CH), 117.7 (Im-C4), 125.3 (C-3´), 
125.8, 126.1, 126.4 (Im-C5, C-7´, C-8´), 127.1 (C-1´), 127.6, 127.8, 128.1, 128.5 (C-3, C-5, C-5´, C-
8´), 129.6 (C-4´), 132.7, 132.6 (C-2, C-6), 136.4 (C-4, C-2´), 137.6 (C-1), 139.4 (Im-C2); MS (ESI): 
m/z = 313 [M++H]. 
1-(3-(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)phenyl)pentan-3-yl)-1H-imidazole, 
21a. Synthesised according to Method A1 using 21b (1.00 g, 2.5 mmol) and CDI (2.06 g, 12.7 
mmol); brown oil; the crude product was directly used in the next step without further 
purification and analysis. 
Method B: Ether cleavage with BBr3. To a solution of the corresponding ether (1 eq) in DCM 
(5 mL / mmol) at -78 °C was added 1 M borontribromide in DCM (5 eq). The resulting mixture 
was stirred at rt for 16 hours. Then water (25 mL) was added and the emulsion was stirred for 
further 30 minutes. The resulting mixture was extracted with ethyl acetate (3 x 25 mL). The 
combined organic phases were washed with brine, dried over Na2SO4 and evaporated under 
reduced pressure. Then the desired product was purified by chromatography on silica gel.  
4-(2-((1H-Imidazol-1-yl)methyl)benzo[b]thiophen-5-yl)phenol, 2. Synthesised according to 
Method B using 1 (0.15 g, 0.47 mmol) and BBr3 (2.35 mL, 2.34 mmol); yield: 0.05 g (32 %); white 
solid: mp 211 °C; Rf = 0.42 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 3349 (w), 2959 (w), 1733 (w), 
1609 (w), 1515 (s), 1448 (w), 1277 (s), 1242 (w), 1231 (w), 1194 (w), 1108 (m), 1030 (w), 951 
(w), 885 (w), 809 (s), 749 (s), 658 (m), 547 (w); δH (CDCl3 + CD3OD, 500 MHz) 5.43 (s, 2H), 6.88 
(d, J = 8.6 Hz, 2H), 7.02 (bs, 1H), 7.11 (bs, 1H), 7.25 (s, 1H), 7.44-7.52 (m, 3H), 7.72 (bs, 1H), 7.76 
(d, J = 8.4 Hz, 1H), 7.85 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 116.3, 122.0, 123.1, 124.4, 124.8, 
128.9, 133.1, 138.9, 138.9, 140.3, 140.6, 157.2. 
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4-(4-((1H-Imidazol-1-yl)methyl)naphthalen-1-yl)phenol, 7. Synthesised according to Method 
B using 6 (0.15 g, 0.48 mmol) and BBr3 (1.90 mL, 1.90 mmol); yield: 0.08 g (52 %); white solid: 
mp 197 °C; Rf = 0.42 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 3600-2900 (w), 1610 (w), 1509 (m), 
1437 (w), 1391 (w), 1264 (s), 1214 (w), 1172 (w), 1091 (m), 951 (w), 834 (s), 770 (w), 734 (s), 
654 (w), 574 (w); δH (CDCl3 + CD3OD, 500 MHz) 6.89 (d, J = 8.4 Hz, 2H), 7.04 (s, 1H), 7.15 (s, 1H), 
7.21 (d, J = 8.4 Hz, 2H), 7.28-7.30 (m, 1H), 7.31 (s, 1H), 7.36-7.39 (m, 1H), 7.44-7.47 (m, 1H), 
7.82 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.29 (bs, 1H); δC (CDCl3 + CD3OD, 125 MHz) 
115.3, 122.4, 126.3, 126.4, 127.2, 127.6, 131.1, 131.3, 132.5, 156.6; (ESI): m/z = 301 [M++H]. 
4-(8-(1-(1H-Imidazol-1-yl)propyl)quinolin-5-yl)phenol, 9. Synthesised according to Method B 
using 8 (0.10 g, 0.29 mmol) and BBr3 (1.46 mL, 1.46 mmol); yield: 0.06 g (63 %); white solid: mp 
174 °C; Rf = 0.42 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 3500-2600 (w), 1610 (m), 1515 (s), 1458 
(w), 1397 (w), 1269 (s), 1227 (w), 1172 (w), 1108 (w), 1089 (w), 826 (s), 797 (w), 736 (s), 669 
(w); δH (CDCl3 + CD3OD, 500 MHz) 0.95 (t, J = 7.2 Hz, 3H), 2.30-2.41 (m, 2H), 6.58 (m, 1H), 6.91 
(d, J = 8.5 Hz, 2H), 6.07 (bs, 1H), 7.14 (bs, 1H), 7.18 (d, J = 8.5 Hz, 2H), 7.28-7.32 (m, 1H), 7.37 (d, 
J = 7.5 Hz, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.99 (bs, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.81 (m, 1H); δC 
(CDCl3 + CD3OD, 125 MHz) 11.3, 27.8, 57.8, 60.7, 115.5, 115.6, 119.0, 121.4, 125.8, 125.9, 126.8, 
127.2, 127.3, 130.0, 131.1, 131.1, 135.3, 135.9, 137.3, 141.4, 145.7, 149.6, 157.1; (ESI): m/z = 
330 [M++H]. 
4-(8-(1-(1H-Imidazol-1-yl)propyl)-2-ethylquinolin-5-yl)phenol, 11. Synthesised according to 
Method B using 10 (0.15 g, 0.40 mmol) and BBr3 (2.00 mL, 2.00 mmol); yield: 0.09 g (58 %); 
white solid: mp 142 °C; Rf = 0.69 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 3600-2800 (w), 2968 
(w), 2932 (w), 1733 (s), 1608 (s), 1579 (w), 1518 (s), 1457 (w), 1398 (w), 1269 (s), 1225 (m), 
1172 (m), 1108 (w), 951 (w), 824 (s), 734 (m), 659 (w); δH (CDCl3 + CD3OD, 500 MHz) 0.94 (t, J = 
7.2 Hz, 3H), 1.30 (t, J = 7.5 Hz, 3H), 2.29-2.43 (m, 2H), 2.89-2.93 (m, 2H), 6.57-6.60 (m, 1H), 6.88 
(d, J = 8.1 Hz, 2H), 6.99 (s, 1H), 7.12 (s, 1H), 7.15-7.18 (m, 3H), 7.29 (d, J = 7.4 Hz, 1H), 7.53 (d, J 
= 7.4 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 8.13 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 11.0, 13.0, 27.1, 
31.6, 58.1, 115.2, 119.1, 121.0, 125.2, 125.33, 125.34, 126.2, 130.2, 130.8, 134.2, 134.8, 137.5, 
141.0, 145.0, 156.4, 162.9; (ESI): m/z = 358 [M++H]. 
Method C: Suzuki-Coupling. The corresponding brominated aromatic compound (1 eq) was 
dissolved in toluene (7 mL / mmol), an aqueous 2.0 M Na2CO3 solution (3.2 mL / mmol) and an 
ethanolic solution (3.2 mL / mmol) of the corresponding boronic acid (1.5-2.0 eq) were added. 
The mixture was deoxygenated under reduced pressure and flushed with nitrogen. After 
repeating this cycle several times Pd(PPh3)4 (4 mol%) was added and the resulting suspension 
was heated under reflux for 8 h. After cooling ethyl acetate (10 mL) and water (10 mL) were 
added and the organic phase was separated. The water phase was extracted with ethyl acetate 
(2 x 10 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered 
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over a short plug of celite® and evaporated under reduced pressure. The compounds were 
purified by flash chromatography on silica gel.  
6-(4-Fluorophenyl)-1H-indole-3-carbaldehyde, 3b. Synthesised according to Method C1 
using 6-bromo-1H-indole-3-carbaldehyde (0.45 g, 2.00 mmol) and 4-fluorophenylboronic acid 
(0.57 g, 4.05 mmol); yield: 0.35 g (73 %); yellow oil; Rf = 0.57 (petrolether / EtOAc, 1:2); IR (ATR) 
υ (cm-1) 3228 (m), 2806 (w), 1646 (s), 1618 (m), 1518 (m), 1386 (m), 1198 (m), 1110 (s), 1083 
(s), 811 (s), 670 (s), 593 (m), 517 (s); δH (CDCl3, 500 MHz) 6.84 (t, J = 8.8 Hz, 2H), 7.15 (dd, J = 1.6 
Hz, 8.2 Hz, 1H), 7.30 (dd, J = 5.4 Hz, 8.8 Hz, 2H), 7.33 (m, 1H), 7.63 (d, J = 3.2 Hz, 1H), 7.96 (d, J = 
8.2 Hz, 1H), 9.71 (s, 1H), 11.42 (bs, 1H); δC (CDCl3, 125 MHz) 109.7 (CH), 114.8 (CH), 118.0 (Cq), 
121.0 (Cq), 121.1 (CH), 123.0 (Cq), 128.1 (CH), 135.3 (Cq), 136.8 (CH), 137.1 (Cq), 137.3 (Cq), 161.4 
(CF), 184.2 (CH); MS (ESI): m/z = 238 [M+-H]. 
2-((1H-Imidazol-1-yl)methyl)-6-(4-fluorophenyl)quinoline, 4. Synthesised according to 
Method C1 using 4a (0.24 g, 0.84 mmol) and 4-fluorophenylboronic acid (0.23 g, 1.68 mmol); 
yield: 0.23 g (92 %); yellow solid, Rf = 0.15 (EtOAc/MeOH 9/1); IR (ATR) υ (cm
-1) 3125 (w), 3094 
(w), 2926 (w), 1602 (m), 1515 (m), 1498 (m), 1431 (m), 1224 (s), 824 (s), 771 (m), 657 (m); δH 
(CDCl3, 500 MHz) 5.43 (s, 2H), 7.04 (t, J = 1.3 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 7.15 (bs, 1H), 7.18 
(t, J = 8.5, 2H), 7.66 (m, 2H), 7.69 (bs, 1H), 7.93 (d, J = 2.2 Hz, 1H), 7.96 (dd, J = 2.2, 8.5 Hz, 1H), 
8.12 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H); δC (CDCl3, 125 MHz) 53.2 (CH2), 115.9 (d, 
2JCF = 22 
Hz, CH), 119.1 (CH), 119.6 (CH), 125.1 (CH), 127.6 (CH), 128.3 (Cq), 128.4 (CH), 129.0 (d,³ J = 7.7 
Hz, CH), 129.6 (CH), 129.7 (CH), 130.2 (CH), 136.2 (d,4 J CF = 2.9 Hz, Cq), 137.7 (CH), 137.8 (CH), 
138.8 (Cq), 146.9 (Cq), 156.2 (Cq), 162.8 (d, 
1J CF = 248.0 Hz, CF); MS (ESI): m/z = 304 [M
++H]. 
2-((1H-Imidazol-1-yl)methyl)-6-(thiophen-3-yl)quinoline, 5. Synthesised according to 
Method C1 using 5a (0.24 g, 0.84 mmol) and 3-thiophenylboronic acid (0.22 g, 1.68 mmol); 
yield: 0.22 g (88 %); yellow solid; Rf = 0.11 (EtOAc/MeOH 9/1); IR (ATR) υ (cm
-1) 3104 (w), 2963 
(w), 2926 (m), 1597 (m), 1506 (m), 1318 (m), 1068 (m), 828 (s), 782 (s), 753 (s), 660 (s); δH 
(CDCl3, 500 MHz) 5.43 (s, 2H), 7.04 (t, J = 1.3 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 7.15 (t, J = 0.9 Hz, 
1H), 7.46 (dd, J = 2.8, 5.0 Hz, 1H), 7.52 (dd, J = 1.6, 5.0 Hz, 1H), 7.62 (dd, J = 1.3, 2.8 Hz, 1H), 7.69 
(bs, 1H), 7.99 (d, J = 1.9 Hz, 1H), 8.02 (dd, J = 2.2, 8.8 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 8.14 (d, J = 
8.5 Hz, 1H); δC (CDCl3, 125 MHz) 53.2 (CH2), 119.1 (CH), 119.6 (CH), 121.5 (CH), 124.2 (CH), 
126.3 (CH), 126.8 (CH), 127.7 (Cq), 129.4 (CH), 129.6 (CH), 130.2 (CH), 134.4 (Cq), 137.6 (CH), 
137.8 (CH), 141.2 (Cq), 146.9 (Cq), 155.9 (Cq); MS (ESI): m/z = 292 [M
++H]. 
(4-(4-Methoxyphenyl)naphthalen-1-yl)methanol, 6a. Synthesised according to Method C2 
using 6b (0.40 g, 1.69 mmol) and 4-methoxyphenylboronic acid (0.39 g, 2.53 mmol); yield: 0.42 
g (94 %); white solid; Rf = 0.57 (petrolether / EtOAc, 1:2); δH (CDCl3, 500 MHz) 3.90 (s, 3H), 5.20 
(s, 2H), 7.04 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 7.2 Hz, 1H), 7.40 (d, J = 8.7 Hz, 2H), 7.45-7.48 (m, 1H), 
7.56 (d, J = 7.2 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H); δC (CDCl3, 125 MHz) 55.4, 
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63.8, 113.7, 123.9, 125.0, 125.9, 126.2, 126.4, 126.9, 131.1, 131.5, 132.2, 133.0, 135.4, 140.5, 
159.0. 
5-(4-Methoxyphenyl)quinoline-8-carbaldehyde, 8b. Synthesised according to Method C2 
using 6-bromo-1H-indole-3-carbaldehyde (3.00 g, 12.71 mmol) and 4-methoxyphenylboronic 
acid (2.90 g, 19.06 mmol); yield: 2.75 g (82 %); white solid; Rf = 0.63 (petrolether / EtOAc, 1:2); 
δH (CDCl3, 500 MHz) 7.06 (d, J = 8.7 Hz, 2H), 7.41 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 4.1 Hz, J = 8.6 Hz, 
1H), 7.61 (d, J = 7.5 Hz, 1H), 8.33-8.34 (m, 2H), 9.03-9.04 (m, 1H), 11.48 (s, 1H); δC (CDCl3, 125 
MHz) 55.4, 114.1, 121.5, 121.8, 126.2, 126.7, 126.9, 128.8, 129.3, 130.5, 130.9, 131.0, 134.2, 
134.8, 136.3, 146.7, 148.1, 150.9, 151.3, 159.8, 192.6. 
4-(Benzo[b]thiophen-5-yl)benzaldehyde, 12b. Synthesised according to Method C1 using 5-
bromobenzo[b]thiophene (1.90 g, 8.92 mmol) and 4-formylphenylboronic acid (1.74 g, 11.6 
mmol); yield: 1.71 g (80 %); white solid; Rf = 0.35 (petrolether / EtOAc, 5:1); δH (CDCl3, 500 
MHz) 7.41 (d, J = 5.4 Hz, 1H), 7.51 (d, J = 5.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 7.9 Hz, 
2H), 7.97 (d, J = 8.2 Hz, 3H), 8.07 (s, 1H), 10.07 (s, 1H, CHO); δC (CDCl3, 125 MHz) 122.3, 123.0, 
123.6, 124.0, 127.5, 127.8, 130.3, 135.0, 126.1, 139.9, 140.2, 147.3, 191.9. 
4-(1H-Indol-5-yl)benzaldehyde, 13b. Synthesised according to Method C1 using 5-bromo-
1H-indole (0.10 g, 0.51 mmol) and 4-formylphenylboronic acid (0.1 g, 0.66 mmol); yield: 0.07 g 
(65 %); white solid; Rf = 0.25 (petrolether / EtOAc, 5:1); δH (CDCl3, 500 MHz) 6.64 (t, J = 2.8 Hz, 
1H), 7.27 (t, J = 3.1 Hz, 1H), 7.48 (s, 1H), 7.74 (dd, J = 1.8, 8.5 Hz, 2H), 7.92 (s, 1H), 8.04 (dd, J = 
1.8, 8.5 Hz, 2H), 8.29 (s, br, 1H), 10.05 (s, 1H, CHO); δC (CDCl3, 125 MHz) 103.2, 111.4, 119.6, 
121.7, 125.1, 127.2, 128.4, 128.5, 132.0, 135.8, 147.0, 192.1. 
4-(Benzofuran-5-yl)benzaldehyde, 14b. Synthesised according to Method C1 using 5-
bromobenzofuran (1.90 g, 9.64 mmol) and 4-formylphenylboronic acid (1.88 g, 12.5 mmol); 
yield: 0.53 g (25 %); yellow oil; Rf = 0.33 (petrolether / EtOAc, 5:1); δH (CDCl3, 500 MHz) 6.83-
6.84 (m, 1H), 7.54-7.60 (m, 2H), 7.68 (d, J = 2.2 Hz, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.84 (d, J = 1.6 
Hz, 1H), 7.94 (dd, J = 1.8, 8.4 Hz, 2H), 10.05 (s, 1H, CHO); δC (CDCl3, 125 MHz) 106.8, 111.8, 
120.1, 123.9, 127.8, 130.2, 134.8, 145.9, 147.6, 155.0, 191.9. 
(4-(Benzo[d]thiazol-6-yl)phenyl)methanol, 17a. Synthesised according to Method C1 using 
6-bromobenzo[d]thiazole (0.50 g, 2.34 mmol) and 4-(hydroxymethyl)phenylboronic acid (0.53 g, 
3.50 mmol); yield: 0.50 g (89 %); white solid; Rf = 0.26 (petrolether / EtOAc, 1:2); δH (CDCl3, 500 
MHz) 4.77 (s, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.64-7.68 (m, 3H), 7.74 (dd, J = 1.8 Hz, J = 8.5 Hz, 1H), 
8.15 (s, 1H), 8.20 (d, J = 8.5 Hz, 1H), 9.03 (s, 1H); δC (CDCl3, 125 MHz) 64.9, 120.1, 123.6, 125.9, 
127.6, 127.6, 128.5, 128.6, 132.0, 132.0, 132.1, 132.1, 134.5, 138.8, 139.7, 140.4. 
(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)methanol, 18a. Synthesised according to 
Method C1 using 6-bromo-2,3-dihydrobenzo[b][1,4]dioxine (0.50 g, 2.33 mmol) and 4-
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(hydroxymethyl)phenylboronic acid (0.53 g, 3.49 mmol); yield: 0.15 g (27 %); white solid; Rf = 
0.62 (petrolether / EtOAc, 1:2); δH (CDCl3, 500 MHz) 4.29 (s, 1H), 4.71 (s, 1H), 6.93 (d, J = 8.3 Hz, 
1H), 7.08 (dd, J = 2.2 Hz, J = 8.3 Hz, 1H), 7.12 (d, J = 2.2 Hz, 1H), 7.40 (d, J = 8.3 Hz, 2H), 7.53 (d, J 
= 8.3 Hz, 2H); δC (CDCl3, 125 MHz) 64.4, 64.4, 65.1, 115.8, 117.5, 120.1, 126.9, 127.4, 134.4, 
139.4, 140.0, 143.2, 143.7. 
Method D: Reduction with NaBH4. To an ice-cooled solution of the corresponding aldehyde 
or ketone (1 eq) in methanol (5 mL / mmol) was added NaBH4 (2 eq). Then the resulting mixture 
was heated to reflux for 30 minutes. After cooling to ambient temperature, the solvent was 
distilled off under reduced pressure. Then water (10 mL) was added, and the resulting mixture 
was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with 
brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product was 
purified by chromatography on silica gel. 
(6-(4-Fluorophenyl)-1H-indol-3-yl)-methanol, 3a. Synthesised according to Method D using 
3b (0.30 g, 1.25 mmol) and NaBH4 (0.86 g, 2.26 mmol); yield: 0.27 g (89 %); Rf = 0.55 (PE / 
EtOAc, 1:2); the crude product was directly used in the next step without further purification 
and analysis. 
(4-(Benzo[b]thiophen-5-yl)phenyl)methanol, 14a. Synthesised according to Method D using 
14b (0.30 g, 1.26 mmol) and NaBH4 (0.10 g, 2.52 mmol); yield: 0.28 g (92 %); Rf = 0.30 (PE / 
EtOAc, 2:1); the crude product was directly used in the next step without further purification 
and analysis. 
1-(4-(Benzo[b]thiophen-5-yl)phenyl)propan-1-ol, 15a. Synthesised according to Method D 
using 15b (0.30 g, 1.36 mmol) and NaBH4 (0.11 g, 2.71 mmol); yield: 0.28 g (91 %); Rf = 0.30 (PE 
/ EtOAc, 2:1); the crude product was directly used in the next step without further purification 
and analysis. 
1-(4-(6-Methoxynaphthalen-2-yl)phenyl)propan-1-ol, 19a. Synthesised according to Method 
D using 19b (1.93 g, 6.40 mmol) and NaBH4 (0.48 g, 12.8 mmol); yield: 0.711 g (38 %); Rf = 0.59 
(DCM / MeOH, 98:2); the crude product was directly used in the next step without further 
purification and analysis. 
1-(4-(Naphthalen-2-yl)phenyl)propan-1-ol, 20a. Synthesised according to Method D using 
20b (1.80 g, 6.40 mmol) and NaBH4 (0.48 g, 12.8 mmol); yield: 1.34 g (80 %); Rf = 0.62(DCM / 
MeOH, 98:2); the crude product was directly used in the next step without further purification 
and analysis. 
6-Bromo-2-(bromomethyl)quinoline 4b. 6-Bromo-2-methylquinoline (3.00 g, 13.5 mmol) 
was dissolved in 40 mL of dry carbon tetrachloride. To this solution was added NBS (2.63 g, 14.8 
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mmol) and dibenzoyl peroxide (0.16 g, 0.70 mmol) and the mixture was refluxed over night. 
After cooling, the succinimide was removed by filtration and the filtrate was concentrated 
under vacuum. The crude product was further purified by flash column chromatography on 
silica gel using petroleum ether / EtOAc (95 : 5) as eluent; yield: 1.71 g (42%); lachrymatory lilac 
oil; Rf = 0.46 (hexane / EtOAc 95 : 5); IR (ATR) υ (cm
-1) 3054 (w), 3038 (w), 2928 (w), 2855 (w), 
1589 (m), 1484 (s), 1373 (m), 1304 (m), 1200 (s), 1190 (s), 1060 (s), 899 (s), 830 (s), 792 (s), 775 
(m), 735 (s), 694 (s), 597 (s), 550 (s); δH (CDCl3, 500 MHz) 4.68 (s, 2H), 7.59 (d, J = 8.5 Hz, 1H), 
7.79 (dd, J = 2.1, 9.1 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.98 (d, J = 2.1 Hz, 1H), 8.08 (d, J = 8.5 Hz, 
1H); δC (CDCl3, 125 MHz) 34.0 (CH2), 121.0 (CH), 122.0 (CH), 128.4 (Cq), 129.6 (CH), 131.0 (CH), 
133.4 (CH), 136.2 (Cq), 157.4 (Cq), 157.9 (Cq); MS (ESI): m/z =302 [M
+ + H]. 
2-(1H-Imidazol-1-ymethyl)-6-bromoquinoline 4a. The α-brominated compound 4b (1.89 g, 
6.28 mmol), imidazole (0.86 g, 12.55 mmol), anhydrous K2CO3 (1.29 g, 9.42 mmol) and a 
catalytical amount of 18-crown-6 in dry acetonitrile were heated under reflux over night. After 
the solution was cooled down, the solvent was removed under reduced pressure. The residue 
was dissolved with water (10 mL/eq) and extracted three times with CH2Cl2 (15 mL/eq). The 
combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and 
evaporated. The crude material was purified by flash chromatography on silica-gel, using 5% 
MeOH in CH2Cl2; yield: 1.1 g (61%); Rf = 0.23 (EtOAc / MeOH 9 : 1); IR (ATR) υ (cm
-1) 3098 (w), 
1593 (m), 1488 (s), 1291 (m), 1235 (m), 1086 (m), 1030 (m), 824 (s), 733 (s), 658 (s); δH (CDCl3, 
500 MHz) 5.39 (s, 2H), 7.01 (t, J = 1.3 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 7.13 (t, J = 1.3 Hz, 1H), 
7.66 (s, 1H), 7.79 (dd, J = 2.2, J = 9.1 Hz, 1H), 7.91 (d, J = 9.1 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 8.03 
(d, J = 8.5 Hz, 1H) ); δC (CDCl3, 125 MHz) 55.0 (CH2), 119.5 (CH), 119.5 (CH), 120.9 (CH), 129.6 
(Cq), 130.2 (CH), 130.8 (CH), 133.6 (CH), 136.6 (CH), 137.7 (Cq), 146.2 (Cq), 156.6 (Cq); MS (ESI): 
m/z = 289 [M+ + H]. 
4-Bromo-1-naphthoic acid, 6c. 4-Bromo-1-methyl naphthalene (20.0 g, 88.65 mmol) was 
preheated to 90 °C in a water / pyridine 1 : 1 mixture (170 mL) and KMnO4 (57.2 g, 354.6 mmol) 
was added over a period of 3 h every 30 in in equal portions. yield: 1.60 g (7 %); Rf = 0.37 (PE / 
EtOAc, 2:1); δH (CDCl3 + CD3OD, 500 MHz) 7.56-7.61 (m, 2H), 7.78 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 
7.9 Hz, 1H), 8.26-8.28 (m, 1H), 8.91-8.93 (m, 1H); δC (CDCl3 + CD3OD, 125 MHz) 126.5, 127.6, 
127.7, 128.4, 128.7, 129.1, 130.5, 132.3, 132.6. 
(4-Bromonaphthalen-1-yl)methanol, 6b. To a solution of 6c (0.60 g, 2.39 mmol) in THF (10 
mL) LiAlH4 (0.91 g, 3.90 mmol) in THF (5 mL) was added slowly and heated to reflux overnight. 
yield: 1.65 g (83 %); Rf = 0.74 (PE / EtOAc, 2:1); δH (CDCl3, 500 MHz) 5.12 (s, 2H), 7.37 (d, J = 7.6 
Hz, 1H), 7.58-7.64 (m, 2H), 7.76 (d, J = 7.6 Hz, 1H), 8.11 (d, J = 7.8 Hz, 1H), 8.31 (d, J = 7.8 Hz, 
1H); δC (CDCl3, 125 MHz) 123.2, 124.0, 125.5, 127.1, 127.2, 127.9, 129.4, 132.1, 132.3, 136.3. 
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Method E: Grignard reaction. Under exclusion of air and moisture a 1.0 M EtMgBr (1.2 eq) 
solution in THF was added dropwise to a solution of the aldehyde or ketone (1 eq) in THF (12 
mL / mmol). The mixture was stirred over night at rt. Then ethyl acetate (10 mL) and water (10 
mL) were added and the organic phase was separated. The organic phase was extracted with 
water and brine, dried over Na2SO4, and evaporated under reduced pressure. The crude 
products were purified by flash chromatography on silica gel. 
1-(5-(4-Methoxyphenyl)quinolin-8-yl)propan-1-ol, 8a. Synthesised according to Method E 
using 8b (1.00 g, 3.80 mmol) and NaBH4 (15.20 mL, 15.20 mmol); yield: 0.47 g (43 %); Rf = 0.47 
(PE / EtOAc, 2:1); δH (CDCl3, 500 MHz) 1.05 (t, J = 7.4 Hz, 3H), 1.97-2.20 (m, 2H), 3.90 (s, 3H), 
5.04-5.07 (m, 1H), 7.04 (d, J = 8.6 Hz, 2H), 7.35-7.38 (m, 3H), 7.43 (d, J = 7.3 Hz, 1H), 7.56 (d, J = 
7.3 Hz, 1H), 8.30 (d, J = 8.6 Hz, 1H), 8.82-8.83 (m, 1H); δC (CDCl3, 125 MHz) 11.0, 31.9, 55.4, 
113.9, 120.6, 126.8, 127.1, 127.4, 131.1, 131.5, 135.4, 139.2, 139.5, 146.8, 147.9, 150.3. 
1-(2-Ethyl-5-(4-methoxyphenyl)quinolin-8-yl)propan-1-ol, 10a. Synthesised according to 
Method E using 8b (1.00 g, 3.80 mmol) and NaBH4 (15.20 mL, 15.20 mmol); yield: 0.43 g (39 %); 
Rf = 0.52 (PE / EtOAc, 2:1); δH (CDCl3, 500 MHz) 1.03 (t, J = 7.4 Hz, 3H), 1.41 (t, J = 7.6 Hz, 3H), 
2.02-2.19 (m, 2H), 2.98-3.03 (m, 2H), 3.89 (s, 3H), 4.95-4.98 (m, 1H), 7.03 (d, J = 8.6 Hz, 2H), 
7.24 (d, J = 8.8 Hz, 1H), 7.34-7.36 (m, 3H), 7.48 (d, J = 7.3 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H). 
1-(4-(Benzo[b]thiophen-5-yl)phenyl)propan-1-ol, 12a. Synthesised according to Method E 
using 12b (0.35 g, 1.47 mmol) and a 1.0 M ethylmagnesium bromide solution in THF (1.91 mL, 
1.91 mmol); yield: 0.34 g (85 %); Rf = 0.30 (PE / EtOAc, 2:1); the crude product was directly used 
in the next step without further purification and analysis. 
1-(4-(1H-Indol-5-yl)phenyl)propan-1-ol, 13a. Synthesised according to Method E using 13b 
(0.50 g, 2.26 mmol) and a 1.0 M ethylmagnesium bromide solution in THF (2.94 mL, 2.94 
mmol); yield: 0.51 g (89 %); Rf = 0.30 (PE / EtOAc, 2:1); the crude product was directly used in 
the next step without further purification and analysis. 
3-(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)phenyl)pentan-3-ol, 21b. Synthesised 
according to Method E using 21c (6.07 g, 16.7 mmol) and EtMgBr (1 M, 18.4 mL, 18.4 mmol, 1.1 
eq); yield: 1.37 g (21%); yellow solid; Rf = 0.73 (hexane / EtOAc, 7 : 3); the crude product was 
directly used in the next step without further purification and analysis. 
(6-Bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane, 21d. To a solution of 6-
bromonaphthalen-2-ol (10 g, 44.8 mmol) and imidazole (3.4 g, 49.3 mmol, 1.1 eq) in 
dichloromethane was slowly added a solution of tert-butyldimethylsilyl chloride (7.4 g, 49.3 
mmol, 1.1 eq) in dichloromethane. After being stirred for 4 h at rt the reaction mixture was 
poured into water, extracted with dichloromethane, washed with water and brine, and dried 
over Na2SO4. Solvent removal under reduced pressure lead to a pale oil, which was purified by 
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chromatography on silica gel; yield: 14.5 g, (96%); yellow oil; Rf = 0.63 (hexane); δH (CDCl3, 500 
MHz) 0.25 (s, 6H), 1.02 (s, 9H), 7.09 (dd, J = 2.2, J = 8.8 Hz, 1H), 7.15 (d, J = 2.2 Hz, 1H), 7.48 (dd, 
J = 2.2, J = 8.8 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H); δC 
(CDCl3, 125 MHz) -4.3 (CH3), 18.2 (Cq), 25.7 (CH3), 114.9 (CH), 117.3 (CBr), 123.1 (CH), 128.3 (CH), 
128.4 (Cq), 129.4 (CH), 129.6 (CH), 130.3 (CH), 133.1 (Cq), 153.8 (COR); MS (ESI): m/z = 337 [M
+ + 
H]. 
6-(4-(3-(1H-Imidazol-1-yl)pentan-3-yl)phenyl)naphthalen-2-ol, 21. To a solution of the silyl-
protected phenol 21a (crude product, 2.5 mmol) in anhydrous tetrahydrofuran (25 mL) was 
added tetrabutylammonium fluoride (3 mL, 1 M) and the solution was stirred for 4 h. The 
reaction was terminated with the addition of methanol and the solvent was removed under 
reduced pressure. Then, the desired product was purified by chromatography on silica gel; yield 
= 50 mg (6%); brown solid; Rf = 0.31 (EtOAc/MeOH 95/5); IR (ATR) υ (cm
-1) 2975 (w), 2874 (w), 
1602 (s), 15 10 (m), 1498 (m), 1251 (s), 1205 (s), 858 (s), 831 (s); δH (CDCl3, 500 MHz) 0.65 (t, J = 
7.3 Hz, 6H), 2.27-2.31 (m, 4H), 6.94 (bs, 1H), 7.06 (bs, 1H), 7.10 (dd, J = 2.4 Hz, J = 8.8 Hz, 1H), 
7.14 (d, J = 2.4 Hz, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.70-7.76 (m, 4H), 7.80 (bs, 1H), 7.82 (d, J = 8.8 
Hz, 1H), 8.07 (bs, 1H), 9.84 (s, 1H); δC (CDCl3, 125 MHz) 7.6 (CH3), 28.9 (CH2), 65.7 (CH), 108.4 
(CH), 117.1 (CH), 118.4 (CH), 119.0 (CH), 125.0 (CH), 125.0 (CH), 126.2 (CH), 126.6 (CH), 126.7 
(CH), 127.9 (Cq), 128.1 (Cq), 129.7 (CH), 133.5 (Cq), 133.8 (Cq), 139.0 (Cq), 142.9 (CH), 155.5 (COH); 
MS (ESI): m/z =357 [M++H]. 
Biological Assays. CYP17 Preparation and Assay. As source of human CYP17, our E. coli 
system17 (co-expressing human CYP17 and NADPH-P450 reductase) was used and the assay was 
performed as previously described7 taking unlabeled progesterone as substrate and applying 
HPLC with UV-detection for separation. 
Inhibition of Hepatic CYP Enzymes. The recombinantly expressed enzymes from baculovirus-
infected insect microsomes (BD Supersomes™) were used and the manufacturer's instructions 
(www.gentest.com) were followed. 
Inhibition of CYP11B1. V79MZh11B1 cells expressing the respective human enzyme were 
used and our assay procedure using [4-14C]-11-deoxycorticosterone was applied.19 
Molecular Modelling. All molecular modelling studies were performed on Intel® P4 CPU 3.00 
GHz running Linux Suse 10.1. 
Ligands. The structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. 
Louis, Missouri, USA) and energy-minimised in MMFF94s force-field24 as implemented in Sybyl. 
The resulting geometries for our compounds were then subjected to ab initio calculation 
employing the B3LYP functional25 in combination with a 6-31G* basis set using the package 
Gaussian03 (Gaussian, Inc., Pittsburgh, PA, USA, 2003). 
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Docking. Various inhibitors of Tables 1 and 2 were docked into our CYP17 homology model 
by means of the GOLD v 3.0.1 software.20 Since the GOLD docking program allows flexible 
docking of the compounds, no conformational search was employed to the ligand structures. 
GOLD gave the best poses by a genetic algorithm (GA) search strategy, and then various 
molecular features were encoded as a chromosome. 
Ligands were docked in 50 independent GA runs using GOLD. Heme iron was chosen as 
active site origin, while its radius was set equal to 19 Å. The automatic active site detection was 
switched on. Furthermore, a distance constraint of a minimum of 1.9 and a maximum of 2.5 Å 
between the sp2-hybridised nitrogen of the imidazole and the iron of the heme was set. 
Additionally, some of the GOLDSCORE parameters were modified to improve the weight of 
hydrophobic interaction and of the coordination between iron and nitrogen. The genetic 
algorithm default parameters were set as suggested by the GOLD authors.20 On the other hand, 
the annealing parameters of fitness function were set at 3.5 Å for hydrogen bonding and 6.5 Å 
for van-der-Waals interactions. 
All 50 poses for each compound were clustered with ACIAP22 and the representative 
structure of each significant cluster was selected. The quality of the docked representative 
poses was evaluated based on the GOLDSCORE values, which give a good measure of the found 
binding mode, and on visual inspection of the putative binding modes of the ligands, as 
outcome of docking simulations and cluster analysis. 
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Abstract 
Two novel classes of non-steroidal substrate mimetics were synthesised and examined for 
their potency as inhibitors of human CYP17. Selected compounds were tested for inhibition of 
hepatic CYP enzymes 3A4, 1A2, 2C9 and 2C19. The most promising compound 15 showed a 
good inhibition of the target enzyme (31% and 66% at 0.2 and 2 µM, respectively), and little 
inhibition of the most important hepatic enzyme CYP3A4 (6% and 19% inhibition at 0.2 and 2 
µM, respectively) and the key enzyme of glucocorticoid biosynthesis CYP11B1 (3% and 23% 
inhibition at 0.2 and 2 µM, respectively). Docking studies revealed that this compound does not 
assume the same binding mode as steroidal ligands. 
 
Introduction 
Prostate cancer is the most common disease and age-related cause of death in elder men 
worldwide.1 Since it is in over 80% of the cases androgen dependent, the standard treatment is 
orchiectomy or its medicinal equivalent the chemical castration by gonadotropin-releasing 
hormone analogues, which reduce the testicular androgen production.2 Because these 
treatments do not affect adrenal androgen production, they are frequently combined with 
androgen receptor antagonists (flutamide, cyproterone acetate) to reduce the stimulatory 
effects of the remaining androgens.3 However, due to mutations in the androgen receptor, anti-
androgens might be recognised as agonists,4,5 making this so-called ‘combined androgen 
blockade’ therapy not suitable for all patients. 
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The antimycotic ketoconazole has proven itself 
clinically as a good adjuvant therapy by reducing 
testosterone biosynthesis through inhibition of CYP17.6,7 
Nevertheless, the toxicity drawbacks it showed have 
forced to suspend it from use.8 On the other hand, the 
steroidal CYP17 inhibitor abiraterone (Fig. 1) passed 
phase II clinical trials showing high activity in post-
docetaxel castration refractory PC patients and seems to 
have no dose-limiting toxicity.9 
All this makes CYP17 an interesting target, since it 
catalyses both the 17a-hydroxylation of pregnenolone 
and progesterone and the subsequent 17,20-lyase 
reaction cleaving the C17-C20 bond to yield the 17-
keto androgens androstendione and dehydroandrostendione, the precursors of testosterone 
(Fig. 2).10 We also developed highly active steroidal inhibitors, which showed up to 3-fold higher 
activities against human CYP17 than abiraterone in vitro.11 In order to selectively inhibit CYP17 
without the potential side effects of steroidal drugs12 non-steroidal substrate mimetics have 
been prepared before.12-16 In this work, in order to find a new core structure, two different 
clases of substrate analogues were synthesised (Fig. 3) which mimic the A-, C- and D-rings 
(compounds 1-11), and the A-, B- and D-rings of the substrate with benzene nuclei (compounds 
12-17). Different nitrogen bearing heterocycles were introduced at different positions, since the 
heme complexation by an aromatic nitrogen is an important prerequisite for a high binding 
affinity.17 From previous work,14-16 it was known that the introduction of a fluorine in the A-ring 
strongly contributed to a better inhibition of our target enzyme. Hydroxyl groups were 
introduced, too, in order to mimic the oxygen functionality of the steroidal substrates. In the 
following, the synthesis, biological activities and molecular modelling studies are presented. 
Besides the CYP17 activity, inhibition 
of other CYP enzymes was examined, 
that is, selectivity towards hepatic CYP 
enzymes and CYP11B1 was 
determined, since the latter is the key 
enzyme in glucocorticoid biosynthesis. 
The most promising structure was 
docked into our protein model, and 
the key interactions with the enzyme 
were elucidated. 
Figure 1. The steroidal CYP17 inhibitor 
abiraterone and ACD- and ABD-ring 
mimetics. 
Het: N-containing heterocycle. 
Figure 2. The role of CYP17 in androgen biosynthesis. 
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Compound R X Y subst. 
pos. 1 H N CH  
2 H CH N  
3 OMe N CH  
4 OH N CH  
6 H   1 
7 OMe   1 
8    2 
9 H   8 
12 OMe N CH  
13 OMe CH N  
14 OH N CH  
15 OH CH N  
16 OMe   3 
17 OH   4 
 
Figure 3: List of synthesised compounds 1-17. 
 
Chemistry 
The syntheses of compounds 1-17 are shown in Schemes 1-9. In our aim to find the correct 
pattern for progesterone mimetics, different core structure alignments were synthetised, hence 
the diverse synthetical pathways.  
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The substances can be divided in pyridyl (Schemes 
1, 2, 3, 7) and imidazolyl (Schemes 4, 5, 6, 8, 9) 
compounds. The introduction of the pyridine moiety 
was achieved by means of Suzuki coupling18 (Method 
A), as well as the coupling of the naphthalenes and 
the phenyl rings. When the necessary bromides for 
the couplings were not commercially available, they 
were prepared either by bromination using NBS 
(Scheme 2) or with triphenylphosphine dibromide 
(Scheme 1). The imidazoles were introduced by 
performing a SNt reaction with 1,1-carbonyl 
diimidazole (CDI) and the corresponding alcohol19 
(Method D) in the last step. The alcohols were 
obtained from either the carboxylic acids (Method C) or from the aldehydes (Method E). In 
some cases the carbonyl group had first to be introduced (Scheme 5) or modified (Scheme 4) 
before reducing it to the corresponding alcohol. In some cases the methoxy-substituted 
compounds were submitted to an ether cleavage (Method B). For the preparation of compound 
17, the hydroxyl group on the naphthalene had to be protected before the Suzuki coupling due 
to otherwise very low yields.18 
Scheme 3. 
Reagents and conditions: (i) Method A: 4-
fluorophenylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (ii) 
Method A: 3-pyridineboronic acid, 
Na2CO3, Pd(PPh3)4, toluene, 110°C, 16 h. 
Br
Br
Br
F
N
F
(i)
(ii)
5
5a
Scheme 1. 
Reagents and conditions: (i) Br2, PPh3, 
acetonitrile, µw, 240°C, 10 min; (ii) Method A: 
1a: 4-fluorophenylboronic acid (5a: 2-methyl-4-
fluorophenylboronic acid), Na2CO3, Pd(PPh3)4, 
toluene, 110°C, 16 h; (iii) Method A: 1, 5: 3-
pyridineboronic acid, Na2CO3, Pd(PPh3)4, toluene, 
110°C, 16 h, for 2: 4-pyridineboronic acid, 
NaHCO3, Pd(PPh3)4, DMF, H2O, µW, 150°C, 15 
min. 
Scheme 2. 
Reagents and conditions: (i) NBS, THF, 75°C, 2 h; (ii) 
Method A: 4a: 4-fluorophenylboronic acid (11a: 3-
pyridineboronic acid), Na2CO3, Pd(PPh3)4, toluene, 
110°C, 16 h; (iii) Method A: 4: 3-pyridineboronic acid 
(11: 4-fluorophenylboronic acid), Na2CO3, Pd(PPh3)4, 
PhMe, 110°C, 16 h; (iv) Method B: BBr3, DCM, -78°C 
to 0°C, 16 h. 
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Scheme 4. 
Reagents and conditions: (i) Br2, Ag2SO4, H2SO4, 
65°C, 6 h; (ii) NaOH, HgO, acetic acid, H2O, 100°C, 4 
d; (iii) Method C: LiAlH4, THF, 75°C, 2 h; (iv) Method 
A: 4-fluorophenylboronic acid, Na2CO3, Pd(PPh3)4, 
toluene, 110°C, 16 h; (v) Method D: CDI, imidazole, 
NMP, 170°C, 3 h. 
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Scheme 5. 
Reagents and conditions: (i) TiCl4, 1,1-
dichloromethylmethylether, DCM, 70°C, 2 h; (ii) 
Method A: 4-fluorophenylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (iii) Method E: 
NaBH4, MeOH, THF, rt, 1 h; (iv) Method D: CDI, 
MeCN, 85°C, 2 d. 
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Scheme 6. 
Reagents and conditions: (i) Method C: LiAlH4, Et2O, 
35°C, 4 h; (ii) Method A: 4-fluorophenylboronic acid, 
Na2CO3, Pd(PPh3)4, toluene, 110°C, 16 h; (iii) Method 
D: CDI, imidazole, NMP, 180°C, 16 h. 
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Het
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Scheme 7. 
Reagents and conditions: (i) Method A: 6-
methoxynaphthalen-2-ylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (ii) Method A: 12: 3-
pyridineboronic acid (13: 4-pyridineboronic acid), 
Na2CO3, Pd(PPh3)4, toluene, 110°C, 16 h; (iii) Method 
B: BBr3, DCM, -78°C to 0°C, 16 h. 
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Results 
Biological Results. Inhibition of human CYP17 was determined by performing our previously 
described assay20 at inhibitor concentrations of 0.2 and 2 µM. As source of human CYP17, our 
Escherichia coli system21 (coexpressing human CYP17 and NADPH-P450 reductase) stably 
expressing human CYP17 was used. After homogenisation the 50,000g sediment was incubated 
with progesterone and NADPH as previously described.22 Separation of the product was 
performed by HPLC using UV-detection. 
The 3- and the 4-pyridyl-substituted ACD mimetics (1-5) showed no or little inhibition, 
respectively, in contrast to the reference compounds ketoconazole and abiraterone (Table 1). 
Amongst our methylene-imidazolyl-substituted compounds (6-9), the 8-substituted one showed 
the best result (9). It can also be observed that the introduction of a 2-methoxy group in 
compound 6 leads to a higher activity (7). Neither the introduction of a methyl substituent in 
the A-ring of 1 (10), nor the switch of the position of the A-ring from 6- to 5- (11) resulted in an 
active compound. 
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16
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Scheme 8. 
Reagents and conditions: (i) Method A: 6-
methoxynaphthalen-2-ylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (ii) Method E: 
NaBH4, MeOH, THF, rt, 1 h; (iii) Method D: CDI, 
acetonitrile, 85°C, 16 h. 
Scheme 9. 
Reagents and conditions: (i) TBDMSCl, 
imidazole, DCM, rt, 16 h; (ii) Method A: 
Na2CO3, Pd(OAc)2, TBAB, toluene, EtOH, H2O, 
110°C, 16 h; (iii) Method E: NaBH4, MeOH, rt, 
16 h; (iv) Method D: CDI, NMP, 170°C, 6 h; (v) 
TBAF, THF, rt, 16 h. 
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Table 1. Inhibition of CYP17 by steroidal ACD-ring mimetics (compounds 1-11) 
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Compound R X Y 
subst. 
pos. 
CYP17 % Inhibition a,b 
0.2 μM 2 μM 
1 H N CH  2 3 
2 H CH N  1 28 
3 OMe N CH  6 7 
4 OH N CH  0 0 
5     0 22 
6 H   1 2 19 
7 OMe   1 13 45 
8    2 3 14 
9 H   8 9 50 
10     3 3 
11     0 1 
 
a
 Ketoconazole (IC50 = 2780 nM); abiraterone (IC50 = 72 nM). 
b
 Data shown are the mean of at least one independent test in duplicate. Concentration of progesterone 
(substrate): 25 μM. The deviations were within < ±5 % 
 
Regarding the ABD mimetics (Table 2) it is striking that the class of the 4-pyridyl compounds 
(13, 15) showed again activity while the 3-pyridyl compounds (12, 14) were inactive. The 
cleavage of their methyl ether led to an enhancement of inhibition (14, 15). An increase in 
activity for compound 13 with 23 - 66% inhibition at 2 µM (15) could be observed, leading to 
the most active compound of this study. Analogous to the work done in the ACD class, the 
heterocycle was replaced by a methylene-imidazole moiety, and moderate activities for 
compounds 16 and 17 were observed.  
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Table 2. Inhibition of CYP17 by steroidal ABD-ring mimetics (compounds 12-17) 
 
R
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                                                                                      12-15                          16, 17 
 
Compound R X Y 
subst. 
pos. 
CYP17 % Inhibition a,b 
0.2 μM 2.0 μM 
12 OMe N CH  3 4 
13 OMe CH N  4 23 
14 OH N CH  0 8 
15 OH CH N  31 66 
16 OMe   3 0 28 
17 OH   4 24 61 
 
a
 Ketoconazole (IC50 = 2780 nM); abiraterone (IC50 = 72 nM). 
b
 Data shown are the mean of at least one independent test in duplicate. Concentration of progesterone 
(substrate): 25 μM. The deviations were within < ±5 % 
 
Since CYP3A4 is the hepatic enzyme responsible for the metabolism of lipophilic substances 
and therefore of about 50% of current prescription drugs,23 a broader spectrum of our 
compounds were studied for their effects on this enzyme. Critical is the fact that this enzyme 
together with CYP2D6 and CYP1A2 shows pronounced genetic polymorphism.24 Selected 
compounds (3, 7, 15, 16) showed moderate to high activity towards the mentioned hepatic CYP 
enzymes (Table 3). Since compound 15 exhibited a very low activity of 19% inhibition at 10 µM 
towards CYP3A425 it was further tested on 2D6. At this enzyme, it showed inhibitions of 80% at 
1 µM and 85% at 10 µM. 
In further terms of selectivity, compound 15 was additionally tested on the steroidogenic 
CYP enzyme CYP11B1 which is involved in the glucocorticoid biosynthesis. For the assay,26 
V79MZh11B1 cells expressing human CYP11B1 were used. Compound 15 showed very low 
activities of 3% at 0.2 µM and 23% at 2 µM. 
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Table 3. Inhibition of hepatic CYP enzymes (1A2, 2C9, 2C19, 3A4) by compounds 3, 7, 15, 16 
 
 
Compound 
CYP1A2 
% Inhibitiona 
CYP2C9 
% Inhibitiona 
CYP2C19 
% Inhibitiona 
CYP3A4 
% Inhibitiona 1.0 μM 10.0 μM 1.0 μM 10.0 μM 1.0 μM 10.0 μM 1.0 μM 10.0 μM 
3 40 87 66 54 68 28 64 86 
7 80 85 100 100 93 96 93 95 
15 98 98 94 97 86 89 6 19 
16 96 97 97 100 95 97 91 96 
KTZ b 8 38 21 75 24 1 1 4 
ABT b 36 53 17 51 3 7 7 7 
 
a
 Data shown are the mean of three independent tests. 
b
 KTZ: ketoconazole; ABT: abiraterone. The deviations were within < ±5 % 
 
Molecular Modelling. Since there is no crystal structure of CYP17 available we built a 
homology model of CYP17 using the X-ray structure of human CYP2C9 (PDB code 1r9o) as 
template, as described before by us.28 Docking simulations were carried out by means of the 
GOLD v3.0.1 software. For the docking studies, our homology model was used running Linux 
Suse 10.1 on Intel® 
P4 CPU 3.00 GHz, 
and the energy 
minimisation was 
also performed as 
previously 
described.28 
Compound 15 and 
the steroidal 
inhibitor 
abiraterone were 
docked as shown 
in Figure 4. 
 
 
 
Figure 4. Docking complex between CYP17 and compounds 15 (cyan) and 
abiraterone (yellow). Heme, interacting residues and ribbon rendered tertiary 
structure of the active site are shown. Figure was generated with Pymol 
(http://www.pymol.org). 
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Besides the already described interaction between the sp2 hybridised nitrogen and the heme 
iron, the key interaction for compound 15 seems to be the H-bond net of the hydroxyl group on 
the naphthalene with the amino acids Arg109, His235, Lys231 and Asn202 in the active site of 
our target enzyme. Further, hydrophobic interactions between the aromatic core and Ile206, 
Gly301, Ala302, Glu305, Val366 and Val482 were observed. 
For abiraterone, the same binding mode as described for the substrates was found.29,30 The 
lone pair of the sp2 hybridised nitrogen pointed perpendicular towards the heme iron. The 
steroidal scaffold was oriented almost parallel to the heme plane in the direction of the BC-
loop. This pose was stabilised by hydrophobic interactions with Ile371, Ile112, Ala113 and 
Phe114.29,30 Additionally, the highly conserved Arg96 which is important for substrate binding 
and recognition, as shown by sitedirected mutagenesis,31 presented interactions of the same 
kind with the steroidal A-ring. Another important interaction was the H-bond between the 
hydroxyl group in C3 position and the backbone carbonyl group of Gln98. 
Discussion and Conclusion 
Relying on our molecular modelling studies, the inhibitory activity of compound 15 is 
supposed to be increased by introducing other polar groups like an H-bond donor in 7 position 
of the naphthalene, which could interact with Asp298. Other possible substitutions to increase 
activity and perhaps also selectivity towards hepatic CYP enzymes are chlorine or fluorine at the 
1 position of the naphthalene, which should improve the hydrophobic interactions with the I-
helix. Also a substituent at 3 position capable of undergoing H-bonds could interact with 
Glu204. 
The selectivity against CYP1A2 and CYP2D6 could also be enhanced through different 
medicinal chemistry strategies. It is described that planar, lipophilic structures32 like compound 
15 have a great affinity towards CYP1A2. This planarity could be abolished by either 
dearomatising one of the benzene rings, or by specific ortho-substitutions. Regarding CYP2D6, 
its high inhibition is not surprising, since compound 15 bears three important pharmacophores 
responsible for its inhibition: the aromatic nitrogen, the H-bond donor and the lipophilic core 
structure.33 Since CYP2D6 has a relatively small binding site, most of the changes or 
substitutions made on compound 15 might increase its selectivity against this enzyme. 
Summarising, we have discovered compound 15 which shows good inhibition values, a good 
selectivity towards the steroidogenic CYP11B1 and a modest selectivity against CYP3A4, the 
most relevant hepatic enzyme in xenobiotic metabolism. Compound 15 might therefore be a 
good candidate for further structure optimisation. Using our protein model, we made some 
suggestions of how to further increase activity and selectivity towards hepatic CYP enzymes. 
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Molecular docking calculations were performed for compound 15. Since the GOLD docking 
program allows flexible docking of the compounds, no conformational search was employed to 
the ligand structures. GOLD gave the best poses by a genetic algorithm (GA) search strategy, 
and then various molecular features were encoded as a chromosome. 
Experimental Section 
Chemistry. Melting points were determined on a Mettler FP1 melting point apparatus and 
are uncorrected. IR spectra were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 
1H-NMR spectra were measured on a Bruker DRX-500 (500 MHz). Chemical shifts are given in 
parts per million (ppm), and TMS was used as an internal standard for spectra obtained in 
CDCl3. All coupling constants (J) are given in Hz. ESI (ElectroSpray Ionisation) and APCI 
(Atmospheric Pressure Chemical Ionisation) mass spectra were determined on a TSQ quantum 
(Thermo Electron Corporation) instrument. EI (Electron Ionisation) mass spectra were 
determined on a Trace GC Ultra (Thermo Electron Corporation) instrument. All reactions in the 
microwave were performed in a closed vessel in a CEM DiscoveryTM instrument equipped with 
an IR-sensor for temperature control. Column chromatography was performed using silica-gel 
60 (50-200 µm), and reaction progress was determined by TLC analysis on Alugram® SIL G/UV254 
(Macherey-Nagel). Boronic acids and bromoaryls and other compounds used as starting 
materials were commercially obtained (CombiBlocks, Chempur, Aldrich, Acros). 
1,6-Dibromonaphthalene, 1b. To an ice-cooled solution of triphenylphosphine (16.40 g, 
62.50 mmol) in acetonitrile (30 mL) was carefully dropped bromine (3.20 mL, 62.50 mmol). 
Then naphthalene-1,6-diol (5.00 g, 31.25 mmol) was added and the resulting mixture was 
heated for 2 hours at 80 °C. After that the solvent was evaporated under reduced pressure and 
the residue was heated in the microwave at 240 °C for 5 minutes. The crude was boiled in 
ethanol for 30 minutes, followed by hot and cold filtration. After evaporation under reduced 
pressure, the desired product was purified by chromatography on silica gel; yield: 6.35 g (71 %); 
white solid; Rf = 0.69 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.32-7.35 (m, 2H), 7.65 (dd, J 
= 1.2, 9.0 Hz, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.78 (d, J = 7.4 Hz, 1H), 7.99 (s, 1H), 8.10 (d, J = 9.0 Hz, 
1H); MS (EI): m/z = 283.8, 285.8, 287.8 [M++H]. 
Method A: Suzuki-Coupling. The corresponding brominated aromatic compound (1 eq) was 
dissolved in toluene (7 mL / mmol), a 10 % Na2CO3 aq solution (2 eq) and the corresponding 
boronic acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced pressure 
and flushed with nitrogen. After repeating this cycle several times, Pd(PPh3)4 (5 mol%) was 
added and the resulting suspension was heated under reflux for 16 hours. After cooling and 
phase separation, the aqueous phase was extracted with ethyl acetate (3 x 25 mL). The 
combined organic phases were washed with brine, dried over Na2SO4, filtered over a short plug 
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of celite® and evaporated under reduced pressure. The compounds were purified by flash 
chromatography on silica gel. 
1-Bromo-6-(4-fluorophenyl)naphthalene, 1a. Synthesised according to Method A using 
compound 1b (0.75 g, 2.62 mmol) and 4-fluorophenylboronic acid (0.45 g, 3.22 mmol); yield: 
0.33 g (42 %); white solid; Rf = 0.78 (hexane / EtOAc, 80:20); MS (EI): m/z = 312.9, 316.0 [M
++H]. 
3-(6-(4-Fluorophenyl)naphthalen-1-yl)pyridine, 1. Synthesised according to Method A using 
compound 1a (0.18 g, 0.58 mmol) and 3-pyridineboronic acid (0.15 g, 1.16 mmol); yield: 0.05 g 
(31 %); light-yellow oil; Rf = 0.57 (DCM / MeOH, 98:2); IR (ATR) υ (cm
-1) 3038 (w), 1602 (w), 
1517 (m), 1501 (s), 1407 (w), 1229 (s), 1159 (m), 1100 (w), 1026 (w), 965 (w), 888 (w), 844 (m), 
823 (s), 792 (s), 759 (m), 715 (s), 659 (m), 539 (m); δH (CDCl3, 500 MHz) 7.16-7.20 (m, 2H), 7.43 
(dd, J = 1.1, 7.0 Hz, 1H), 7.47 (dd, J = 4.5, 7.7 Hz, 1H), 7.59 (dd, J = 7.1, 8.2 Hz, 1H), 7.66-7.69 (m, 
2H), 7.84-7.88 (m, 1H), 7.88-7.89 (m, 1H), 7.96 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 1.8 Hz, 1H), 8.71 
(d, J = 3.6 Hz, 1H), 8.79 (d, J = 1.1 Hz, 1H); δC (CDCl3, 125 MHz) 115.7, 115.9, 123.2, 125.9, 126.0, 
126.1, 127.5, 128.7, 128.9, 129.0, 130.6, 134.1, 136.2, 136.3, 136.79, 136.81, 137.3, 137.8, 
148.5, 148.7, 150.6, 162.7 (d, J = 247.0 Hz, C-F); MS (ESI): m/z = 299.9 [M++H]. 
4-(6-(4-Fluorophenyl)naphthalen-1-yl)pyridine, 2. Synthesised according to Method A using 
compound 1a (0.10 g, 0.33 mmol) and 4-pyridineboronic acid (0.06 g, 0.43 mmol); yield: 0.09 g 
(94 %); light-yellow oil; Rf = 0.69 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 3054 (w), 1732 (w), 
1601 (m), 1504 (s), 1432 (w), 1409 (w), 1264 (w), 1231 (s), 1159 (m), 879 (w), 823 (s), 794 (s), 
760 (s), 654 (m), 605 (w), 518 (w); δH (CDCl3, 500 MHz) 7.16-7.20 (m, 2H), 7.43 (dd, J = 1.0, 7.1 
Hz, 1H), 7.56-7.60 (m, 3H), 7.66-7.70 (m, 3H), 7.89 (d, J = 8.8 Hz, 1H), 7.98 (d, J = 8.3 Hz, 1H), 
8.08 (d, J = 1.8 Hz, 1H), 8.84 (d, J = 3.3 Hz, 2H); δC (CDCl3, 125 MHz) 115.8, 115.9, 125.5, 125.6, 
125.9, 126.2, 126.3, 127.0, 128.9, 129.0, 129.4, 129.6, 134.0, 136.5, 136.6, 138.0, 149.5, 150.0, 
162.7 (d, J = 247.1 Hz, C-F); MS (ESI): m/z = 300.0 [M++H]. 
1-Bromo-6-(4-fluorophenyl)-2-methoxynaphthalene, 3a. Synthesised according to Method 
A using compound 3b (1.00 g, 3.17 mmol) and 4-fluorophenylboronic acid (0.45 g, 3.17 mmol); 
yield: 0.84 g (84 %); white solid; Rf = 0.57 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.05 (s, 
3H), 7.15-7.19 (m, 2H), 7.31 (d, J = 9.0 Hz, 1H), 7.66 (dd, J = 5.3, 8.8 Hz, 2H), 7.77 (dd, J = 1.9, 8.9 
Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.93 (d, J = 1.7 Hz, 1H), 8.28 (d, J = 8.9 Hz, 1H); δC (CDCl3, 125 
MHz) 57.1 (CH3), 108.6, 114.1, 115.7, 115.9, 125.6, 126.9, 127.2, 128.76, 128.83, 129.1, 130.0, 
132.3, 136.1, 136.6, 136.7, 152.9, 162.6 (d, J = 246.7 Hz, C-F); MS (EI): m/z = 329.9, 332.9 
[M++H].  
3-(6-(4-Fluorophenyl)-2-methoxynaphthalen-1-yl)pyridine, 3. Synthesised according to 
Method A using compound 3a (0.30 g, 0.91 mmol) and 3-pyridineboronic acid (0.14 g, 1.09 
mmol); yield: 0.20 g (66 %); white solid: mp 147 °C; Rf = 0.57 (DCM / MeOH, 95:5); IR (ATR) υ 
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(cm-1) 2926 (m), 1599 (m), 1516 (m), 1496 (m), 1460 (w), 1344 (w), 1257 (s), 1164 (w), 1134 (w), 
1067 (s), 1025 (w), 823 (s), 804 (s), 750 (w), 717 (m), 626 (w), 522 (w); δH (CDCl3, 500 MHz) 3.87 
(s, 3H), 7.14-7.17 (m, 2H), 7.41 (d, J = 9.1 Hz, 1H), 7.47 (dd, J = 4.9, 7.7 Hz, 1H), 7.53 (d, J = 8.9 
Hz, 1H), 7.59 (dd, J = 1.9, 8.9 Hz, 1H), 7.65 (dd, J = 5.3, 8.8 Hz, 2H), 7.76 (td, J = 1.9, 7.8 Hz, 1H), 
7.97-7.99 (m, 2H), 8.66 (d, J = 1.5 Hz, 1H), 8.68 (dd, J = 1.5, 4.9 Hz, 1H); MS (APCI): m/z = 320.3 
[M++H]. 
2-Bromo-6-(4-fluorophenyl)naphthalene, 5a. Synthesised according to Method A using 2,6-
dibromonaphthalene (0.70 g, 2.47 mmol) and 4-fluorophenylboronic acid (0.35 g, 2.47 mmol); 
yield: 0.23 g (37 %); white solid; Rf = 0.80 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.16-
7.19 (m, 2H), 7.58 (dd, J = 2.0, 8.7 Hz, 1H), 7.66 (dd, J = 5.3, 8.8 Hz, 2H), 7.71 (dd, J = 1.8, 8.6 Hz, 
1H), 7.75 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 8.6 Hz, 1H), 7.95 (d, J = 1.0 Hz, 1H), 8.03 (d, J = 1.7 Hz, 
1H); δC (CDCl3, 125 MHz) 115.7, 115.9, 119.9, 125.5, 126.5, 127.6, 128.88, 128.94, 129.70, 
129.74, 129.8, 132.1, 133.6, 136.78, 136.80, 138.1, 162.7 (d, J = 247.0 Hz, C-F); MS (EI): m/z = 
299.8, 302.9 [M++H]. 
3-(6-(4-Fluorophenyl)naphthalen-2-yl)pyridine, 5. Synthesised according to Method A using 
compound 5a (0.15 g, 0.50 mmol) and 3-pyridineboronic acid (0.08 g, 0.65 mmol); yield: 0.07 g 
(47 %); light-yellow solid: mp 126 °C; Rf = 0.72 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 2961 (m), 
1728 (s), 1605 (m), 1516 (m), 1487 (m), 1377 (w), 1286 (s), 1240 (s), 1122 (s), 1072 (s), 981 (w), 
896 (m), 812 (s), 744 (m), 706 (m), 666 (m), 544 (w), 527 (m); δH (CDCl3, 500 MHz) 7.17-7.21 (m, 
2H), 7.46 (dd, J = 4.9, 7.7 Hz, 1H), 7.53 (dd, J = 3.3, 5.7 Hz, 1H), 7.69 (dd, J = 5.3, 8.8 Hz, 2H), 7.73 
(dd, J = 3.3, 5.7 Hz, 1H), 7.75 (dd, J = 1.9, 4.7 Hz, 1H), 7.77 (dd, J = 1.9, 4.7 Hz, 1H), 7.98-8.02 (m, 
2H), 8.03 (d, J = 1.2 Hz, 1H), 8.05-8.08 (m, 2H), 8.65 (d, J = 3.7 Hz, 1H), 9.01 (s, 1H); δC (CDCl3, 
125 MHz) 115.7, 115.9, 123.8, 125.4, 125.5, 126.0, 126.2, 128.84, 128.89, 128.92, 128.99, 
132.7, 133.2, 134.97, 135.02, 136.94, 136.97, 138.3, 147.92, 147.94, 162.7 (d, J = 247.2 Hz, C-F); 
MS (ESI): m/z = 300.2 [M++H]. 
6-(4-Fluorophenyl)-1-naphthoic acid, 6a. Synthesised according to Method A using 
compound 6b (0.50 g, 2.11 mmol) and 4-fluorophenylboronic acid (0.39 g, 2.74 mmol); yield: 
0.45 g (85 %); white solid; Rf = 0.44 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 5.16 (s, 2H), 7.16-
7.20 (m, 2H), 7.46-7.53 (m, 2H), 7.68 (dd, J = 5.3, 8.7 Hz, 2H), 7.75 (dd, J = 1.9, 8.7 Hz, 1H), 7.86 
(d, J = 8.0 Hz, 1H), 8.02 (d, J = 1.7 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H); δC (CDCl3, 125 MHz) 63.7 
(CH2), 115.7, 115.8, 124.4, 125.4, 125.8, 126.0, 126.3, 128.8, 128.9, 130.3, 134.0, 136.2, 136.91, 
136.93, 137.5, 162.6 (d, J = 246.8 Hz, C-F); MS (EI): m/z = 252.0 [M++H]. 
6-(4-Fluorophenyl)-2-methoxy-1-naphthaldehyde, 7b. Synthesised according to Method A 
using compound 7c (1.00 g, 3.77 mmol) and 4-fluorophenylboronic acid (0.54 g, 3.77 mmol); 
yield: 0.63 g (60 %); white solid; Rf = 0.32 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.08 (s, 
3H), 7.15-7.19 (m, 2H), 7.34 (d, J = 9.2 Hz, 1H), 7.66 (dd, J = 5.3, 8.8 Hz, 2H), 7.84 (dd, J = 2.1, 9.0 
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Hz, 1H), 7.92 (d, J = 2.0 Hz, 1H), 8.11 (d, J = 9.1 Hz, 1H), 9.34 (d, J = 9.0 Hz, 1H); MS (APCI): m/z = 
322.2 [M++H]. 
(6-(4-Fluorophenyl)naphthalen-2-yl)methanol, 8a. Synthesised according to Method A using 
compound 8b (0.40 g, 1.69 mmol) and 4-fluorophenylboronic acid (0.29 g, 2.03 mmol); yield: 
0.36 g (84 %); white solid; Rf = 0.52 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 4.88 (s, 2H), 7.16-
7.19 (m, 2H), 7.51 (dd, J = 1.4, 8.4 Hz, 1H), 7.68 (dd, J = 5.3, 8.7 Hz, 2H), 7.70 (dd, J = 1.8, 8.5 Hz, 
1H), 7.83 (s, 1H), 7.89 (dd, J = 5.2, 8.4 Hz, 2H), 7.98 (s, 1H); δC (CDCl3, 125 MHz) 65.4 (CH2), 
115.6, 115.8, 125.2, 125.4, 125.7, 128.5, 128.6, 128.86, 128.93, 132.4, 133.1, 137.10, 137.12, 
137.6, 138.5, 162.5 (d, J = 246.6 Hz, C-F); MS (APCI): m/z = 235.1, 236.0, 237.0 [M++H]. 
3-(4-Fluorophenyl)-1-naphthoic acid, 9a. Synthesised according to Method A using 
compound 9b (0.50 g, 2.11 mmol) and 4-fluorophenylboronic acid (0.39 g, 2.74 mmol); yield: 
0.42 g (78 %); white solid; Rf = 0.50 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 5.22 (s, 2H), 7.16-
7.19 (m, 2H), 7.52-7.58 (m, 2H), 7.69 (dd, J = 5.3, 8.8 Hz, 2H), 7.76-7.77 (m, 1H), 7.92-7.94 (m, 
1H), 7.96 (s, 1H), 8.11-8.13 (m, 1H); δC (CDCl3, 125 MHz) 63.7 (CH2), 103.2, 115.7, 115.8, 123.5, 
126.0, 126.42, 126.44, 128.86, 128.92, 130.3, 134.1, 137.0, 162.6 (d, J = 246.9 Hz, C-F); MS (EI): 
m/z = 252.0 [M++H]. 
1-Bromo-6-(4-fluoro-2-methylphenyl)naphthalene, 10a. Synthesised according to Method A 
using compound 1b (0.75 g, 2.62 mmol) and 2-methyl-4-fluorophenylboronic acid (0.50 g, 3.28 
mmol); yield: 0.26 g (31 %); white solid; Rf = 0.85 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 
2.29 (s, 3H), 6.98 (dt, J = 2.3, 8.4 Hz, 1H), 7.03 (dd, J = 2.5, 9.7 Hz, 1H), 7.27 (dd, J = 5.9, 8.6 Hz, 
1H), 7.34-7.37 (m, 1H), 7.54 (dd, J = 1.7, 8.7 Hz, 1H), 7.74 (d, J = 1.5 Hz, 1H), 7.80 (dd, J = 1.0, 7.6 
Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 8.28 (d, J = 8.7 Hz, 1H); δC (CDCl3, 125 MHz) 20.6 (CH3), 112.6, 
112.8, 116.8, 116.9, 117.0, 122.7, 126.5, 126.6, 126.8, 127.0, 127.3, 127.7, 127.9, 128.19, 
128.23, 128.7, 129.1, 129.4, 129.9, 130.1, 130.2, 130.6, 130.9, 131.3, 131.4, 131.6, 134.5, 
137.09, 137.12, 137.9, 138.0, 139.5, 162.2 (d, J = 246.0 Hz, C-F); MS (ESI): m/z = not ionisable 
[M++H]. 
3-(6-(4-Fluoro-2-methylphenyl)naphthalen-1-yl)pyridine, 10. Synthesised according to 
Method A using compound 10a (0.15 g, 0.48 mmol) and 3-pyridineboronic acid (0.09 g, 0.71 
mmol); yield: 0.05 g (31 %); colourless oil; Rf = 0.51 (DCM / MeOH, 98:2); IR (ATR) υ (cm
-1) 3049 
(w), 1585 (w), 1493 (s), 1408 (w), 1270 (m), 1222 (s), 1186 (w), 1152 (m), 1025 (w), 965 (m), 866 
(m), 836 (w), 810 (s), 794 (s), 761 (s), 717 (s), 657 (m), 583 (m); δH (CDCl3, 500 MHz) 2.30 (s, 3H), 
6.98 (dt, J = 2.7, 8.4 Hz, 1H), 7.02 (dd, J = 2.6, 9.8 Hz, 1H), 7.28 (dd, J = 6.0, 8.4 Hz, 1H), 7.42 (dd, 
J = 1.8, 8.7 Hz, 1H), 7.45 (dd, J = 0.9, 7.1 Hz, 1H), 7.46 (dd, J = 4.9, 7.8 Hz, 1H), 7.60 (dd, J = 7.1, 
8.2 Hz, 1H), 7.83 (d, J = 1.6 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.87 (td, J = 1.8, 7.8 Hz, 1H), 7.93 (d, J 
= 8.3 Hz, 1H), 8.71 (dd, J = 1.6, 4.9 Hz, 1H), 8.80 (d, J = 2.1 Hz, 1H); δC (CDCl3, 125 MHz) 20.6, 
20.7, 112.0, 112.6, 112.7, 116.8, 117.0, 123.2, 125.1, 125.9, 127.4, 128.4, 128.5, 128.6, 130.4, 
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130.8, 131.3, 131.4, 133.7, 136.3, 137.3, 137.4, 138.0, 138.9, 148.6, 150.6, 162.2 (d, J = 245.9 
Hz, C-F); MS (ESI): m/z = 313.9 [M++H]. 
3-(5-Bromo-6-methoxynaphthalen-2-yl)pyridine, 11a. Synthesised according to Method A 
using compound 3b (0.75 g, 2.41 mmol) and 3-pyridineboronic acid (0.36 g, 2.89 mmol); yield: 
0.19 g (25 %); white solid; Rf = 0.22 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 3.98 (s, 3H), 7.26 
(d, J = 9.0 Hz, 1H), 7.34 (ddd, J = 0.7, 4.8, 7.9 Hz, 1H), 7.72 (dd, J = 1.9, 8.8 Hz, 1H), 7.82 (d, J = 
9.0 Hz, 1H), 7.90-7.92 (m, 2H), 8.25 (d, J = 8.8 Hz, 1H), 8.56 (dd, J = 1.5, 4.8 Hz, 1H), 8.90 (d, J = 
1.9 Hz, 1H); δC (CDCl3, 125 MHz) 57.1, 108.5, 114.2, 123.6, 126.1, 126.8, 127.2, 129.3, 129.9, 
132.7, 133.6, 134.4, 136.0, 148.4, 148.6, 154.2, 190.7; MS (EI): m/z = 314.9, 316.0 [M++H]. 
3-(5-(4-Fluorophenyl)-6-methoxynaphthalen-2-yl)pyridine, 11. Synthesised according to 
Method A using compound 11a (0.10 g, 0.32 mmol) and 4-fluorophenylboronic acid (0.07 g, 
0.48 mmol); yield: 0.08 g (77 %); white solid; Rf = 0.23 (DCM / MeOH, 98:2); IR (ATR) υ (cm
-1) 
2840 (w), 1735 (w), 1599 (w), 1512 (m), 1488 (m), 1463 (w), 1281 (w), 1256 (s), 1214 (m), 1159 
(w), 1132 (w), 1068 (s), 1018 (w), 914 (w), 900 (w), 833 (m), 808 (s), 758 (w), 715 (s), 689 (w), 
625 (w), 556 (m), 535 (m); δH (CDCl3, 500 MHz) 3.87 (s, 3H), 7.19-7.23 (m, 2H), 7.36 (dd, J = 5.5, 
8.7 Hz, 2H), 7.42 (dd, J = 4.9, 7.8 Hz, 1H), 7.43 (d, J = 9.1 Hz, 1H), 7.56-7.60 (m, 2H), 7.96-8.00 
(m, 2H), 8.04 (s, 1H), 8.63 (dd, J = 1.3, 4.8 Hz, 1H), 8.96 (d, J = 1.8 Hz, 1H); δC (CDCl3, 125 MHz) 
56.6, 114.3, 115.2, 115.3, 123.7, 124.1, 125.5, 126.1, 126.2, 129.1, 129.7, 131.79, 131.81, 
132.48, 132.54, 132.6, 133.2, 134.6, 136.6, 148.2, 148.3, 154.3, 162.1 (d, J = 245.9 Hz, C-F); MS 
(ESI): m/z = 329.9 [M++H]. 
2-(3-Bromophenyl)-6-methoxynaphthalene, 12a. Synthesised according to Method A using 
1,3-dibromobenzene (0.93 mL, 7.43 mmol) and 3-methoxyphenylboronic acid (1.50 g, 7.43 
mmol); yield: 1.82 g (78 %); white solid; Rf = 0.68 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 4.88 
(s, 2H), 7.17 (d, J = 2.5 Hz, 1H), 7.19 (dd, J = 2.6, 8.9 Hz, 1H), 7.32-7.35 (m, 2H), 7.47-7.49 (m, 
1H), 7.61-7.63 (m, 1H), 7.66 (dd, J = 1.8, 8.4 Hz, 1H), 7.79-7.82 (m, 2H), 7.84-7.85 (m, 1H), 7.95 
(d, J = 1.7, 1H); δC (CDCl3, 125 MHz) 55.4 (CH3), 105.6, 119.4, 123.0, 125.7, 125.78, 125.82, 
127.4, 128.5, 129.1, 129.8, 129.9, 130.2, 130.3, 131.1, 134.1, 134.8, 143.4, 158.0; MS (EI): m/z = 
312.9, 316.0 [M++H]. 
3-(3-(6-Methoxynaphthalen-2-yl)phenyl)pyridine, 12. Synthesised according to Method A 
using compound 12a (0.30 g, 0.96 mmol) and 3-pyridineboronic acid (0.15 g, 1.15 mmol); yield: 
0.22 g (74 %); light-yellow solid: mp 157 °C; Rf = 0.71 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 
2925 (w), 1605 (w), 1483 (w), 1385 (w), 1268 (w), 1244 (m), 1205 (s), 1165 (m), 1026 (m), 858 
(s), 819 (s), 792 (s), 714 (s); δH (CDCl3, 500 MHz) 3.95 (s, 3H), 7.19-7.21 (m, 2H), 7.42 (dd, J = 4.9, 
7.7 Hz, 1H), 7.59 (m, 2H), 7.73-7.77 (m, 2H), 7.82 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.90 
(s, 1H), 7.99 (td, J = 1.6, 7.9 Hz, 1H), 8.03 (s, 1H), 8.63 (d, J = 4.1 Hz, 1H), 8.95 (d, J = 1.3 Hz, 1H); 
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δC (CDCl3, 125 MHz) 55.4, 105.6, 119.3, 123.7, 125.80, 125.84, 125.9, 126.1, 127.1, 127.4, 129.1, 
129.6, 129.7, 134.0, 134.7, 135.8, 142.2, 148.2, 148.3, 157.9; MS (ESI): m/z = 312.2 [M++H]. 
4-(3-(6-Methoxynaphthalen-2-yl)phenyl)pyridine, 13. Synthesised according to Method A 
using compound 12a (0.40 g, 1.28 mmol) and 4-fluorophenylboronic acid (0.19 g, 1.53 mmol); 
yield: 0.26 g (67 %); white solid; Rf = 0.54 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 3058 (w), 1593 
(s), 1546 (w), 1489 (m), 1386 (w), 1268 (w), 1244 (m), 1205 (s), 1164 (w), 1025 (m), 895 (w), 857 
(s), 828 (w), 816 (s), 795 (s), 707 (w), 616 (m), 573 (w), 537 (w), 510 (w); δH (CDCl3, 500 MHz) 
3.95 (s, 3H), 7.18 (d, J = 2.5 Hz, 1H), 7.20 (dd, J = 2.5, 8.9 Hz, 1H), 7.58-7.63 (m, 4H), 7.76 (dd, J = 
1.8, 8.5 Hz, 1H), 7.77 (td, J = 1.5, 7.4 Hz, 1H), 7.81 (d, J = 8.9 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 
7.93-7.94 (m, 1H), 8.02 (d, J = 1.5 Hz, 1H), 8.69-8.70 (m, 2H); δC (CDCl3, 125 MHz) 55.3, 105.5, 
119.3, 121.6, 121.7, 125.6, 125.7, 125.8, 125.9, 126.9, 127.4, 127.8, 129.05, 129.07, 129.1, 
129.5, 129.7, 133.9, 135.7, 138.7, 142.1, 148.3, 150.18, 150.24, 157.9; MS (ESI): m/z = 312.1 
[M++H]. 
3-(6-Methoxynaphthalen-2-yl)benzaldehyde, 16b. Synthesised according to Method A using 
3-bromobenzaldehyde (1.50 g, 7.58 mmol) and 3-methoxyphenylboronic acid (1.00 mL, 8.33 
mmol); yield: 1.81 g (91 %); white solid; Rf = 0.51 (hexane / EtOAc, 80:20); MS (EI): m/z = 262.0 
[M++H]. 
4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)benzaldehyde, 17c. Synthesised accord-ing 
to Method A using compound 17d (6.18 g, 18.30 mmol) and 4-formylphenylboronic acid (4.13 g, 
27.50 mmol). Then the desired product was taken to the next step without further purification; 
yield: 6.07 g (91 %); Rf = 0.43 (hexane / EtOAc, 90:10). 
1,6-Dibromo-2-methoxynaphthalene, 3b. To a solution of 2-bromo-6-methoxynaphthalene 
(3.65 g, 15.24 mmol) in THF (30 mL) was added N-bromosuccinimide (3.01 g, 16.76 mmol). Then 
the solution was heated to reflux for 2 hours. After cooling to ambient temperature, it was 
diluted with water (50 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic 
phases were washed with 1 N HCl, brine, dried over Na2SO4 and evaporated under reduced 
pressure. Then the desired product was taken to the next step without further purification; 
yield: 4.82 g (100 %); white solid; Rf = 0.48 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.02 (s, 
3H), 7.27 (d, J = 9.5 Hz, 1H), 7.60 (d, J = 9.1 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.92 (s, 1H), 8.08 (d, 
J = 9.1 Hz, 1H); δC (CDCl3, 125 MHz) 57.0 (CH3), 108.7, 114.5, 118.1, 128.0, 129.8, 130.6, 130.9, 
131.7, 154.0, 171.0; MS (ESI): m/z = not ionisable [M++H]. 
Method B: Ether cleavage with BBr3. To a solution of the corresponding ether (1 eq) in DCM 
(5 mL / mmol) at -78 °C was added 1 M borontribromide in DCM (5 eq). The resulting mixture 
was stirred at rt for 16 hours. Then water (25 mL) was added and the emulsion was stirred for 
further 30 minutes. The resulting mixture was extracted with ethyl acetate (3 x 25 mL). The 
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combined organic phases were washed with brine, dried over Na2SO4 and evaporated under 
reduced pressure. Then the desired product was purified by chromatography on silica gel. 
6-(4-Fluorophenyl)-1-(pyridin-3-yl)naphthalen-2-ol, 4. Synthesised according to Method B 
using 3 (0.14 g, 0.43 mmol) and BBr3 (2.20 mL, 2.20 mmol); yield: 0.10 g (75 %); light-yellow 
solid: mp 234 °C; Rf = 0.42 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 2922 (w), 1595 (w), 1498 (s), 
1350 (m), 1324 (w), 1291 (m), 1257 (w), 1228 (m), 1188 (w), 1159 (w), 1052 (w), 943 (m), 846 
(w), 816 (s), 769 (w), 710 (s), 662 (w), 638 (m), 520 (m); δH (CDCl3 + CD3OD, 500 MHz) 7.01-7.04 
(m, 2H), 7.16 (d, J = 8.9 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.42-7.46 (m, 2H), 7.51-7.53 (m, 2H), 
7.72 (d, J = 8.9 Hz, 1H), 7.78 (dd, J = 1.6, 7.8 Hz, 1H), 7.84 (s, 1H), 8.48 (d, J = 4.6 Hz, 1H), 8.51 (s, 
1H).; δC (CDCl3 + CD3OD, 125 MHz) 115.8, 116.0, 117.59, 117.60, 118.8, 124.1, 124.7, 126.1, 
126.4, 128.87, 128.94, 129.1, 130.5, 133.0, 133.4, 135.2, 137.29, 137.32, 140.2, 147.4, 151.2, 
152.4, 162.7 (d, J = 245.9 Hz, C-F); MS (ESI): m/z = 314.0 [M++H]. 
6-(3-(Pyridin-3-yl)phenyl)naphthalen-2-ol, 14. Synthesised according to Method B using 12 
(0.09 g, 0.29 mmol) and BBr3 (1.00 mL, 1.00 mmol); yield: 0.06 g (67 %); light-yellow solid: mp 
223 °C; Rf = 0.47 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 2962 (w), 1626 (w), 1596 (m), 1482 (w), 
1428 (m), 1396 (w), 1260 (m), 1236 (m), 1199 (m), 1104 (s), 1020 (s), 848 (w), 783 (s), 703 (s), 
674 (w); δH (CDCl3 + CD3OD 500 MHz) 7.11 (dd, J = 2.4, 8.8 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 7.45-
7.48 (m, 1H), 7.50-7.52 (m, 2H), 7.52-7.56 (q, J = 7.6 Hz, 1H), 7.65-7.67 (dd, J = 1.8, 8.6 Hz, 1H), 
7.70-7.72 (m, 2H), 7.74 (d, J = 8.8 Hz, 1H), 7.83-7.84 (m, 1H), 7.95 (s, 1H), 8.04 (d, J = 7.9 Hz, 1H), 
8.56 (s, 1H), 8.88 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 109.0, 113.1, 118.8, 125.6, 125.7, 125.8, 
126.0, 127.0, 127.3, 128.6, 129.6, 129.8, 134.3, 135.0, 149.9, 155.0, 156.9, 160.2; MS (ESI): m/z 
= 298.3 [M++H]. 
6-(3-(Pyridin-4-yl)phenyl)naphthalen-2-ol, 15. Synthesised according to Method B using 13 
(0.20 g, 0.64 mmol) and BBr3 (2.60 mL, 2.60 mmol); yield: 0.16 g (86 %); light-yellow solid; Rf = 
0.38 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 3300-2450 (w), 1625 (w), 1598 (m), 1546 (w), 1494 
(w), 1450 (w), 1398 (w), 1240 (m), 1218 (w), 1203 (m), 1126 (w), 1069 (w), 1007 (m), 981 (w), 
860 (m), 835 (m), 812 (w), 785 (s), 697 (m), 624 (m), 571 (w); δH ((CD3)2SO, 500 MHz) 7.13 (dd, J 
= 2.4, 8.8 Hz, 1H), 7.17 (d, J = 2.2 Hz, 1H), 7.63-7.65 (m, 1H), 7.77-7.81 (m, 2H), 7.84-7.88 (m, 
5H), 8.13-8.14 (m, 1H), 8.22 (s, 1H), 8.66-8.68 (m, 2H), 9.83 (s, 1H); δC ((CD3)2SO, 125 MHz) 
108.4, 119.0, 121.4, 125.0, 125.3, 125.4, 126.7, 127.4, 127.9, 129.78, 129.81, 133.7, 134.0, 
137.9, 141.2, 147.0, 150.1, 155.6; MS (ESI): m/z = 298.2 [M++H]. 
5-Bromobenzo[de]isochromene-1,3-dione, 6d. Synthesised according to Mitchell et al.34 To 
a solution of benzo[de]isochromene-1,3-dione (20.00 g, 100.92 mmol) in sulfuric acid (400 mL) 
was added silver sulfate (16.00 g, 51.32 mmol) and then bromine (6.41 mL, 125.15 mmol) was 
carefully dropped. Then the resulting mixture was heated at 65 °C for 6 hours. After cooling to 
ambient temperature, the reaction mixture was filtered and then carefully poured into ice 
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water (3.2 L). The precipitate was filtrated and washed first with water and then with ethanol. A 
further purification was not necessary; yield: 27.26 g (100 %); white-off solid; Rf = 0.72 (DCM / 
MeOH, 95:5); MS (EI): m/z = 275.8, 278.9 [M++H]. 
6-Bromo-1-naphthoic acid, 6c. Synthesised according to Leuck et al.35 To a solution of 6d 
(10.10 g, 36.45 mmol) and sodium hydroxide in water (240 mL) was added a solution of yellow 
mercury oxide (11.00 g, 50.86 mmol) in water (30 mL) and acetic acid (10 mL). The resulting 
mixture was heated under reflux for 4 days. Then 5 N hydrochloric acid (200 mL) was added and 
the mixture heated to reflux for 4 hours. After that, the crude was filtered at 0 °C. After 
fractional recrystallisation from acetic acid, the more soluble 6c remained in the mother liquor; 
yield: 2.10 g (23 %); white-off solid; Rf = 0.49 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.42-
7.47 (m, 2H), 7.51-7.52 (m, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H), 8.16 (d, J = 7.3 
Hz, 1H), 8.86 (d, J = 8.6 Hz, 1H); δC (CDCl3, 125 MHz) 124.6, 126.0, 126.2, 127.5, 127.7, 128.6, 
130.6, 133.5, 134.0; MS (EI): m/z = 249.8, 252.9 [M++H]. 
3-Bromo-1-naphthoic acid, 9c. Synthesised according to Leuck et al.35 To a solution of 6d 
(10.10 g, 36.45 mmol) and sodium hydroxide in water (240 mL) was added a solution of yellow 
mercury oxide (11.00 g, 50.86 mmol) in water (30 mL) and acetic acid (10 mL). The resulting 
mixture was heated under reflux for 4 days. Then 5 N hydrochloric acid (200 mL) was added and 
the mixture heated to reflux for 4 hours. After that, the crude was filtered at 0 °C. After 
fractional recrystallisation from acetic acid, the less soluble 9c came in the early fractions; yield: 
4.90 g (54 %); white-off solid; Rf = 0.39 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.51-7.54 
(m, 1H), 7.59-7.62 (m, 1H), 7.76 (d, J = 8.2 Hz, 1H), 8.18 (d, J = 2.0 Hz, 1H), 8.40 (d, J = 2.1 Hz, 
1H), 8.94 (d, J = 8.7 Hz, 1H); δC (CDCl3, 125 MHz) 118.2, 126.0, 127.4, 127.8, 128.5, 130.1, 134.6, 
136.2; MS (EI): m/z = 249.8, 252.9 [M++H]. 
Method C: Reduction with LiAlH4. To an ice-cooled solution of the corresponding carboxylic 
acid (1 eq) in THF or diethylether (5 mL / mmol) was carefully dropped LiAlH4 (10 eq) in 
diethylether (5 mL / mmol). Then the resulting mixture was heated to reflux for 1 hour. After 
cooling to ambient temperature, water (25 mL) was added, and after phase separation the 
aqueous phase was extracted with ethyl acetate (3 x 25 mL). The combined organic phases 
were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Then the 
desired product was purified by chromatography on silica gel. 
(6-Bromonaphthalen-1-yl)methanol, 6b. Synthesised according to Method C using 6c (2.50 
g, 9.96 mmol), LiAlH4 (3.90 g, 99.55 mmol) and additional 25 mL THF; yield: 2.19 g (87 %); white-
off solid; Rf = 0.44 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 5.09 (s, 2H), 7.44-7.47 (m, 1H), 
7.51 (d, J = 6.9 Hz, 1H), 7.60 (dd, J = 2.1, 9.0 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 9.0 Hz, 
1H), 8.02 (d, J = 2.0 Hz, 1H); MS (EI): m/z = 235.9, 238.9 [M++H]. 
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(6-Bromonaphthalen-2-yl)methanol, 8b. Synthesised according to Method C using 6-bromo-
2-naphthoic acid (3.00 g, 11.95 mmol) and LiAlH4 (4.68 g, 119.48 mmol); yield: 2.78 g (90 %); 
white solid; Rf = 0.19 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.85 (s, 2H), 7.50 (dd, J = 1.6, 
8.5 Hz, 1H), 7.55 (dd, J = 2.0, 8.8 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.78 (s, 
1H), 8.00 (d, J = 1.6, 1H); δC (CDCl3, 125 MHz) 65.2, 65.5, 119.8, 125.1, 125.3, 125.4, 125.9, 
126.15, 126.18, 127.4, 127.7, 127.9, 128.3, 129.5, 129.6, 129.8, 131.8, 134.0, 138.9; MS (EI): 
m/z = 235.9, 238.9 [M++H]. 
(3-Bromonaphthalen-1-yl)methanol, 9b. Synthesised according to Method C using 6c (2.50 
g, 9.96 mmol), LiAlH4 (3.90 g, 99.55 mmol) and additional 25 mL THF; yield: 2.46 g (98 %); white-
off solid; Rf = 0.34 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 5.14 (s, 2H), 7.52-7.56 (m, 2H), 
7.65 (d, J = 1.9 Hz, 1H), 7.78 (dd, J = 1.9, 7.6 Hz, 1H), 7.97 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H); δC 
(CDCl3, 125 MHz) 62.8 (CH2), 119.4, 123.6, 126.6, 126.9, 127.8, 128.1, 129.5, 130.1, 134.9, 
138.4; MS (EI): m/z = 235.9, 238.9 [M++H]. 
Method D: CDI reaction. To a solution of the corresponding alcohol (1 eq) in NMP or 
acetonitrile (10 mL / mmol) was added CDI (5 eq) and imidazole (2 eq). Then the solution was 
heated to reflux for 16 hours. After cooling to ambient temperature, it was diluted with water 
(50 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic phases were 
washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Then the 
desired product was purified by chromatography on silica gel. 
1-((6-(4-Fluorophenyl)naphthalen-1-yl)methyl)-1H-imidazole, 6. Synthesised according to 
Method D using 6a (0.15 g, 0.60 mmol), CDI (0.39 g, 2.38 mmol) and imidazole (0.04 g, 0.60 
mmol); yield: 0.12 g (67 %); white solid; Rf = 0.39 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 3047 
(w), 1604 (w), 1502 (s), 1287 (w), 1226 (s), 1159 (m), 1107 (w), 1075 (w), 906 (w), 817 (s), 
759(m), 736 (m), 662 (m), 508 (m); δH (CDCl3, 500 MHz) 5.61 (s, 2H), 6.95 (s, 1H), 7.12 (s, 1H), 
7.16-7.21 (m, 3H), 7.46-7.49 (m, 1H), 7.63 (s, 1H), 7.66 (dd, J = 5.3, 8.6 Hz, 2H), 7.74 (dd, J = 1.8, 
8.7 Hz, 1H), 7.91 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 9.0 Hz, 1H), 8.04 (d, J = 1.6 Hz, 1H); δC (CDCl3, 125 
MHz) 48.8, 115.4, 115.8, 115.9, 119.4, 119.5, 123.1, 126.0, 126.3, 126.4, 126.5, 126.6, 128.9, 
129.0, 129.5, 129.9, 131.1, 134.1, 136.5, 138.0, 141.2, 141.9, 162.7 (d, J = 247.1 Hz, C-F); MS 
(ESI): m/z = 303.1 [M++H]. 
1-((6-(4-Fluorophenyl)-2-methoxynaphthalen-1-yl)methyl)-1H-imidazole, 7. Synthesised 
according to Method D using 7a (0.10 g, 0.35 mmol) and CDI (0.12 g, 0.71 mmol) in acetonitrile 
as solvent; yield: 0.06 g (49 %); light-yellow solid: mp 128 °C; Rf = 0.52 (DCM / MeOH, 95:5); IR 
(ATR) υ (cm-1) 1601 (w), 1503 (s), 1257 (s), 1235 (s), 1162 (w), 1096 (s), 1075 (w), 1056 (w), 1026 
(w), 904 (w), 844 (w), 823 (w), 788 (w), 733 (w), 662 (m), 623 (m), 551 (m), 505 (s); δH (CDCl3, 
500 MHz) 4.00 (s, 3H), 5.58 (s, 2H), 6.97 (d, J = 10.7 Hz, 2H), 7.14-7.18 (m, 2H), 7.34 (d, J = 9.1 
Hz, 1H), 7.58 (s, 1H), 7.63 (dd, J = 5.3, 8.7 Hz, 2H), 7.73 (dd, J = 1.9, 8.8 Hz, 1H), 7.93 (d, J = 9.1 
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Hz, 1H), 7.96 (d, J = 1.8 Hz, 1H), 7.99 (d, J = 8.9 Hz, 1H); δC (CDCl3, 125 MHz) 40.6, 56.3, 113.3, 
115.6, 115.7, 115.8, 119.0, 122.5, 126.4, 127.1, 128.6, 128.7, 128.9, 129.2, 131.1, 131.9, 135.5, 
136.6, 137.1, 155.7, 162.5 (d, J = 246.7 Hz, C-F); MS (ESI): m/z = 333.1 [M++H]. 
1-((6-(4-Fluorophenyl)naphthalen-2-yl)methyl)-1H-imidazole, 8. Synthesised according to 
Method D using 8a (0.15 g, 0.60 mmol) and CDI (0.50 g, 3.08 mmol) in acetonitrile as solvent; 
yield: 0.12 g (67 %); white solid: mp 114 °C; Rf = 0.50 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 
3099 (w), 1603 (m), 1503 (s), 1439 (w), 1293 (w), 1231 (s), 1160 (w), 1105 (w), 1089 (w), 910 
(m), 842 (m), 816 (s), 772 (w), 657 (s), 558 (m), 519 (w); δH (CDCl3, 500 MHz) 5.29 (s, 2H), 6.96 
(s, 1H), 7.13 (s, 1H), 7.15-7.19 (m, 2H), 7.29 (dd, J = 1.5, 8.5 Hz, 1H), 7.61 (s, 1H), 7.64-7.67 (m, 
3H), 7.72 (dd, J = 1.8, 8.5 Hz, 1H), 7.85-7.88 (m, 2H), 7.97 (s, 1H); δC (CDCl3, 125 MHz) 51.0, 
115.7, 115.9, 119.4, 125.4, 126.1, 126.2, 128.5, 128.9, 129.0, 129.2, 129.8, 132.3, 133.2, 133.7, 
136.85, 136.88, 137.5, 138.3, 162.6 (d, J = 246.9 Hz, C-F); MS (ESI): m/z = 302.9 [M++H]. 
1-((3-(4-Fluorophenyl)naphthalen-1-yl)methyl)-1H-imidazole, 9. Synthesised according to 
Method D using 9a (0.15 g, 0.60 mmol), CDI (0.39 g, 2.38 mmol) and imidazole (0.04 g, 0.60 
mmol); yield: 0.13 g (71 %); light-yellow oil; Rf = 0.23 (DCM / MeOH, 98:2); IR (ATR) υ (cm
-1) 
3057 (w), 1606 (w), 1511 (s), 1229 (s), 1160 (m), 1107 (w), 1077 (w), 832 (s), 790 (w), 749 (m), 
663 (m), 519 (w); δH (CDCl3, 500 MHz) 5.64 (s, 2H), 6.97 (s, 1H), 7.13 (s, 1H), 7.14-7.17 (m, 2H), 
7.38 (s, 1H), 7.53-7.58 (m, 2H), 7.60 (dd, J = 5.3, 8.6 Hz, 2H), 7.69 (s, 1H), 7.87-7.89 (m, 1H), 
7.94-7.96 (m, 1H), 8.00 (s, 1H); δC (CDCl3, 125 MHz) 48.9, 115.7, 115.8, 116.0, 119.5, 122.2, 
123.6, 124.7, 125.7, 126.3, 126.79, 126.82, 127.1, 127.2, 128.8, 128.9, 129.3, 129.5, 129.9, 
131.9, 132.7, 134.1, 136.27, 136.29, 137.2, 162.7 (d, J = 247.4 Hz, C-F); MS (ESI): m/z = 
303.0[M++H]. 
1-(3-(6-Methoxynaphthalen-2-yl)benzyl)-1H-imidazole, 16. Synthesised according to 
Method D using 7a (0.20 g, 0.76 mmol) and CDI (0.38 g, 2.27 mmol) in acetonitrile as solvent; 
yield: 0.12 g (51 %); white solid: mp 130 °C; Rf = 0.38 (DCM / MeOH, 95:5); IR (ATR) υ (cm
-1) 
2966 (w), 1626 (w), 1603 (w), 1492 (w), 1453 (w), 1388 (w), 1256 (m), 1227 (m), 1212 (m), 1073 
(m), 1022 (s), 883 (w), 855 (s), 814 (s), 791 (m), 745 (s), 662 (s); δH (CDCl3, 500 MHz) 3.94 (s, 3H), 
5.20 (s, 2H), 6.97 (s, 1H), 7.13-7.16 (m, 3H), 7.19 (dd, J = 2.5, 8.9 Hz, 1H), 7.44-7.47 (m, 1H), 
7.48-7.49 (m, 1H), 7.63-7.66 (m, 3H), 7.78-7.81 (m, 2H), 7.92 (d, J = 1.5 Hz, 1H); δC (CDCl3, 125 
MHz) 51.0, 55.3, 105.7, 119.3, 125.7, 125.8, 125.9, 126.1, 127.2, 127.4, 129.1, 129.5, 129.7, 
134.0, 135.5, 136.7, 142.1, 158.0; MS (ESI): m/z = 315.0 [M++H]. 
1-(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)benzyl)-1H-imidazole, 17a. Synthesi-sed 
according to Method D using 17b (3.46 g, 9.50 mmol) and CDI (7.70 g, 47.40 mmol). Then the 
desired product was taken to the next step without further purification; yield: 3.11 g (79 %); 
white solid; Rf = (DCM / MeOH, 98:2). 
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6-Bromo-2-methoxy-1-naphthaldehyde, 7c. To a solution of 2-bromo-6-methoxy-
naphthalene (5.00 g, 21.09 mmol) in DCM (100 mL) was added TiCl4 (4.00 g, 21.09 mmol) and 
1,1-dichloromethylmethylether (2.43 g, 21.09mmol). Then the resulting mixture was stirred at 
40 °C for 2 hours. After complete conversion, water (25 mL) was added, the phases were 
separated, and the aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined 
organic phases were washed with brine, dried over Na2SO4 and evaporated under reduced 
pressure. Then the desired product was taken to the next step without further purification; 
yield: g (100 %); white solid. 
Method E: Reduction with NaBH4. To an ice-cooled solution of the corresponding aldehyde 
(1 eq) in THF (5 mL / mmol) was added NaBH4 (2 eq) in methanol (5 mL / mmol). Then the 
resulting mixture was stirred at rt for 1 hour. After complete conversion, the solvent was 
distilled off under reduced pressure. Then water (25 mL) was added, and the resulting mixture 
was extracted with ethyl acetate (3 x 25 mL). The combined organic phases were washed with 
brine, dried over Na2SO4 and evaporated under reduced pressure. Then the desired product 
was purified by chromatography on silica gel. 
(6-(4-Fluorophenyl)-2-methoxynaphthalen-1-yl)methanol, 7a. Synthesised according to 
Method E using 7b (0.28 g, 0.98 mmol) and NaBH4 (0.08 g, 1.96 mmol); yield: 0.25 g (91 %); 
white solid; Rf = 0.56 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 4.01 (s, 3H), 5.21 (s, 2H), 7.15-
7.18 (m, 2H), 7.33 (d, J = 9.1 Hz, 1H), 7.66 (dd, J = 5.3, 8.9 Hz, 2H), 7.74 (dd, J = 1.9, 8.9 Hz, 1H), 
7.89 (d, J = 9.1 Hz, 1H), 7.95 (d, J = 1.9 Hz, 1H), 8.18 (d, J = 8.9 Hz, 1H); δC (CDCl3, 125 MHz) 55.9, 
56.5, 113.5, 115.6, 115.8, 121.2, 123.7, 126.1, 126.5, 128.66, 128.72, 129.4, 130.3, 131.9, 135.3, 
136.98, 137.00, 155.3, 162.4 (d, J = 246.5 Hz, C-F); MS (APCI): m/z = 266.9 [M++H]. 
(3-(6-Methoxynaphthalen-2-yl)phenyl)methanol, 16a. Synthesised according to Method E 
using 16b (0.40 g, 1.53 mmol) and NaBH4 (0.12 g, 3.05 mmol); yield: 0.40 g (100 %); white solid; 
Rf = 0.50 (DCM / MeOH, 98:2); MS (EI): m/z = 312.9, 316.0 [M
++H]. 
(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)phenyl)methanol, 17b. Synthesised 
according to Method E using 17c. (4.55 g, 12.50 mmol) and NaBH4 (0.95 g, 25.00 mmol). Then 
the desired product was taken to the next step without further purification; yield: 3.46 g (76 %); 
white solid; Rf = 0.35 (hexane / EtOAc, 70:30). 
(6-Bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane, 17d. To a solution of 6-
bromonaphthalen-2-ol (10.00 g, 44.80 mmol) and imidazole (3.40 g, 49.30 mmol) in DCM (100 
mL) was added dropwise a TBDMS-Cl (7.40 g, 49.30 mmol) solution in DCM (50 mL). Then the 
resulting mixture was stirred at rt for 16 hours. After complete conversion, water (25 mL) was 
added, the phases separated, and the aqueous layer extracted with ethyl acetate (3 x 25 mL). 
The combined organic phases were washed with brine, dried over Na2SO4 and evaporated 
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under reduced pressure. Then the desired product was taken to the next step without further 
purification; yield: 14.81 g (98 %); white solid. 
6-(4-((1H-Imidazol-1-yl)methyl)phenyl)naphthalen-2-ol, 17. To a solution of 17a (3.11 g, 
7.50 mmol) in THF (50 mL) was added dropwise a 1 M TBAF solution in THF (7.50 mL, 7.50 
mmol). Then the resulting mixture was stirred at rt for 16 hours. After complete conversion, 
water (25 mL) and ethyl acetate (25 mL) were added, the phases separated, and the aqueous 
layer extracted with ethyl acetate (3 x 25 mL). The combined organic phases were washed with 
brine, dried over Na2SO4 and evaporated under reduced pressure. Then the desired product 
was purified by chromatography on silica gel; yield: 1.96 g (87 %); brown solid; Rf = 0.50 (EtOAc 
/ MeOH, 95:5); IR (ATR) υ (cm-1) 3113 (w), 3026 (w), 1603 (m), 1516 (m), 1235 (s), 1198 (s), 1108 
(m), 1080 (m), 831 (s), 806 (s); δH (CDCl3, 500 MHz) 5.21 (s, 2H), 6.90 (t, J = 1.0 Hz, 1H), 7.08 (dd, 
J = 2.4 Hz, J = 8.7 Hz, 1H), 7.11 (d, J = 2.3 Hz, 1H), 7.20 (t, J = 1.2 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 
7.67 (dd, J = 1.8 Hz, J = 8.6 Hz, 1H), 7.70-7.74 (m, 3H), 7.77 (t, J = 0.9 Hz, 1H), 7.79 (d, J = 8.9 Hz, 
1H), 8.03 (d, J = 1.3 Hz, 1H), 9.82 (s, 1H); δC (CDCl3, 125 MHz) 49.1 (CH2), 108.4, 119.0, 119.5, 
125.0, 125.1, 126.7, 126.8, 127.9, 128.1, 128.7 (Cq), 129.8, 133.7 (Cq), 133.8 (Cq), 136.5 (Cq), 
137.4 , 139.6 (Cq), 155.5 (C-OH); MS (ESI): m/z = 301.0 [M
++H]. 
Molecular Modelling. Compound 15 was docked in 50 independent genetic algorithm (GA) 
runs using GOLD. Heme iron was chosen as active-site origin, while the radius was set equal to 
19 Å. The automatic active-site detection was switched on. A distance constraint of a minimum 
of 1.9 and a maximum of 2.5 Å between the sp2-hybridised nitrogen of the pyridine and the iron 
was set. Further, some of the GOLDSCORE parameters were modified to improve the weight of 
hydrophobic interaction and of the coordination between iron and nitrogen. The genetic 
algorithm default parameters were set as suggested by the GOLD authors. On the other hand, 
the annealing parameters of fitness function were set at 3.5 Å for hydrogen bonding and 6.5 Å 
for Van der Waals interactions. 
All 50 poses for compound 15 were clustered with ACIAP36, 37 and the representative 
structure of each significant cluster was selected. The quality of the docked representative 
poses was evaluated based on visual inspection of the putative binding modes of the ligands, as 
outcome of docking simulations and cluster analysis. 
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Abstract 
Abiraterone, a steroidal cytochrome P450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is 
currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-
dependent prostate cancer. Since steroidal compounds often show side effects attributable to 
their structure, we have tried to replace the sterane scaffold by nonsteroidal core structures. 
The design and synthesis of 20 new abiraterone mimetics are described. Their activities have 
been tested with recombinant human CYP17 expressed in E. coli. Promising compounds were 
further evaluated for selectivity against CYP11B1, CYP11B2, and the hepatic CYP3A4. 
Compounds 19 and 20 showed comparable activity to abiraterone (IC50 values of 144 and 64 
nM vs 72 nM) and similar or even better selectivity against the other CYP enzymes. Selected 
compounds were also docked into our homology model, and the same binding modes as for 
abiraterone were found. 
 
Introduction 
Prostate cancer (PC) is the most common tumor and age-related cause of death in elder men 
worldwide.1 Because of the advanced age of the patients, less invasive approaches are needed. 
Accordingly, the treatment of choice is ‘watchful waiting,’2 followed by radiation therapy only 
when it is necessary. Since PC is androgen dependent in over 80% of the cases, another current 
standard treatment is orchiectomy, the surgical removal of the testes, usually applied to 
patients under 70 years old. The reduction of testicular androgen production by gonadotropin-
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releasing hormone (GnRH) analogues,3 a ‘medical castration’, is often preferred over the 
surgical one and can also be used for treating older patients. Nevertheless, castration whether 
surgical or medical reduces maximally 90-95% of the daily testosterone production, which is 
often not enough to stop the tumor from growing, since prostate levels of testosterone and 
dihydrotestosterone are still about 25% and 10%, respectively, even after three months of 
treatment with a GnRH agonist.4 
The remaining 5-10% of the androgens are produced in the adrenals. In the 1980s, Labrie5 
hypothesized that additionally counteracting adrenal androgens by application of 
antiandrogens would further inhibit tumor growth. This approach, known as ‘combined 
androgen blockade’ (CAB), has been widely used in the past. The results have been partially 
positive, especially in patients with minimal disease and good performance status. However, it 
must be mentioned that antiandrogen therapy is associated with notable side effects.6 Another 
drawback of CAB is that in refractory PC regression is observed after discontinuation of 
antiandrogen administration. This led to the hypothesis that under antiandrogen treatment 
androgen receptor mutations occur causing PC cells to recognize antagonists as agonists.7 
An alternative target proposed in the recent past is the cytochrome P450 enzyme 17α-
hydroxylase-17,20-lyase (CYP17). This enzyme is localized in the endoplasmic reticulum in the 
testes as well as in the adrenals and is the key enzyme for androgen biosynthesis. Its inhibition 
should stop the production of androgens both in the testes and in the adrenals, and therefore, 
inhibitors of CYP17 should be more effective for treating androgen-dependent PC than GnRH 
analogues. Proof of principle was achieved by the unspecific CYP inhibitor ketoconazole, which 
clinically turned out to be a good adjuvant therapeutic capable of reducing testosterone levels.8 
Nevertheless, the side effects shown by this antimycotic compound are the reason that it is not 
used anymore.9 
CYP17 catalyzes two reactions, the 17α-hydroxylation of pregnenolone and progesterone to 
the corresponding 17α alcohols and the subsequent 17,20-lyase reaction cleaving the C17-C20 
bond. This yields the 17-keto androgens androstendione and dehydroepiandrosterone, 
precursors of all other androgens, including testosterone (Chart 1). 
 
 
 
 
 
Chart 1. The role of CYP17 in androgen biosynthesis 
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The side effects of ketoconazole caused others10 and our group to develop steroidal11 and 
nonsteroidal12,13 inhibitors. One compound, the steroidal CYP17 inhibitor abiraterone (Chart 2), 
is currently undergoing phase II clinical trials showing high activity in postdocetaxel castration 
refractory PC patients. In contrast to ketoconazole, it seems to have no dose-limiting toxicity.14 
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Chart 2. Substrate, abiraterone and synthesized mimetics 
Because steroidal compounds often show side effects due to interactions with steroid 
receptors,15 it is our aim to develop nonsteroidal compounds. In this work, we present the 
design, synthesis, in vitro evaluation regarding activity and selectivity and modeling studies of 
nonsteroidal analogues of abiraterone (Chart 3). 
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                                                1-7                                               8-14                                            15-20 
 
Compound R1 R2 n N 
1 F H 1 3 
2 F H 1 4 
3 OMe H 1 4 
4 OMe F 1 4 
5 F H 2 4 
6 F F 2 4 
7 OMe F 2 4 
8 F H 1 3 
9 F H 1 4 
10 OMe H 1 4 
11 F H 2 4 
12 F F 2 4 
13 OH OH 2 4 
14 OH F 2 4 
15 F H 1 3 
16 F H 1 4 
17 F H 2 4 
18 F F 2 4 
19 OH OH 2 4 
20 OH F 2 4 
 
Chart 3. List of synthesized compounds 1-20 
 
Design 
The three most important structural features of abiraterone are the aromatic nitrogen-
containing heterocycle, the hydrophobic steroidal core, and the hydroxy group mimicking the 
oxygen at the 3-position of the substrates. All of them are similarly important for a high affinity 
  
 
V. Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone Analogues: Novel 
CYP17 Inhibitors for the Treatment of Prostate Cancer 
103 
to the enzyme. CYP enzymes have the particularity of bearing a heme moiety in their binding 
site. The complexation of the Fe2+ of the heme with an sp2 hybridized nitrogen as in pyridyl and 
imidazolyl is widely described.16 In recent studies13 we showed that a biphenyl moiety can 
replace the steroidal core AC-rings and that a biphenyl moiety furnished with an imidazolyl-
methylene group ensures high CYP17 inhibitory activity (Chart 2). Introduction of alkyl 
substituents at the methylene bridge13b,f (for example, compound A13f) and first attempts to 
rigidify the structures resulting in indane compounds (like compound B13b) increased activity. 
Interestingly, 4-fluoro substituted compounds in general showed very high inhibitory activity. 
Compound A, the indane ring opened analogue to compound B, was more active in the rat and 
showed a longer plasma half-life and higher bioavailability compared to abiraterone, while its in 
vitro activity with regard to potency and selectivity was not as outstanding as that of the 
steroidal compound. In this work we want to elucidate whether it is possible to further increase 
activity and especially selectivity by additional attempts to rigidify the biphenyl structure and to 
exchange the heterocycle. The resulting compounds are mimics of the steroidal compound 
abiraterone. For the design of the synthesized compounds, the steroidal core was replaced by 
an indane (mimicking the steroidal C- and D-rings) or tetrahydronaphthalene scaffold (for 
expansion of the D-ring) connected to an A-ring mimicking phenyl moiety. Electron donating 
and withdrawing substituents (including hydroxy and fluoro) were introduced in different 
positions at the phenyl ring. The iron-complexing aromatic nitrogen was represented by a 3- or 
4-pyridine moiety. 
Three classes of mimetically relevant compounds were synthesized. Compounds 1-7, 
hydroxylated at the C17 mimicking position, are analogues of the steroidal substrates for the 
second enzymatic step (lyase reaction). Compounds 7-14 bearing a double bond are structurally 
analogous to abiraterone. The saturated alkanes 15-20 show the highest similarity to the first-
step (hydroxylase reaction) substrates. 
In the following, the synthesis, determination of activity, and selectivity and molecular 
modeling studies of the synthesized abiraterone analogues are presented. Besides CYP17 
inhibitory activity, inhibition of other CYP enzymes was examined to exclude possible side 
effects due to unspecific heme iron complexation. Thus, selectivity toward CYP11B1 and 
CYP11B2 was determined, since their biological relevance relies on the fact that CYP11B1 is 
involved in glucocorticoid biosynthesis while CYP11B2 catalyzes the last step in 
mineralocorticoid formation. Special attention was given to the most crucial hepatic enzyme 
CYP3A4, since it is involved in the metabolism of over 50% of all prescription drugs.17 The most 
interesting compounds were docked into our homology-approach derived protein model and 
the binding modes in the active site discussed. 
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Chemistry 
The syntheses of compounds 1-20 are shown in Schemes 1 and 2. In our aim to rigidify our 
biphenylic core structure by connecting the methylene bridge with the C-ring mimicking phenyl 
moiety, we synthesized indane derivatives (Scheme 1), which can be considered abiraterone 
analogues, and expanded the nonaromatic ring by one methylene group yielding 
tetrahydronaphthalene derivatives (Scheme 2). Different substitution patterns at the A-ring 
mimicking phenyl substituent were used. Suzuki coupling18 (Method A) using 5-bromoindanone 
for the abiraterone analogues and 1-tetralon-6-yl trifluoromethanesulfonate, synthesized from 
the respective alcohol, for the tetrahydronaphthalenes yielded the indanones 1a-4a and the 
tetralones 5a-7a. The pyridine moiety was introduced by means of a nucleophilic addition 
(Method B) with the corresponding lithium pyridinyl salt to yield the tertiary alcohols 1-7 and 
13a. The condensation to the corresponding alkenes was performed in HCl/isopropanol (8-12, 
Method C) or in HBr/H2O (13 and 14, Method E). The latter method was applied when a 
simultaneous ether cleavage was desired. The hydration to the saturated rings was carried out 
with Pearlman’s catalyst (Pd(OH)2), resulting in compounds 15-20 (Method D). 
a
b c
d
1 - 4
1a - 4a
O
Br
O
R1
R2
R1
R2
HO Ar
R1
R2
Ar
R1
R2
Ar
8 - 10
15, 16
1: R1 = F, R2 = H, Ar = 3-Py
2: R1 = F, R2 = H, Ar = 4-Py
3: R1 = OMe, R2 = H, Ar = 4-Py
4: R1 = OMe, R2 = F, Ar = 4-Py
8: R1 = F, R2 = H, Ar = 3-Py
9: R1 = F, R2 = H, Ar = 4-Py
10: R1 = OMe, R2 = H, Ar = 4-Py
15: R1 = F, R2 = H, Ar = 3-Py
16: R1 = F, R2 = H, Ar = 4-Py
xHCl
xHCl
O
O
O
HO
O
TfO
O
R2
R1
R2
R1
HO
R2
R1
R2
R1
5: R1 = F, R2 = H
6: R1 = F, R2 = F
7: R1 = OMe, R2 = F
11: R1 = F, R2 = H
12: R1 = F, R2 = F
13: R1 = OH, R2 = OH
14: R1 = OH, R2 = F
17: R1 = F, R2 = H
18: R1 = F, R2 = F
19: R1 = OH, R2 = OH
20: R1 = OH, R2 = F
d
a b c
e f
5 - 7, 13a 11 - 14 17 - 20
N
N N
5a - 7a, 13b5b5c
or a for
7 and 13a
11, 12, 17 and 18 as HCl salts
13, 14, 19 and 20 as HBr salts  
Scheme 1 (left). Synthesis of indane derivatives 
Reagents and conditions: a: Method A: Na2CO3, 
R
1
R
2
C6H3B(OH)2, Pd(PPh3)4, toluene, H2O, reflux, 8 h; 
b: Method B: 3-iodopyridine or 4-bromopyridine, n-
BuLi, THF, Et2O, -78 °C - rt, 3h; c: Method C: HCl in i-
propanol, rt, 2h; d: Method D: Pd(OH)2, ethanol, 
THF, H2, rt, 3h. 
Scheme 2 (down). Synthesis of 
tetrahydronaphthalene derivatives 
Reagents and conditions: a: Method E: HBr, reflux, 
16 h; b: pyridine, Tf2O, DCM, 0 °C - rt, 3h; c: 
Method A: Na2CO3, R
1
R
2
C6H3B(OH)2, Pd(PPh3)4, 
toluene, H2O, reflux, 8 h; d: Method B: 3-
iodopyridine or 4-bromopyridine, n-BuLi, THF, Et2-
O, -78 °C - rt, 3h; e: Method C: HCl in i-propanol, rt, 
2h; f: Method D: Pd(OH)2, ethanol, THF, H2, rt, 3h. 
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Results 
Biological Results. Inhibition of human CYP17 was determined by performing our previously 
described assay.13d For the source of human CYP17, E. coli19 coexpressing human CYP17 and 
NADPH-P450 reductase were used. After homogenization, the 50 000 g sediment was 
incubated with progesterone (25 μM) and the inhibitor.12a Separation of the product was 
performed by HPLC using UV detection. The IC50 values determined for compounds 1-20 are 
shown in Table 1. 
Table 1. Inhibition of CYP17 by alcohols 1-7, alkenes 8-4 and alkanes 15-20 
 
 
 
 
                                                1-7                                               8-14                                            15-20 
 
Structures a CYP17 IC50 [nM] 
b 
R1 R2 n N Comp. 
a 
Alcohols Comp. 
a 
Alkenes Comp. 
a 
Alkanes 
Indanes       
F H 1 3 1 > 20,000 8 2346 15 > 20,000 
F H 1 4 2 333 9 > 20,000 16 233 
OMe H 1 4 3 > 20,000 10 > 5,000   
OMe F 1 4 4 > 10,000     
Hydronaphthalenes       
F H 2 4 5 587 11 > 5,000 17 163 
F F 2 4 6 423 12 > 5,000 18 1222 
OMe F 2 4 7 > 5,000     
OH OH 2 4   13 307 19 144 
OH F 2 4   14 188 20 64 
 
KTZ c 2780 
ABT d 72 
 
a
 Compounds 8-12 and 15-18 were tested as HCl salts and 13, 14, 19 and 20 as HBr salts 
b
 Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. 
Concentration of progesterone (substrate) was 25 μM 
c
 KTZ: ketoconazole 
d 
ABT: abiraterone 
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The compounds can be divided into two classes according to the CD-ring mimicking moiety, 
namely in indane and hydronaphthalene derivatives, and also into three classes regarding the 
pyridyl bearing C atom, that is in alcohols, alkenes, and alkanes. Most of the indane derivatives, 
either bearing a 3-pyridyl or a 4-pyridyl substituent, showed no or little CYP17 inhibition. Only 
compound 2, with a moderate inhibition of 333 nM, and compound 16 (IC50 = 233 nM) were 
active. Interestingly, both compounds contain a 4-pyridyl group as iron-complexing heterocycle 
and a fluorine at R1. 
The hydronaphthalenes were more potent than the indanes, showing a broad range of 
activity. The alkenes (11-14) were weaker inhibitors than the corresponding compounds with a 
single bond, the alcohols (5-7) and tetrahydronaphthalenes (17-20). The inhibition values range 
from about 200 to over 5000 nM, while for the single bond compounds the values range mostly 
from around 100 to 500 nM. An important condition for inhibitory activity in the class of the 
alkanes is a 4-pyridyl substituent. In the 4-position of the phenyl ring (R1) a F or OH group and in 
3-position (R2) H, F, or OH led to highly active compounds. Interestingly, the 3,4-di-F-substituted 
compound 18 only showed moderate activity. One explanation for this finding might be the 
electron withdrawing effect of the two F atoms at the phenyl ring. The most potent compounds 
were the 4-OH compounds 19 and 20 (IC50 = 144 and 64 nM). A hydroxy substituent in 4-
position of the phenyl ring also makes the alkenes from the 4-pyridyl substituted 
dihydronaphthalene type potent inhibitors (compounds 13 and 14). In the class of the indenes, 
3-pyridyl substitution, as in abiraterone, led to an active compound (8) whereas 4-pyridyl 
substitution does not (9). It is striking, that 11 out of the 20 synthesized compounds were more 
active than ketoconazole. The most potent compound 20 showed a slightly higher inhibition 
compared to abiraterone (IC50 = 72 nM). Our seven most potent compounds from this work 
were more active than compound A (345 nM), and regarding compound B (670 nM), nine 
showed significantly higher inhibitory activities for CYP17. In the whole cell assay, i.e., E. coli 
coexpressing human CYP17 and NADPH-P450 reductase,12f the most active compound of this 
series, 20, was also highly active (IC50 < 200 nM). 
Since the target enzyme contains a heme in its binding site, hence CYP/P450 enzyme, which 
is crucial for the enzymatic reaction and for binding the iron-complexing nitrogen containing 
inhibitors, the latter compounds were tested for selectivity against other CYP enzymes. 
Accordingly, selected compounds were tested for inhibitory activity on the steroidogenic CYP 
enzymes CYP11B1 and CYP11B2, key enzymes in glucocorticoid and mineralocorticoid 
biosynthesis. For the assay,20 V79MZh11B1 cells expressing human CYP11B1 and V79MZh11B2 
cells expressing human CYP11B2 were used. The IC50 values determined for selected 
compounds are shown in Table 2. 
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Table 2. Inhibition of CYP11B1, CYP11B2 and CYP3A4 by compounds 1-20 
 
 
 
 
                                                1-7                                               8-14                                            15-20 
 
Comp. a 
Structures CYP11B1 b CYP11B2 b CYP3A4 b 
R1 R2 n N IC50 [nM] IC50 [nM]
 IC50 [nM] 
1 F H 1 3 n.d. c n.d. > 20,000 
2 F H 1 4 > 10,000 816 3231 
3 OMe H 1 4 n.d. n.d. 3291 
4 OMe F 1 4 291 436 3364 
5 F H 2 4 1159 840 8757 
6 F F 2 4 3109 1676 13841 
7 OMe F 2 4 686 945 15190 
8 F H 1 3 n.d. n.d. 6947 
9 F H 1 4 n.d. n.d. 159 
10 OMe H 1 4 n.d. n.d. 2394 
11 F H 2 4 > 10,000 121 4199 
12 F F 2 4 > 20,000 311 3643 
13 OH OH 2 4 > 10,000 1492 357 
14 OH F 2 4 2748 991 2114 
15 F H 1 3 n.d. n.d. 1697 
16 F H 1 4 1076 543 1093 
17 F H 2 4 > 5,000 518 2173 
18 F F 2 4 > 20,000 567 2300 
19 OH OH 2 4 2135 2324 632 
20 OH F 2 4 1370 587 3386 
KTZ d 127 67 72 
ABT e 1608 1751 2704 
 
a
 Compounds 8-12 and 15-18 were tested as HCl salts and 13, 14, 19 and 20 as HBr salts 
b
 Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. 
Concentration of progesterone (substrate) was 25 μM 
c
 n.d.: not determined 
d 
KTZ: ketoconazole 
e 
ABT: abiraterone 
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With the exception of compounds 4 and 7 showing IC50 values of 291 and 686 nM toward 
CYP11B1, respectively, the other tested compounds exhibited IC50 values above 1 μM. Most of 
the compounds (2, 6, 11-14, 17-19) turned out to be more selective than abiraterone (IC50 = 
1608 nM), and all compounds were more selective compared to ketoconazole (127 nM) 
regarding the cortisol forming enzyme. Concerning compound A (66% inhibition at 0.2 μM), all 
compounds from this study showed much higher selectivity. 
The inhibition of CYP11B2 observed with the evaluated compounds was a little higher 
showing IC50 values between 121 and 2324 nM. Compared to abiraterone (IC50 = 1751 nM), 
compounds 6 and 13 exhibited a similar selectivity whereas compound 19 (IC50 = 2324 nM) was 
more selective than the reference. Compared to ketoconazole (IC50 = 67 nM) and compound A 
(66% inhibition at 0.2 μM), all compounds were more selective with the exception of compound 
11 (IC50 = 121 nM). 
The synthesized compounds were also evaluated for inhibition of the most crucial hepatic 
CYP enzyme CYP3A4 in regard to its important role in drug metabolism. Except for compound 9 
(IC50 = 159 nM) and compound 13 (IC50 = 357 nM), the IC50 values for compounds 1-20 were 
between 632 and >20000 nM. These compounds were more selective than ketoconazole (72 
nM) and compound A (88% at 1 μM). Most of the compounds were even more selective than 
abiraterone (IC50 = 2704 nM). 
Molecular Modeling. Since there is no crystal structure of CYP17 available, we recently built 
a homology model using the X-ray structure of human CYP2C9 (PDB ID 1r9o) as template.13e 
Docking simulations with energy minimized compounds were carried out by means of the GOLD 
3.2 software running Linux CentOS 5.1 on an Intel® P4 CPU 3.00 GHz computer, using a slightly 
modified GOLDSCORE function with goldscore.P450_pdb parameters, for a better evaluation of 
hydrophobic interactions. From every class, the most potent compounds were docked into this 
protein model, and in the case of chiral compounds, both enantiomers were docked. 
In Figure 1 two binding modes of the substrate pregnenolone are shown: one already 
described by others21 (SM1 mode) and an additional one (SM2). Poses in SM1 occur more often 
(approximately 7:3) with an overall better scoring with respect to those in SM2. Furthermore, 
pregnenolone was also docked with CHEMSCORE, a scoring function with a higher assessment 
of the hydrophobic interactions, showing poses mostly in SM1 (>9:1). Interestingly, great 
similarities between SM2 and the orientation of our previously described biphenyl compound A 
can be observed (there are actually two very similar modes described as BM1 and BM213e). Like 
the substrate, the steroidal inhibitor abiraterone is also able to bind in both modes but showing 
a good complexation with the heme iron only in SM1 (Figure 1). The same is true for compound 
B, the ring-closed analogue of compound A (not shown). 
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Figure 1. Both binding modes of the substrate pregnenolone (SM1, cyan, and SM2, yellow; the red arrow 
indicates the position of the C17 atoms, rendered as red spheres) are shown as docking complex with CYP17. 
For comparison, the two orientations of compound A (in the formerly described binding modes BM1, blue, and 
BM2, green
13f
) and abiraterone (magenta) are given. Heme, interacting residues and ribbon rendered tertiary 
structure of the active site are also represented. Figures were generated with Pymol (http://www.pymol.org). 
 
The R and S configurated abiraterone analogues of the alcohol and alkane class also bind in 
both modes. Interestingly, a correlation between the inhibitory activities of the compounds of 
each class and the score values could be observed. In the case of highly active compounds, the 
percentage of poses presenting a good iron-nitrogen coordination is higher than for weak 
inhibitors. For enantiomers of a given racemic compound, one enantiomer always shows a 
preference for poses in one binding mode while the other enantiomer prefers to dock in the 
alternative one. In the case of the alcohols, in Figure 2 exemplified by compound 5, the R 
enantiomer binds predominantly in the SM1 mode (9:1) while the S enantiomer binds in SM2 
(8:2). The opposite relation can be seen for the alkanes (Figure 2). 
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Figure 2. Docking complexes of CYP17 and compounds 5 (R enantiomer in SM1 - bluegreen; S enantiomer in 
SM2 - violet) and 20 (S enantiomer in SM1 - magenta; R enantiomer in SM2 - green). A dashed yellow line is 
representing the H-bond between the OH in C17 and the Gly301. 
 
The most important interactions in SM1, besides heme iron complexation, are hydrophobic 
interactions with Ala113, Phe114, Ile371, Pro372, and Val482 and, depending on substituents 
R1 and R2, polar ones with the backbone of Glu98 and Met99 and the carboxyl group of 
Asp103. Furthermore, an H-bond formation between the OH group of R-alkohols and the 
backbone carbonile of Gly301 was observed, which could act as an additional stabilizing factor. 
Regarding SM2, the same interactions as described in refs 13e and 13f were found. 
Low activity compounds did not show a real clustering in SM1 mode and were characterized 
by an unsuitable binding angle between the N lone electron pair and the heme plane 
(compound 12, Figure 3). On the other hand, the highly active alkenes 13 and 14 bind 
preferentially in SM2 mode and present a good complexation of the heme iron and a strong 
binding due to their 3,4-di-OH or 3-F,4-OH substitution. 
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Figure 3. Docking complexes of CYP17 and compounds 11 (yellow; its lone electron pair at the nitrogen and 
the axis of the octahedral heme iron atom are shown), 13 (cyan) and 14 (magenta). 
 
Discussion and Conclusion 
In the class of the indanes the 3-pyridyl substituted unsaturated compound 8, which is 
analogous to abiraterone, showed inhibitory activity in contrast to the respective alcohols and 
alkanes. In the case of the corresponding 4-pyridyl substituted compounds, it is the other way 
around: the alcohols and the alkanes were active, while the unsaturated compounds did not 
show activity. However, it became apparent that the five-membered ring, though analogous to 
the substrate and abiraterone, is not favorable for CYP17 inhibition. On the other hand, the 
expansion of this ring by one methylene group resulting in the hydronaphthalenes led to very 
potent and selective compounds. Summarizing, we have discovered nine very potent 
abiraterone analogues, four of them (14, 17, 19, and 20) showing an IC50 value below 200 nM 
and one of them (20, IC50 = 64 nM) being slightly more active than abiraterone. These 
compounds showed low inhibition of the CYP enzymes considered for selectivity issues 
CYP11B1, CYP11B2 and the hepatic CYP3A4. Owing to their promising in vitro profile, presently 
compounds 20 and 19 are separated into their enantiomers and extensively evaluated for their 
in vivo activities and pharmacokinetics in the rat. 
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Experimental Section 
Chemistry. IR spectra were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-
NMR spectra were measured on a Bruker DRX-500 (500 MHz). Chemical shifts are given in parts 
per million (ppm), and TMS was used as an internal standard for spectra obtained in CDCl3. All 
coupling constants (J) are given in Hz. ESI (electrospray ionization) mass spectra were 
determined on a TSQ quantum (Thermo Electron Corporation) instrument. Column 
chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was 
determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and 
bromoaryls used as starting materials were commercially obtained (CombiBlocks, Chempur, 
Aldrich, Acros). 
Method A: Suzuki-Coupling. 5-Bromoindan-1-one (10 mmol) for compounds 1-4 or 5b (10 
mmol) for compounds 5-7 and the corresponding boronic acid (15 mmol) were dissolved in 
toluene (70 mL) and Na2CO3 (30mL, 2.0 M, aq). The mixture was deoxygenated under reduced 
pressure and flushed with N2. After repeating this 3 times, Pd(PPh3)4 (5 mol %) was added and 
the resulting suspension was heated under reflux for 8 h. After cooling, the phases were 
separated and the water phase was extracted 2 times with EtOAc. Then the combined organic 
extracts were dried over Na2SO4, and concentrated under reduced pressure. The purification 
was performed by Si-gel flash-chromatography. 
5-(4-Fluorophenyl)-2,3-dihydroinden-1-one (1a). Synthesized from 5-Bromoindan-1-one and 
4-fluorophenylboronic acid according to Method A; yield = 95 %; δH (CDCl3, 500 MHz) 2.66-2.69 
(m, 2H), 3.12-3.14 (m, 2H), 7.09 (t, J = 8.7 Hz, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.53 (dd, J = 5.3 Hz, J = 
8.7 Hz, 2H), 7.56 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H); δC (CDCl3, 125 MHz) 14.08, 22.63, 25.86, 26.97, 
31.57, 36.50, 49.43, 115.84, 116.01, 124.17, 125.02, 126.62, 129.11, 129.17, 136.01, 146.64, 
155.86, 162.07, 164.05, 206.40. 
5-(4-Methoxyphenyl)-2,3-dihydroinden-1-one (3a). Synthesized from 5-Bromoindan-1-one 
and 4-methoxyphenylboronic acid according to Method A; yield = 42 %. Since the so obtained 
ketone was used directly for the nucleophilic addition no analytics was performed. 
5-(3-Fluoro-4-methoxyphenyl)-2,3-dihydroinden-1-one (4a). Synthesized from 5-
Bromoindan-1-one and 3-fluoro-4-methoxyphenylboronic acid according to Method A; yield = 
99 %; δH (CDCl3, 500 MHz) 2.64-2.67 (m, 2H), 3.11 (t, J = 5.7 Hz, 2H), 3.87 (s, 3H), 6.97 (t, J = 8.7 
Hz, 1H), 7.27-7.32 (m, 2H), 7.46 (d, J = 8.7 Hz, 1H), 7.53 (s, 1H), 7.71 (d, J = 8.0 Hz, 1H); δC (CDCl3, 
125 MHz) 25.85, 36.50, 56.35, 113.71, 115.01, 115.20, 123.20, 123.23, 124.17, 124.58, 126.24, 
128.43, 128.55, 131.91, 131.94, 132.04, 132.14, 133.15, 133.22, 135.91, 146.03, 147.90, 148.01, 
151.37, 153.82, 155.93, 206.40. 
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6-(4-Fluorophenyl)-3,4-dihydronaphthalen-1(2H)-one (5a). Synthesized from 5b and 4-
fluorophenylboronic acid according to Method A; yield = 89 %; δH (CDCl3, 500 MHz) 2.05-2.10 
(m, 2H), 2.59 (t, J = 6.8 Hz, 2H), 2.92 (t, J = 6.1 Hz, 2H), 7.05 (t, J = 8.7 Hz, 1H), 7.32 (s, 1H), 7.38 
(dd, J = 1.7 Hz, J = 8.2 Hz, 1H), 7.48 (dd, J = 5.3 Hz, J = 8.8 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H); δC 
(CDCl3, 125 MHz) 23.29, 29.91, 39.14, 115.76, 115.93, 125.33, 127.12, 127.90, 128.89, 128.96, 
131.46, 136.13, 144.92, 145.01, 161.98, 163.95, 198.00. 
6-(3,4-Difluorophenyl)-3,4-dihydronaphthalen-1(2H)-one (6a). Synthesized from 5b and 3,4-
difluorophenylboronic acid according to Method A; yield = 87 %. Since the so obtained ketone 
was used directly for the nucleophilic addition no analytics was performed. 
6-(3-Fluoro-4-methoxyphenyl)-3,4-dihydronaphthalen-1(2H)-one (7a). Synthesized from 5b 
and 3-fluoro-4-methoxyphenylboronic acid according to Method A; yield = 59 %; δH (CDCl3, 500 
MHz) 2.07-2.12 (m, 2H), 2.60 (t, J = 6.3 Hz, 2H), 2.94 (t, J = 6.1 Hz, 2H), 3.86 (s, 3H), 6.96 (t, J = 
8.7 Hz, 1H), 7.27-7.30 (m, 2H), 7.33 (s, 1H), 7.39 (dd, J = 1.6 Hz, J = 8.2 Hz, 1H), 8.00 (d, J = 8.2 
Hz, 1H); δC (CDCl3, 125 MHz) 23.28, 29.92, 39.14, 56.33, 113.62, 114.82, 114.98, 123.01, 124.97, 
126.70, 127.94, 131.37, 132.98, 133.03, 144.39, 145.04, 147.80, 147.88, 151.59, 153.55, 198.01. 
6-(3,4-Dimethoxyphenyl)-3,4-dihydronaphthalen-1(2H)-one (13b). Synthesized from 5b and 
3,4-dimethoxyphenylboronic acid according to Method A; yield = 87 %. Since the so obtained 
ketone was used directly for the nucleophilic addition no analytics was performed. 
Method B: Nucleophilic Addition of the Heterocycle. 3-Iodopyridine (4 mmol) – or either 4-
Bromopyridine (4 mmol) for the 4-pyridyl compounds, after basic extraction of its 
hydrochloride salt with Et2O (20 mL) and NaHCO3 (satd, aq), followed by drying over Na2SO4 and 
concentration under reduced pressure – was prepared in Et2O and THF (3:2, 50 mL) at -78°C. 
Then n-BuLi in hexanes (1.6 N, 4.4 mmol) was added and after 5 sec the corresponding ketone 
(4 mmol) in THF (20 mL) was added at once and the mixture was left stirring for additional 3 h 
at room temperature. After neutralization with NH4Cl (satd, aq), the phases were separated, 
the aqueous layer extracted 2 times with EtOAc and the combined organic extracts dried over 
Na2SO4 and concentrated under reduced pressure. The purification was performed by Si-gel 
flash-chromatography. 
5-(4-Fluorophenyl)-1-(pyridin-3-yl)-2,3-dihydro-1H-inden-1-ol (1). Synthesized from 1a and 
3-Iodopyridine according to Method B; yield = 55 %; IR (ATR) υ (cm-1) 2925, 1604, 1516, 1482, 
1418, 1223, 1159, 1060, 1027, 822, 713, 685, 605, 537, 507; δH (CDCl3, 500 MHz) 2.36-2.47 (m, 
2H), 2.85-2.89 (m, 1H), 3.08-3.14 (m, 1H), 6.98-7.04 (m, 3H), 7.14-7.16 (m, 1H), 7.24-7.26 (d, J = 
7.9 Hz, 1H), 7.36 (s, 1H), 7.41-7.44 (m, 2H), 7.69 (d, J = 7.9 Hz, 1H), 8.29 (s, 1H), 8.48 (s, 1H); δC 
(CDCl3, 125 MHz) 14.19, 21.03, 29.89, 44.96, 60.41, 83.55, 115.57, 115.74, 123.07, 123.69, 
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124.34, 126.30, 128.44, 128.54, 128.73, 128.79, 132.03, 132.11, 133.88, 137.15, 141.02, 142.31, 
144.74, 146.32, 147.32, 147.77, 161.54, 163.50, 171.20; m/z = 305.17 [M++H]. 
5-(4-Fluorophenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol (2). Synthesized from 2a and 
4-Bromopyridine according to Method B; yield = 50 %;IR (ATR) υ (cm-1) 2931, 1601, 1515, 1482, 
1412, 1223, 1159, 1066, 822, 676, 601, 533, 518; δH (CDCl3 + CD3OD, 500 MHz) 2.37-2.47 (m, 
2H), 2.92-2.98 (m, 1H), 3.15-3.21 (m, 1H), 7.00 (d, J = 7.9 Hz, 1H), 7.04 (t, J = 8.6 Hz, 2H), 7.29-
7.31 (m, 3H), 7.41 (s, 1H), 7.41-7.47 (m, 2H), 8.38 (d, J = 4.8 Hz, 2H); δC (CDCl3 + CD3OD, 125 
MHz) 29.90, 44.32, 83.82, 115.44, 115.61, 121.16, 123.46, 124.31, 126.17, 128.63, 128.69, 
137.05, 140.95, 144.75, 145.90, 148.70, 156.88, 161.46, 163.42; m/z = 306.21 [M++H]. 
5-(4-Methoxyphenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol (3). Synthesized from 3a 
and 4-Bromopyridine according to Method B; yield = 45 %; IR (ATR) υ (cm-1) 3165, 2957, 2837, 
1606, 1519, 1482, 1456, 1287, 1249, 1182, 1113, 1069, 1039, 1022, 1002, 815, 671, 510, 542; δH 
(CDCl3 + CD3OD, 500 MHz) 2.34-2.46 (m, 2H), 2.91-2.97 (m, 1H), 3.12-3.20 (m, 1H), 3.77 (s, 3H), 
6.90 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 7.9 Hz, 1H), 7.30-7.32 (m, 3H), 7.42 (s, 1H), 7.44 (d, J = 8.8 Hz, 
2H), 8.38 (d, J = 6.2 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 29.95, 44.43, 55.29, 83.93, 114.19, 
121.15, 123.15, 124.20, 125.93, 128.16, 133.49, 141.61, 144.69, 145.29, 148.81, 156.77, 159.17; 
m/z = 318.18 [M++H]. 
5-(3-Fluoro-4-methoxyphenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol (4). Synthesized 
from 4a and 4-Bromopyridine according to Method B; yield = 56 %; δH (CDCl3, 500 MHz) 2.39-
2.48 (m, 2H), 2.93-2.98 (m, 1H), 3.14-3.19 (m, 1H), 3.85 (s, 3H), 6.93-6.98 (m, 2H), 7.21-7.30 (m, 
5H), 7.40 (s, 1H), 8.40 (d, J = 6.2 Hz, 2H); δC (CDCl3, 125 MHz) 30.03, 44.69, 56.36, 84.27, 113.65, 
114.81, 114.96, 120.92, 122.74, 123.37, 124.30, 126.11, 134.09, 134.14, 140.74, 144.92, 145.99, 
147.16, 147.24, 149.23, 151.57, 153.53, 155.83; m/z = 336.11 [M++H]. 
6-(4-Fluorophenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (5). Synthesized from 
5a and 4-Bromopyridine according to Method B; yield = 44 %; δH (CDCl3 + CD3OD, 500 MHz) 
1.75-1.82 (m, 1H), 2.00-2.08 (m, 2H), 2.09-2.16 (m, 1H), 2.86-3.00 (m, 2H), 6.98 (d, J = 8.1 Hz, 
1H), 7.07 (t, J = 8.8 Hz, 2H), 7.27 (dd, J = 2.0 Hz, J = 8.1 Hz, 1H), 7.33-7.34 (m, 3H), 7.51 (dd, J = 
5.4 Hz, J = 8.6 Hz, 2H), 8.40 (d, J = 6.3 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 23.05, 33.68, 44.68, 
77.96, 119.19, 119.40, 126.04, 128.82, 131.06, 132.35, 132.43, 133.59, 140.68, 140.71, 141.91, 
143.24, 143.34, 152.16, 153.76. 165.19, 167.64; m/z = 320.06 [M++H]. 
6-(3,4-Difluorophenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (6). Synthesized 
from 6a and 4-Bromopyridine according to Method B; yield = 40 %; IR (ATR) υ (cm-1) 3063, 
1603, 1568, 1525, 1492, 1411, 1320, 1272, 1230, 1198, 1119, 1068, 986, 907, 874, 816, 773, 
734, 671; δH (CDCl3 + CD3OD, 500 MHz) 1.81-1.89 (m, 1H), 1.99-2.07 (m, 2H), 2.12-2.18 (m, 1H), 
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2.89-3.00 (m, 2H), 6.99 (d, J = 8.1 Hz, 1H), 7.19 (q, J = 8.4 Hz, 1H), 7.24-7.26 (m, 2H), 7.30-7.37 
(m, 4H), 8.48 (d, J = 6.0 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 20.77, 31.35, 42.36, 117.31, 
117.45, 118.95, 119.09, 123.19, 124.35, 124.38, 124.40, 124.43, 126.74, 128.95, 131.14, 139.75, 
140.18, 141.49, 150.36, 159.83, 192.24; m/z = 338.13 [M++H]. 
6-(3-Fluoro-4-methoxyphenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (7). 
Synthesized from 7a and 4-Bromopyridine according to Method B; yield = 64 %; δH (CDCl3 + 
CD3OD, 500 MHz) 1.70-1.77 (m, 1H), 1.94-2.03 (m, 2H), 2.03-2.10 (m, 1H), 2.82-2.93 (m, 2H), 
3.84 (s, 3H), 6.92 (dd, J = 2.7 Hz, J = 8.1 Hz, 2H), 6.96 (dt, J = 2.4 Hz, J = 8.4 Hz, 1H), 7.19-7.28 (m, 
6H), 8.35-8.36 (m, 2H); δC (CDCl3 + CD3OD, 125 MHz) 19.02, 29.67, 40.64, 56.06, 73.93, 113.57, 
114.23, 114.42, 121.91, 122.37, 122.40, 124.55, 126.74, 129.50, 133.67, 133.73, 137.88, 138.78, 
139.11, 146.84, 146.94, 148.20, 151.14, 153.58, 159.42; m/z = 350.13 [M++H]. 
6-(3,4-Dimethoxyphenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (13a). 
Synthesized from 13b and 4-Bromopyridine according to Method B; yield = 48 %. Since the so 
obtained alcohol was used directly for the condensation no analytics was performed. 
Method C: Condensation with HCl. The corresponding alcohol (1 mmol) was refluxed in HCl 
in i-PrOH (10 mL, 3N) for 2 h. Afterwards, the resulting solution was concentrated under 
reduced pressure and washed 3 times with Et2O. No further purification was necessary. 
3-(5-(4-Fluorophenyl)-3H-inden-1-yl)pyridine hydrochloride (8). Synthesized from 1 
according to Method C; yield = 96 %; IR (ATR) υ (cm-1) 3051, 1601, 1514, 1468, 1229, 1189, 
1161, 1104, 1027, 976, 940, 879, 821, 772, 716, 678, 557, 521; δH (CDCl3, 500 MHz) 3.53 (s, 2H), 
6.61-6.62 (m, 1H), 7.06 (t, J = 8.7 Hz, 2H), 7.32 (dd, J = 4.8 Hz, J = 7.8 Hz, 1H), 7.44 (dd, J = 1.4 Hz, 
J = 7.8, 1H), 7.49-7.52 (m, 3H), 7.65 (s, 1H), 7.83-7.85 (m, 1H), 8.55-8.56 (d, J = 4.0 Hz, 1H), 8.81 
(s, 1H); δC (CDCl3, 125 MHz) 38.54, 115.56, 115.73, 120.16, 123.06, 123.50, 125.46, 128.70, 
128.76, 131.75, 132.81, 134.83, 137.51, 137.59, 141.72, 142.47, 145.37, 148.79, 148.91, 161.41, 
163.37; MS (ESI): m/z = 288.13 [M++H]. 
4-(5-(4-Fluorophenyl)-3H-inden-1-yl)pyridine hydrochloride (9). Synthesized from 2 
according to Method C; yield = 100 %; IR (ATR) υ (cm-1) 3482, 3414, 3100-2500, 2075, 1997, 
1632, 1602, 1679, 1555, 1469, 1383, 1262, 1221, 1190, 1157, 1097, 1029, 948, 882, 829, 819, 
787, 562, 552, 527; δH (CDCl3, 500 MHz) 3.20-3.22 (m, 2H), 7.08 (t, J = 8.8 Hz, 2H), 7.30 (s, 1H), 
7.54 (dd, J = 1.7 Hz, J = 8.1 Hz, 1H), 7.58 (dd, J = 5.4 Hz, J = 8.8 Hz, 2H), 7.69 (d, J = 8.1 Hz, 1H), 
7.76 (d, J = 1.4 Hz, 1H), 8.30 (d, J = 6.8 Hz, 2H), 8.81 (d, J = 6.8 Hz, 2H); δC (CDCl3, 125 MHz) 
116.53, 116.71, 121.29, 124.36, 126.43, 126.75, 129.90, 129.96, 138.56, 139.74, 141.01, 141.67, 
142.35, 142.96, 146.93, 155.08, 162.98, 164.93; m/z = 287.96 [M++H]. 
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4-(5-(4-Methoxyphenyl)-3H-inden-1-yl)pyridine hydrochloride (10). Synthesized from 3 
according to Method C; yield = 99 %; IR (ATR) υ (cm-1) 3404, 3061, 1632, 1605, 1517, 1496, 
1469, 1244, 1185, 1036, 1020, 815, 768, 566; δH (CDCl3 + CD3OD, 500 MHz) 3.24-3.27 (m, 2H), 
3.78 (s, 3H), 6.92 (d, J = 8.8 Hz, 2H), 7.43 (s, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.53 (dd, J = 1.7 Hz, J = 
8.1 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.73 (d, J = 1.7 Hz, 1H), 8.23 (d, J = 6.7 Hz, 2H), 8.80 (d, J = 
6.7 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 54.88, 114.03, 119.55, 122.91, 124.95, 125.20, 
127.89, 133.02, 138.59, 139.21, 140.25, 140.92, 141.10, 144.94, 153.90, 159.08; m/z = 301.16 
[M++H]. 
4-(6-(4-Fluorophenyl)-3,4-dihydronaphthalen-1-yl)pyridine hydrochloride (11). Synthesized 
from 4 according to Method C; yield = 100 %; IR (ATR) υ (cm-1) 3047, 2536, 1634, 1601, 1489, 
1228, 1160, 825, 754, 733; δH (CDCl3, 500 MHz) 2.58-2.61 (m, 2H), 2.94 (t, J = 7.8 Hz, 2H), 6.55 
(t, J = 4.7 Hz, 1H), 6.95 (d, J = 7.9 Hz, 1H), 7.14 (t, J = 8.7 Hz, 2H), 7.38 (d, J = 7.9 Hz, 1H), 7.46 (s, 
1H), 7.56 (dd, J = 5.3 Hz, J = 8.7 Hz, 2H), 7.93 (d, J = 5.6 Hz, 2H), 8.79 (d, J = 5.6 Hz, 2H); δC 
(CDCl3, 125 MHz) 23.92, 27.76, 115.72, 115.90, 124.88, 125.37, 125.91, 127.01, 128.50, 128.56, 
130.58, 135.87, 136.21, 137.39, 140.65, 140.67, 158.45, 161.71, 163.68, 190.74; m/z = 302.10 
[M++H]. 
4-(6-(3,4-Difluorophenyl)-3,4-dihydronaphthalen-1-yl)pyridine hydrochloride (12). 
Synthesized from 5 according to Method C; yield = 98 %;IR (ATR) υ (cm-1) 3067, 1634, 1604, 
1522, 1493, 1276, 1200, 1119, 911, 815, 773, 729, 614; δH (CDCl3, 500 MHz) 2.57-2.61 (m, 2H), 
2.94 (t, J = 8.0 Hz, 2H), 6.57 (t, J = 4.8 Hz, 1H), 6.96 (d, J = 8.0 Hz, 2H), 7.23 (q, J = 8.5 Hz, 1H), 
7.29-7.31 (m, 1H), 7.36 (d, J = 8.5 Hz, 1H), 7.37-7.41 (m, 1H), 7.44 (s, 1H), 7.92 (s, 1H), 7.93 (s, 
1H), 8.81 (s, 1H), 8.82 (s, 1H); δC (CDCl3, 125 MHz) 23.86, 27.71, 115.77, 115.91, 117.63, 117.76, 
122.83, 122.85, 122.87, 122.90, 124.97, 125.35, 125.91, 126.94, 131.12, 136.10, 136.14, 137.54, 
139.48, 140.73, 149.11, 149.21, 149.52, 149.62, 151.10, 151.20, 151.50, 151.60, 158.26, 190.74; 
m/z = 320.11 [M++H]. 
Method D: Hydration with Pearlman's catalyst. Pearlman's catalyst (10 mass %) and the 
corresponding alkene was prepared in EtOH and THF (2:1, 5mL) under H2 atmosphere. The 
mixture was left stirring for 3 h, then the catalyst was filtered off 3 times and the solution 
concentrated under reduced pressure. The obtained solid was washed 3 times with Et2O. No 
further purification was necessary. 
3-(5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-1-yl)pyridine hydrochloride (15). Synthesized 
from 8 according to Method D; yield = 99 %; δH (CDCl3, 500 MHz) 1.92-1.98 (m, 1H), 2.65-2.71 
(m, 1H), 2.95-3.06 (m, 2H), 4.51 (s, 1H), 6.84 (d, J = 6.9 Hz, 1H), 7.00 (t, J = 8.6 Hz, 2H), 7.24 (d, J 
= 6.9 Hz, 1H), 7.38-7.41 (m, 3H), 7.76 (s, 1H), 8.13 (d, J = 5.0 Hz, 1H), 8.49 (s, 1H), 8.55 (s, 1H); δC 
(CDCl3, 125 MHz) 31.60, 36.55, 48.36, 115.64, 115.66, 115.83, 115.87, 123.89, 123.91, 124.83, 
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126.54, 126.56, 128.78, 128.84, 140.48, 144.91, 145.03; m/z = 290.10 [M++H]. 
4-(5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-1-yl)pyridine hydrochloride (16). Synthesized 
from 9 according to Method D; yield = 100 %;IR (ATR) υ (cm-1) 3220, 2927, 2855, 1700, 1621, 
1578, 1507, 1439, 1349, 1251, 1215, 1153, 1040, 1027, 986, 914, 831, 806, 784, 748, 699, 668; 
δH (CDCl3, 500 MHz) 2.03-2.09 (m, 1H), 2.72-2.78 (m, 1H), 3.03-3.13 (m, 2H), 4.60 (s, 1H), 6.93 
(d, J = 7.1 Hz, 1H), 7.06 (t, J = 8.6 Hz, 2H), 7.32 (d, J = 6.7 Hz, 1H), 7.45-7.47 (m, 3H), 7.68 (s, 2H), 
8.71 (s, 2H); δC (CDCl3, 125 MHz) 31.80, 36.19, 51.29, 115.66, 115.83, 123.80, 125.02, 126.28, 
126.45, 128.72, 128.78, 136.83, 140.75, 140.99, 141.34, 145.22, 161.61, 166.50; m/z = 290.17 
[M++H]. 
4-(6-(4-Fluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)pyridine hydrochloride (17). 
Synthesized from 11 according to Method D; yield = 97 %; IR (ATR) υ (cm-1) 3049, 1634, 1605, 
1518, 1492, 1223, 1160, 1098, 997, 911, 823, 727, 642; δH (CDCl3, 500 MHz) 1.82-1.90 (m, 3H), 
2.33-2.37 (m, 1H), 2.94-3.00 (m, 2H), 4.46 (s, 1H), 6.78 (d, J = 7.5 Hz, 1H), 7.12 (t, J = 8.6 Hz, 2H), 
7.30 (d, J = 6.8 Hz, 1H), 7.39 (s, 1H), 7.53 (dd, J = 5.3 Hz, J = 8.6 Hz, 2H), 7.67 (s, 2H), 8.71 (s, 2H); 
δC (CDCl3, 125 MHz) 20.06, 29.23, 32.58, 45.49, 115.54, 115.71, 125.26, 126.85, 128.21, 128.43, 
128.49, 130.20, 133.17, 136.25, 136.28, 138.09, 139.61, 140.45, 161.51, 163.48, 168.11, 190.64; 
m/z = 304.10 [M++H]. 
4-(6-(3,4-Difluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)pyridine hydrochloride (18). 
Synthesized from 12 according to Method D; yield = 98 %; IR (ATR) υ (cm-1) 3392, 1634, 1604, 
1522, 1494, 1269, 1197, 1119, 998, 925, 909, 875, 811, 772, 726, 643; δH (CDCl3, 500 MHz) 1.82-
1.90 (m, 3H), 2.33-2.37 (m, 1H), 2.94-3.00 (m, 2H), 4.46 (s, 1H), 6.79 (d, J = 6.2 Hz, 1H), 7.22 (q, J 
= 8.4 Hz, 2H), 7.26-7.28 (m, 2H), 7.34-7.38 (m, 2H), 7.66 (s, 2H), 8.72 (s, 2H); δC (CDCl3, 125 MHz) 
20.12, 29.31, 32.64, 45.58, 115.82, 115.96, 117.55, 117.69, 122.86, 122.88, 125.28, 126.94, 
128.29, 130.45, 133.90, 138.39, 138.61, 140.64, 167.99, 190.74; m/z = 322.11 [M++H]. 
4-(5-(Pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)benzene-1,2-diol hydrobromide (19). 
Synthesized from 13 according to Method D; yield = 98 %;IR (ATR) υ (cm-1) 3172, 2930, 1634, 
1603, 1524, 1495, 1446, 1263, 1196, 1114, 805, 634; δH (CDCl3 + CD3OD, 500 MHz) 1.73-1.80 
(m, 3H), 2.19-2.24 (m, 1H), 2.81-2.89 (m, 2H), 4.27-4.32 (m, 1H), 6.63-6.65 (m, 1H), 6.81 (d, J = 
8.2 Hz, 1H), 6.88-6.90 (m, 1H), 7.00 (s, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.28 (s, 1H), 7.45-7.51 (m, 
2H), 8.59 (s, 2H); δC (CDCl3 + CD3OD, 125 MHz) 20.18, 29.33, 32.56, 45.39, 113.74, 115.36, 
118.77, 124.72, 126.50, 127.66, 129.98, 137.81, 144.22, 144.65; m/z = 318.65 [M++H]. 
2-Fluoro-4-(5-(pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)phenol hydrobromide (20). 
Synthesized from 14 according to Method D; yield = 96 %; IR (ATR) υ (cm-1) 3066, 1635, 1607, 
1525, 1494, 1366, 1293, 1215, 1117, 911, 872, 812, 780, 727, 644; δH (CDCl3 + CD3OD, 500 MHz) 
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1.84-1.92 (m, 3H), 2.34-2.40 (m, 1H), 2.92-3.00 (m, 2H), 4.48-4.50 (m, 1H), 6.76 (d, J = 8.0 Hz, 
1H), 7.02 (t, J = 8.8 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.26-7.28 (m, 2H), 7.38 (s, 1H), 7.73 (s, 1H), 
7.74 (s, 1H), 8.79 (s, 1H), 8.80 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 24.03, 33.17, 36.48, 49.51, 
118.12, 118.27, 121.90, 126.73, 128.77, 131.08, 131.69, 134.12, 136.34, 136.39, 136.79, 142.06, 
143.29, 144.45, 148.04, 148.15, 154.59, 156.50, 173.21; m/z = 320.08 [M++H]. 
Method E: Ether Cleavage and Condensation with HBr. The corresponding ether was 
refluxed overnight in HBr (100 mL for compound 5c, 3 mL for compounds 13 and 14). For 
compound 5c, after reaction completion water (100 mL) was added, the mixture was cooled 
down and filtered. The solid was washed 3 times with water and no further purification was 
needed. For compounds 13 and 14, after reaction completion the mixture was neutralized with 
solid NaHCO3 and extracted 3 times with EtOAc. The combined organic extracts were dried over 
Na2SO4, concentrated under reduced pressure and purified by Si-gel flash-chromatography. 
6-Hydroxy-1-tetralone (5c). Synthesized from 6-methoxy-1-tetralone according to Method E; 
yield = 89 %; δH (CDCl3, 500 MHz) 2.01-2.06 (m, 2H), 2.56 (t, J = 6.8 Hz, 2H), 2.83 (t, J = 6.1 Hz, 
2H), 6.66 (d, J = 6.1 Hz, 1H), 6.74 (dd, J = 2.4 Hz, J = 8.6 Hz, 1H), 7.38 (s, 1H), 7.91 (d, J = 8.6 Hz, 
1H); δC (CDCl3, 125 MHz) 23.27, 29.92, 38.80, 114.60, 114.66, 125.75, 130.20, 147.82, 161.28, 
198.69. 
4-(5-(Pyridin-4-yl)-7,8-dihydronaphthalen-2-yl)benzene-1,2-diol hydrobromide (13). 
Synthesized from 13a according to Method E; yield = 65 %; IR (ATR) υ (cm-1) 3127, 1634, 1605, 
1533, 1503, 1396, 1315, 1252, 1205, 1123, 806, 788, 752, 617; δH (CDCl3 + CD3OD, 500 MHz) 
2.53-2.55 (m, 2H), 2.87 (t, J = 7.8 Hz, 2H), 6.53-6.55 (m, 1H), 6.83-6.89 (m, 2H), 6.94-6.96 (m, 
1H), 7.28-7.31 (m, 1H), 7.40-7.41 (m, 1H), 7.94-7.96 (m, 2H), 8.77-8.79 (m, 2H); δC (CDCl3 + 
CD3OD, 125 MHz) 27.23, 31.01, 117.13, 118.87, 122.01, 127.96, 128.02, 128.97, 129.45, 129.78, 
131.43, 132.96, 135.65, 139.43, 139.55, 140.53, 144.17, 144.88, 148.02, 148.27, 162.74; m/z = 
316.18 [M++H]. 
2-Fluoro-4-(5-(pyridin-4-yl)-7,8-dihydronaphthalen-2-yl)phenol hydrobromide (14). 
Synthesized from 7 according to Method E; yield = 28 %; IR (ATR) υ (cm-1) 3385, 1605, 1522, 
1489, 1437, 1416, 1313, 1291, 1278, 1221, 1199, 1168, 117, 1067, 1008, 909, 891, 874, 823, 
806778, 735, 667, 621; δH (CDCl3 + CD3OD, 500 MHz) 2.49-2.53 (m, 2H), 2.94 (t, J = 7.9 Hz, 2H), 
6.25-6.27 (m, 1H), 7.02 (q, J = 8.4 Hz, 2H), 7.26 (d, J = 8.1 Hz, 1H), 7.31 (s, 1H), 7.34 (d, J = 5.8 Hz, 
1H), 7.39-7.42 (m, 3H), 8.58 (d, J = 5.7 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 24.90, 29.47, 50.22, 
50.37, 50.39, 50.55, 50.57, 115.51, 115.66, 117.44, 119.29, 124.08, 124.10, 125.27, 125.75, 
126.63, 127.40, 131.57, 133.51, 134.13, 134.18, 138.60, 1388.77, 140.54, 145.40, 145.52, 
150.25 150.87, 152.09; m/z = 318.08 [M++H]. 
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1-Tetralon-6-yl trifluoromethanesulfonate (5b). 6-Hydroxy-1-tetralone (5 g, 30.83 mmol) 
was prepared with pyridine (2.77 mL, 33.91 mmol) in dry DCM (100 mL) at 0°C. After carefully 
adding trifluoromethanesulfonic anhydride (5.10 g, 30.83 mmol) over 1 min, the reaction 
mixture was left stirring for 3 h at room temperature. Afterwards, excess 
trifluoromethanesulfonic anhydride was neutralized and the crude was washed 2 times with 
water, the organic phase dried over Na2SO4 and concentrated under reduced pressure. Further 
purification was performed by Si-gel flash-chromatography; yield = 30 %; δH (CDCl3, 500 MHz) 
2.08-2.14 (m, 2H), 2.61 (t, J = 6.8 Hz, 2H), 2.95 (t, J = 6.1 Hz, 2H), 7.12-7.14 (m, 2H), 8.06 (d, J = 
8.4 Hz, 1H); δC (CDCl3, 125 MHz) 22.90, 29.73, 38.77, 119.68, 119.94, 121.36, 130.04, 132.39, 
147.11, 152.34, 196.40. 
Biological Assays. CYP17 Preparation and Assay. As source of human CYP17, our E. coli 
system19 (coexpressing human CYP17 and NADPH-P450 reductase) was used and the assay was 
performed as previously described12a using unlabeled progesterone as substrate and applying 
HPLC with UV-detection for separation. 
Inhibition of CYP11B1 and CYP11B2. V79MZh11B1 or V79MZh11B222 cells expressing the 
respective human enzyme were used and our assay procedure using [4-14C]-11-
deoxycorticosterone was performed.20 
Inhibition of CYP3A4. The recombinantly expressed enzymes from baculovirus-infected insect 
microsomes and cytochrome b5 (BD Supersomes™) were used and the manufacturer’s 
instructions (www.gentest.com) were followed. 
Molecular Modeling. Various inhibitors of Tables 1 were docked into our CYP17 homology 
model by means of the GOLD v3.2 software23 using GOLDSCORE and CHEMSCORE. Since the 
GOLD docking program allows flexible docking of the compounds, no conformational search 
was employed to the ligand structures. GOLD gave the best poses by a genetic algorithm (GA) 
search strategy, and then various molecular features were encoded as a chromosome. 
The structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, 
Missouri, USA) and energy-minimized in MMFF94s force-field24 as implemented in Sybyl.  
Ligands were docked in 50 independent GA runs using GOLD. Heme iron was chosen as active 
site origin, while its radius was set equal to 19 Å. The automatic active site detection was 
switched on. Furthermore, a distance constraint of a minimum of 1.9 and a maximum of 2.5 Å 
between the sp2-hybridized nitrogen of the pyridine and the iron of the heme was set. 
Additionally, the goldscore.p450_pdb parameters were used and some of the GOLDSCORE 
parameters were modified to improve the weight of hydrophobic interaction and of the 
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coordination between iron and nitrogen. The genetic algorithm default parameters were set as 
suggested by the GOLD authors.23 On the other hand, the annealing parameters of fitness 
function were set at 3.5 Å for hydrogen bonding and 6.5 Å for Van der Waals interactions. 
All 50 poses for each compound were clustered with ACIAP25 and the representative structure 
of each significant cluster was selected. After the docking simulations and cluster analysis were 
performed, the quality of the docked representative poses was evaluated based on visual 
inspection of the putative binding modes of the ligands. The latter were further evaluated by 
means of Silver v3.1.1, the postprocessing tool of GOLD, and at last by GOLDSCORE. 
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VI.1.a. CYP17 Inhibitors. Annulations of Additional Rings in Methylene Imidazole 
Substituted Biphenyls: Synthesis, Biological Evaluation and Molecular Modelling 
In our aim to explore the spatial limitations surrounding both areals corresponding to the 
substrates A- and C-ring, two main classes of differently A- and C-ring annulated compounds 
were synthesized. The C-ring annulated compounds (11 compounds) showed no to moderate 
inhibition of CYP17 at 2 µM with exception of compound III.9 (Figure 11), which showed 71 % 
inhibition, much higher than the reference compound ketoconazole (19%). The A-ring 
annulated compounds (10 compounds) presented much better activities, and the most potent 
ones, compounds III.13 (75%), III.19 (75%) and III.21 (74%) showed comparable ones to 
compound III.9. 
 
Regarding selectivity over other CYP enzymes, all compounds exhibited inhibition, higher 
than 85% at 2 µM except from III.21 (32% at 2 µM and 64% at 10 µM). III.9 and III.21, most 
active compounds of each substance class, were subsequently tested on CYP11B1, showing 
both of them similarly strong inhibitions of 86 and 94% at 0.2 and 2 µM for compound III.9, and 
81 and 95% at the same concentrations for III.21. 
Based on our biological results and molecular modeling studies of this and previous work, it 
is striking that the correct spatial extension in both areals is favorable for both activity and 
selectivity. The importance of the presence of an ethyl group at the methylene linker for 
achieving higher potencies was reiterated. 
Figure 11. Most active compounds of the A- (III.13, III.19 and III.21) and C-ring (III.9) annulated classes. 
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VI.1.b. Synthesis, Biological Evaluation and Molecular Modelling Studies of Novel 
ACD- and ABD-Ring Steroidomimetics as Inhibitors of CYP17 
Since we observed good results at the expansion of both A- and C-ring mimicking benzenes, 
we expanded both with a rigid core to the corresponding ABD- and ACD-ring mimetics. Thus, 
we synthesized 11 ACD- and 6 ABD-ring mimetics and again, the expansion at the A-ring was 
overall more favorable for activity than at the C-ring. The 3- and 4-pyridyl substituted ACD-ring 
mimetics were slightly active, the 4-pyridyls minimally better, while the methylene-imidazolyl 
ones were moderately active, among them compound IV.9 (Figure 12) showed a CYP17 
inhibition of 50% at 2 µM. The same relationship was observed for the ABD-ring mimetics, 
yielding the 4-pyridyl IV.15 with 66% and the methylene-imidazolyl IV.17 with 61% inhibition, 
both measured at 2 µM.  
 
 
 
 
 
As for selectivity against CYP3A4, only compound IV.15 showed low inhibition at 1 µM (6%) 
and 10 µM (19%). In contrast to the A- and C-ring annealed compounds, IV.15 exhibited very 
low activities of 3 and 23% at 0.2 and 2 µM respectively on CYP11B1. 
Again, good inhibition values were achieved by occupying the areals surrounding the 
steroidal A- and C-rings, as observed in our enzyme model and through appropriate 
substitution, selectivity over other CYP enzymes was shown. The rigidity attained through 
mimicking the D-ring with a benzene showed good results, similar to the rigidity gained through 
the ethyl group at the methylene linker in other substance classes. 
 
 
 
 
Figure 12. Most active compounds of the ACD- (IV.9) and ABD-ring (III.15 and IV.17) mimetics classes. 
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VI.1.c. Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone 
Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer 
Through the knowledge gained so far about the spatial limitations and geometry of a good 
CYP17 inhibitor, as well as of the binding site, we went on to replace the D-ring by a 
nonaromatic ring, in some way a hybrid between our ethyl-substituted (olefinic) and 
naphthalenic (aromatic ) compounds. In such way, we obtained nonsteroidal 3-pyridyl 
substituted abiraterone mimetics, which showed inactive, and other 4-pyridyl indane 
derivatives (altogether 9 indane derivatives were prepared), which showed none to moderate 
CYP17 inhibition, except for compound V.16 (IC50 = 233 nM, Figure 13). Another synthesized 
class was the class of hydronaphthalenes (11 compounds), in which the synthesized alcohols 
showed none to moderate activities, the alkenes exhibited a very wide range of activities (the 
most potent one: 4-hydroxyl compound V.14: IC50 = 188 nM), and the alkanes proved the most 
potent ones, being the 4-hydroxyl compounds V.19 (IC50 = 144 nM) and V.20 (IC50 = 64 nM) the 
most active ones together with the 4-F V.17 (IC50 = 163 nM). 11, out of the 20 synthesized 
compounds, were more active than ketoconazole (IC50 = 2780 nM), and V.20 even slightly 
better than abiraterone (IC50 = 72 nM) and also highly active in the whole cell assay (IC50 < 200 
nM). 
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Figure 13. Most active compounds of the indane (V.16) and hydronaphthalene (V.14, V.17, V.19 and V.20) classes. 
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These five most potent compounds proved much better selectivities over CYP3A4, CYP11B1 
and CYP11B2 than ketoconazole. Compared to abiraterone, they were all comparable to it 
regarding CYP3A4 (IC50 = 2704 nM), with the exception of V.16 and V.19 with higher inhibitions, 
and V.20 with a lower one (IC50 = 3386 nM). They all showed comparable or even higher 
selectivities regarding CYP11B1 than abiraterone (IC50 = 1608 nM), but regarding CYP11B2, only 
V.14 and V.19 showed respectively slightly higher and lower inhibitions, while most of them 
were much less selective, all around 500 nM, compared to abiraterone (1751 nM). This makes 
compounds V.19 and V.20 respectively potent and selective CYP17, and dual CYP17 and 
CYP11B2 inhibitors. 
After docking of both substrates, abiraterone, and our biphenyls and abiraterone analogues 
into our enzyme model, two separate binding modes were observed. The substrates show more 
poses in one of both binding modes, thus they seem to bind rather in that one, which is the 
same binding mode preferred by the most potent compounds, both biphenyls and abiraterone 
analogues. Good polar interactions are contemplated between the 4-hydroxy groups and the 
backbone of Glu98 and Met99 and the carboxyl group of Asp103. 
 
VI.2. Summary 
 
In the class of the annulated compounds, two sub-classes were synthesized: A-ring 
annulated and C-ring annulated compounds. In the first class, one highly active compound was 
found (71% inhibition at 2 µM), while in the second one three showed around 75% inhibition. 
Only III.21, belonging to the C-ring annulated class, was selective over CYP3A4 and none of 
them over CYP11B1. 
Among the classes of the ACD- and ABD-ring mimetics, one moderate active compound with 
50% inhibition was found for the ACD-mimetics, while in the other class 2 compounds with 
inhibitions around 65% were discovered. Only IV.15, an ABD-mimetic, was selective against 
both CYP3A4 and CYP11B1. 
The abiraterone analogues were divided in 5- and 6-membered ring analogues, and 
additionally in alcohol, alkene, and alkane classes. The most potent compounds were 6-
membered ring alkanes; four of them were highly active, one of which was good (V.19) and 
another one very good selective (V.20) against both CYP3A4 and CYP11B1, and furthermore 
V.19 was additionally selective against CYP11B2. 
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Close to half of the presented compounds were more active and selective than the off-label 
drug ketoconazole, while regarding abiraterone acetate, a drug undergoing clinical trials, four 
exhibited comparable or even better activities, and two of them showed good selectivities for 
CYP11B1 and CYP3A4, while one of the latter was also highly selective against CYP11B2. 
The importance of our three main pharmacophores was present throughout the work. The 
complexation by the sp2 nitrogen with the heme iron, the rigidity of the core structure, 
especially in the D-ring areal and the polar interactions between the substituents mimicking the 
substrate’s 3-hydroxy group always contributed to better activities, and sometimes even to 
selectivities. OH and F substituents were overall optimal, while the moiety and substitution 
pattern of the sp2 nitrogen bearing aromatic ring varies according to the nature of the core 
structure. 
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VII. Discussion and Conclusion 
 
VII.1. Relevance of this Work 
 
The motivation for this work was the absence of effective mild treatments for prostate 
cancer, disease which affects a large sector of elder male population. The purpose of our 
research was to find a new medical therapy for the treatment of prostate cancer which suits 
the real necessities of the patients, based on recent scientific discoveries. Tumor growth is 
stimulated by androgens, produced by a series of enzymatic steps, in which CYP17 takes a key 
role for the biosynthesis of all of them. Other, androgen suppressing therapies have been 
widely used in the past, proving effective therapeutic results in the treatment of prostate 
cancer, leading in many cases to tumor shrinkage and eradication, but created heart problems 
and promoted the development of the disease, and were then unable to treat the mutated 
tumor. Recent discoveries show that through inhibition of CYP17 tumor growth may be 
successfully stopped in all prostatic adenocarcinomas at all stages. These discoveries acquaint 
CYP17 not only as the most promising current target for the treatment of prostate cancer, but 
also as a self-sufficient future therapy option. Ketoconazole is the only CYP17 inhibitor which 
was used off-label for the treatment of prostate cancer, which had low activity and no 
selectivity toward other CYP enzymes, but still showed significant clinical improvements. 
Several other research groups are investigating in this field, leading to one promising steroidal 
drug, abiraterone acetate, currently undergoing clinical studies. 
Nonsteroidal and selective drugs have the advantage over the steroidal ones of having 
strongly reduced side effects. Such endocrine and intracrine drugs have furthermore a 
comfortable form of administration, as they can be taken orally. Thus, nonsteroidal medicines 
which inhibit CYP17 selectively represent a mild, safe and efficient treatment option for 
prostate cancer which is even more crucial in the handling of prostate cancer patients, since the 
large majority is of advanced age. All this makes successfully designed nonsteroidal CYP17 
inhibitors optimal medicines for the treatment of prostate cancer. 
The in vivo suppression of plasma testosterone levels in rats has been proven several times 
by us through the administration of compounds belonging to some of these classes, pointing to 
an accomplished proof of concept. In such manner, after the appropriate, still outstanding 
trials, some of the presented lead compounds would be optimal candidates for future clinical 
studies, aiming the approval of novel, innovative drugs for the treatment of prostatic 
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adenocarcinoma for any stage of disease, while some others could be ideal hit compounds for 
the development of other such drugs. For the latter compounds, proposals for the 
improvement of both activity and selectivities were explained for each class based on the 
biological activities, and our enzyme model and diverse data available for our and other CYP 
enzymes. 
 
VII.2. Achievements and Future Perspectives 
 
Through our medicinal chemistry approaches, we were successful in finding several highly 
active and selective lead compounds in three different classes, and to further develop the 
concept of inhibitors of CYP17, essential for a safe therapy for the kind of patients affected by 
prostate cancer, patients in advanced age. Altogether we present four highly active compounds 
with activities similar or better than abiraterone (72 nM) in our enzymatic test. One of them is 
not only more active, but also much more selective than abiraterone regarding CYP11B1 and 
CYP11B2, and only slightly more active at CYP3A4. 
The organic compounds found, suitable as new drugs for the treatment of prostate cancer 
through inhibition of CYP17, are still to undergo many other preclinical studies after 
enantiomeric separation, such as other in vitro cell-free and whole-cell assays of different 
enzymes, and in vivo tests in different animal species with a high enzyme homology to the 
human phenotype, such as rats, dogs and monkeys. Just after the successful completion of such 
tests, clinical tests may be started. 
The results of this work also serve as a very good starting point for future new generation 
CYP17 inhibitors, regarding the functionalities (A- and C-ring substitutions, core rigidity, heme-
complexing nitrogen) described before found to lead to good activities and selectivities in most 
of the investigated classes. 
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